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Methamphetamine (METH) causes partial dopamine (DA) loss in the 
caudate/putamen and has long-term detrimental effects on cognitive function. We 
have previously shown that the positive correlation between expression of the 
immediate-early gene Arc in dorsomedial (DM) striatum and learning on a motor 
response reversal task is lost in rats with METH-induced striatal DA loss, despite 
normal behavioral performance. This discrepancy suggests that METH-
pretreated rats no longer use DM striatum in this task. When function of or Arc 
expression in DM striatum of saline (SAL)-pretreated rats is disrupted, reversal 
learning and retention of learning, respectively, are impaired. However, METH-
pretreated rats are unaffected by either treatment, suggesting that METH-
pretreated rats no longer use DM striatum to perform this task. In situ 
hybridization histochemical staining for Arc mRNA expression in various brain 
regions of rats revealed a correlation between Arc and response reversal 
learning in nucleus accumbens (NAc) shell of METH-pretreated rats that did not 
exist in SAL-pretreated rats. When Arc was knocked down in the NAc shell, 
memory consolidation on the reversal task in METH-pretreated rats was 
impaired, whereas it was unaffected in SAL-pretreated rats, suggesting that 
METH-pretreated rats are relying on the NAc shell instead of DM striatum to 
consolidate reversal memories. Since the above evidence strongly suggests that 
METH-induced damage to the striatum forces rats to rely on a different brain 
region to complete this reversal task, we attempted to restore striatal function in 
METH-pretreated rats by manipulating extracellular DA levels. METH-pretreated 
rats are selectively deficient in phasic DA signaling, which generates transient 
DA changes in response to rewards and their cues. We stimulated the brains of 
METH- and SAL-pretreated rats in a phasic-like manner and found that the 
reduced striatal preprotachykinin gene expression in METH-pretreated rats was 
restored to control levels. Furthermore, we found that L-DOPA, the biochemical 
precursor to DA, restored phasic DA signals in METH-pretreated rats back to the 
baseline levels in SAL-pretreated rats. These results suggest that METH-induced 
neurotoxicity results in altered circuitry used in the brain during a reversal 
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 Methamphetamine (METH) is a highly addictive psychostimulant drug. 
Thirteen million Americans reported using METH in 2010 (National Survey on 
Drug Use and Health, SAMHSA). Abuse of METH in humans is associated with 
decreases in dopamine (DA) transporter (DAT) (Wilson et al., 1996; McCann et 
al., 1998; Volkow et al., 2001a; Volkow et al., 2001b; McCann et al., 2008) and 
serotonin (5-HT) transporter (SERT) binding (Sekine et al., 2006; Kish et al., 
2009) in the caudate-putamen. Not only are these decreases in DAT and SERT 
long-lasting, but recent evidence has shown that individuals with a history of 
hospitalization for METH use also have an increased risk of developing 
Parkinsonism later in life (Callaghan et al., 2012). Study of the damage that 
METH abuse induces in the brain is thus important in order to better treat 
recovering METH addicts. 
METH effects in humans. Presently, there is disagreement in the field as 
to whether METH abuse results in cognitive deficits in humans. On the one hand, 
two well-designed and controlled studies found no differences in cognitive 
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functioning between METH abusers and control subjects (Chang et al., 2005; 
Simon et al., 2010). On the other hand, the reduction in DAT binding has been 
shown to correlate with cognitive deficits seen in individuals who have abused 
METH (Volkow et al., 2001). Further, other studies have found cognitive 
impairments in METH abusers, including impairments in executive function, 
learning, and memory (for review, see Scott et al., 2007; Marshall and O'Dell, 
2012; Dean et al., 2013; but see Hart et al., 2012). For example, 
neuropsychological studies of METH abusers have discovered deficits in verbal 
learning and memory (Kalechstein et al., 2003; Gonzalez et al., 2004; Rippeth et 
al., 2004; Woods et al., 2005; Hoffman et al., 2006), attention (Kalechstein et al., 
2003; Salo et al., 2007; Salo et al., 2009), executive control (Kim et al., 2006; 
King et al., 2010), and social and “real-life” skills, such as prospective memory for 
events to be done during the week (Henry et al., 2009; Rendell et al., 2009; 
Henry et al., 2010). Increased impulsivity also has been noted in a delay-
discounting test (Hoffman et al., 2006). Thus, despite the controversy, the 
evidence is compelling that METH abuse is associated with cognitive deficits on 
certain tasks. 
Modeling METH-induced neurotoxicity. It is important to be able to model 
the consequences of METH exposure in animals in order to study how 
neurotoxicity to monoamine systems comes about, what the effects of the toxicity 
are, and ultimately, how cognitive and physiological deficits arising as a result of 
METH abuse can be treated in order to increase quality of life for recovering 
addicts. One way to model METH-induced neurotoxicity in rats is via a “binge” 
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regimen of METH, in which rats are given multiple injections of METH over the 
course of one day. This regimen causes long-lasting partial depletions of DA and 
5-HT levels in the brain, especially in the caudate-putamen/striatum (Seiden et 
al., 1976; Hotchkiss and Gibb, 1980; Morgan and Gibb, 1980; Ricaurte et al., 
1980; Wagner et al., 1980; Ricaurte et al., 1982) comparable to what is seen in 
human METH abusers (Marshall and O'Dell, 2012). 
Similar to observations in humans, METH-induced neurotoxicity in rats is 
associated with cognitive impairments. Behavioral performance on learning tasks 
after METH-induced neurotoxicity has been studied more extensively in rats than 
in humans, due to the tractability of the model organism, allowing researchers to 
probe in detail the basis of impairments associated with METH, including the 
extent to which cognitive deficits arise as a consequence of METH-induced 
neurotoxicity. Rats pretreated with a neurotoxic regimen of METH are impaired 
on tasks examining motor-sequence learning (Chapman et al., 2001; Daberkow 
et al., 2005), novel object recognition (Schröder et al., 2003; Belcher et al., 2005; 
Marshall et al., 2007; Herring et al., 2008; Reichel et al., 2012), visual 
discrimination and attentional set-shifting (Izquierdo et al., 2010), odor 
recognition (O'Dell et al., 2011), and spatial learning (Friedman et al., 1998, but 
see Schröder et al., 2003; Herring et al., 2008). METH-pretreated rats are also 
more work-averse than normal rats, as demonstrated by choosing a smaller, but 
easier-to-obtain reward over a larger reward that could only be reached by 
climbing over a wall (Kosheleff et al., 2012). These experiments have shown that 
METH-induced partial loss of DA in rodents models cognitive impairments seen 
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in human METH addicts, suggesting a causal role of METH-induced neurotoxicity 
in cognitive impairments in humans. 
Despite obvious impairments on many behavioral tasks, METH-pretreated 
rats appear to be normal on other tasks, such as conditioned place aversion 
(Achat-Mendes et al., 2005), motor response-reversal learning (Daberkow et al., 
2008; Pastuzyn et al., 2012; Chapters 2 and 3), and operant conditioning (Son et 
al., 2011; Son et al., 2013). These tasks can be deceptive, however, as recent 
research has demonstrated that METH-pretreated rats can appear to be 
behaving normally, but in reality have subtle impairments on the task or 
differences from normal rats in the brain regions used to perform the task. For 
example, METH-pretreated rats have no apparent gross motor impairments and 
are outwardly indistinguishable from normal rats. However, in the case of 
instrumental learning tasks, METH-pretreated rats appear to behave normally, 
but the associations underlying the instrumental behavior are different. 
Specifically, when those associations are probed by devaluing the reward using 
conditioned taste aversion, it becomes apparent that METH-pretreated rats never 
transition from goal-directed responding to habitual, or stimulus-response, 
responding (Son et al., 2011). METH-pretreated rats also perseverate more 
during their operant responding than do normal rats (Son et al., 2013). Finally, 
even though METH-pretreated rats appear to perform the response-reversal 
learning task as well as normal rats (Daberkow et al., 2008; Pastuzyn et al., 
2012), normal rats rely on brain circuitry involving the dorsomedial (DM) striatum 
(Palencia and Ragozzino, 2004; Pastuzyn et al., 2012; Chapter 2), whereas rats 
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with METH-induced neurotoxicity rely on circuitry involving the nucleus 
accumbens (NAc) shell (Pastuzyn and Keefe, in press; Chapter 3). METH-
induced neurotoxicity can therefore result in both gross and subtle impairments 





In order to further explore the nature of METH-induced cognitive and 
behavioral deficits, we turned our attention to the activity-regulated cytoskeleton-
associated gene Arc/Arg 3.1 (Link et al., 1995; Lyford et al., 1995). Almost 20 
years of research have cemented Arc’s critical role in mediating synaptic 
plasticity, and it is now known that aberrant Arc transcription or translation plays 
a significant role in many diseases (e.g., Greer et al., 2010; Auerbach et al., 
2011; Osterweil et al., 2012). The mechanisms of Arc’s role in synapse-level 
plasticity have been well described in other recent reviews (Bramham et al., 
2010; Korb and Finkbeiner, 2011; Shepherd and Bear, 2011). Therefore, this 
review will focus on the role of Arc in specific behavioral and systems-level 
learning and memory tasks. 
Arc at the synapse. Because the recent findings concerning Arc’s role in 
synaptic plasticity have been reviewed in excellent detail elsewhere (Korb and 
Finkbeiner, 2011; Shepherd and Bear, 2011), we will only give a brief overview in 
this review. Arc is an immediate-early gene that is transcribed rapidly upon 
synaptic activity in the absence of new protein synthesis; e.g., within five minutes 
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of exploration of a novel environment (Guzowski et al., 1999; Vazdarjanova et al., 
2002; Barker-Haliski et al., 2012). Arc’s rapid induction is due in part to the 
presence of a negative elongation factor at the Arc promoter region that stalls 
RNA polymerase II at the transcription start site and allows for almost immediate 
transcription of Arc after neuronal activity (Saha et al., 2011). Transcription of Arc 
begins upon calcium influx via L-type voltage-sensitive calcium channels and 
activation of metabotropic glutamate receptors (Park et al., 2008; Adams et al., 
2009); the mRNA is then trafficked to dendrites and Arc protein is translated 
locally at activated synapses (Steward et al., 1998). The story may be more 
complicated, however, because recently Arc was shown to play a role in 
regulating surface GluA1 expression even at inactive synapses (Okuno et al., 
2012). Arc is necessary for long-term depression (LTD) (Park et al., 2008; 
Waung et al., 2008) and homeostatic scaling of α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors (AMPARs) at postsynaptic 
membranes (Rial Verde et al., 2006; Shepherd et al., 2006) by promoting 
endocytosis of AMPARs (Chowdhury et al., 2006); correspondingly, neurons 
lacking Arc have increased surface expression of AMPARs. Furthermore, local 
knockdown of Arc mRNA using an antisense oligonucleotide directed against Arc 
prevents maintenance of long-term potentiation (LTP) (Guzowski et al., 2000; 
Messaoudi et al., 2007). Thus, the evidence points to Arc playing an important 
role in synaptic plasticity processes (LTD, LTP, and homeostatic scaling) critical 
for consolidation of learning and memory in the mammalian brain. 
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 The experiments discussed above determining the role of Arc in synaptic 
plasticity have mostly been carried out in culture or ex vivo. An excellent system 
for studying plasticity in vivo is experience-dependent plasticity in visual cortex, 
since simple monocular deprivation results in a shift in ocular dominance (Wiesel 
and Hubel, 1963), caused by a strengthening in open eye inputs and 
corresponding weakening in closed eye inputs (Gordon and Stryker, 1996; 
Frenkel and Bear, 2004). Because the inputs weaken as a result of AMPAR 
endocytosis (Allen et al., 2003; Heynen et al., 2003; Crozier et al., 2007; Yoon et 
al., 2009), two labs examined whether Arc was responsible for ocular dominance 
shift in monocular deprivation. Arc KO mice were found to lack ocular dominance 
plasticity after monocular deprivation (McCurry et al., 2010) and to have an 
altered balance of excitatory and inhibitory inputs in visual cortex (Gao et al., 
2010), leading to aberrant experience-dependent plasticity. Thus, the in vitro and 
in vivo data concur, and point to the significant and essential need for Arc in 
synaptic plasticity and thus learning and memory. 
Arc in spatial learning. Arc knockout (KO) mice have intact short-term 
memory, but are unable to consolidate long-term memories in a variety of 
behavioral tasks (Plath et al., 2006). For example, although KOs were able to 
learn to find the hidden platform in a Morris water maze in a manner similar to 
that observed in wild-type mice, they were impaired in both remembering the 
location of a hidden platform in the Morris water maze in a probe test and in 
“reversal,” in which the platform was moved to the opposite quadrant. These 
latter impairments suggest that Arc is needed for memory consolidation, in 
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remembering the platform’s location, and for relearning, in the case of the new 
platform location. 
Guzowski and colleagues provided similar findings using an Arc antisense 
oligonucleotide to knock down Arc expression in the hippocampus (2000). Rats 
infused with a scrambled oligonucleotide showed a preference for the trained 
quadrant in a probe test 48 hr later, whereas rats infused with Arc antisense 
either three hours before or immediately after being trained on the Morris water 
maze showed no preference, suggesting that they had not consolidated the 
learning during training. Another study by Martínez and colleagues further 
demonstrates Arc’s role in spatial learning, as measured by how much time rats 
spend exploring a familiar environment (2012). Whereas rats that were infused 
with a scrambled oligonucleotide showed less exploratory behavior when 
retested in the open field apparatus 24 hr later, rats that were infused with Arc 
antisense oligonucleotides into dorsal hippocampus three hours before the initial 
exposure to the open field did not show such a decrease in exploratory behavior 
when tested in the same context 24 hr later. Rather, they explored the 
environment as if it were novel. It is thus apparent that either genetic deletion of 
Arc or knockdown of Arc in hippocampus results in impaired spatial memory 
consolidation. 
Arc in fear conditioning. Recently, much research has been focused on 
the role of Arc in fear conditioning, mainly with respect to the function it plays in 
the amygdala, but also regarding its role in the hippocampus in contextual fear 
behavioral paradigms. Pavlovian fear conditioning is a task in which a tone is 
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paired with a foot shock, and rats are subsequently tested in a novel environment 
for freezing when the tone is played. Plath et al. (2006) trained the Arc KO mice 
on this task, and found that when mice were tested for freezing 24 hr later in 
either the original chamber (contextual test) or in a novel chamber with the tone 
played (cue test), the KOs demonstrated significantly less freezing than wild-type 
mice. The role of Arc in a specific brain region during fear conditioning was 
examined by knockdown of Arc in the lateral amygdala via an infusion of Arc 
antisense six hours before Pavlovian fear conditioning (Ploski et al., 2008). While 
short-term memory was intact when rats were tested for freezing to the tone 
three hours later, long-term memory was impaired when tested 24 hr later. 
Similar to the spatial memory studies discussed above, Arc knockdown-induced 
disruption of long-term fear memories is further evidence for Arc’s specific role in 
long-term consolidation of memories, rather than in short-term plasticity 
processes underlying the initial learning and short-term memory. 
 Arc also appears to be critical for reconsolidation of the memory 
underlying conditioned fear. For example, in another study by Schafe and 
colleagues (Maddox and Schafe, 2011), rats underwent Pavlovian fear 
conditioning, but Arc antisense was not infused into the lateral amygdala until 24 
hr after training. Ninety minutes later, rats were presented with the tone in the 
absence of any acute foot shock in a novel chamber to reactivate the fear 
memory. The rats were then tested for freezing three and 24 hr later to assess 
short-term and long-term memory, respectively. Knockdown of Arc did not impair 
short-term memory, but did impair long-term memory, as evidenced by less 
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freezing on the 24-hr test. Importantly, if the tone was not presented before 
infusion of Arc antisense, and thus the fear memory was not reactivated or made 
labile, knockdown of Arc had no impact on long- or short-term memory formation. 
These findings therefore demonstrate that Arc is necessary for consolidation, as 
well as reconsolidation of an “active”/labile memory. 
 A fear conditioning paradigm that is similar to the Pavlovian conditioning 
discussed above is trace fear conditioning, in which 30 s is allowed to elapse 
between the presentation of the tone and the delivery of the foot shock. Such 
conditioning has been shown to be dependent on the hippocampus (Yoon and 
Otto, 2007). Czerniawski and colleagues (2011) infused Arc antisense into 
hippocampus three hours before training rats on the trace fear conditioning 
paradigm. When rats were tested in a novel environment and the tone was 
presented 48 hr later, the knockdown of Arc was found to have disrupted 
memory consolidation, as Arc antisense-infused rats exhibited less freezing than 
control rats. Knockdown of Arc also impaired memory consolidation in a simpler 
paradigm in which rats were given a foot shock in a chamber, and then tested for 
freezing when returned to that same chamber 48 hr later. These studies again 
demonstrate the essential role of Arc in consolidation of fear conditioning 
memories. 
 Finally, inhibitory avoidance is another common fear-conditioning task, in 
which a shock is paired with one side of a chamber, and rats can avoid this 
shock by spending more time in the other side of the chamber. The role of Arc in 
this task has been tested in two brain regions. In one study, rats were trained on 
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the task, and then Arc antisense was infused into anterior cingulate cortex either 
immediately after or six or 45 hr later (Holloway and McIntyre, 2011). Long-term 
memory for the fear conditioning was assessed by testing for latency to enter the 
shock-paired compartment 48 hr after the initial training. Rats infused with Arc 
antisense either immediately or six hours after training had impaired memory 
consolidation, measured by shorter latencies than controls to enter the shock-
paired chamber, whereas those infused with Arc antisense 45 hr posttraining did 
not differ from controls. Another study showed that infusion of Arc antisense 
three hours before inhibitory avoidance training disrupted memory consolidation, 
again as demonstrated by the Arc antisense-infused rats having shorter latencies 
to enter the shock-paired chamber (McIntyre et al., 2005; Martínez et al., 2012). 
In these studies, however, Arc antisense was infused into hippocampus, 
suggesting that multiple brain regions are involved in this kind of fear 
conditioning, and that Arc is a common link across those brain regions that are 
engaged in the task. Arc has thus been shown to be important for long-term 
memory consolidation of fear memories in three different kinds of fear 
conditioning tasks and across two brain regions. 
Arc in extinction of drug-seeking behavior. Although much research has 
been performed examining Arc’s role in learning and memory in behavioral tasks 
mediated by the hippocampus and amygdala, comparatively little has been done 
in another brain region important for learning, the striatum. In particular, with 
respect to drug addiction, it is apparent that synaptic plasticity underlies the long-
lasting changes in circuitry that mediate drug-seeking and cue-invoked relapse 
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(for review, see Van den Oever et al., 2012); however, despite Arc’s well-known 
role in synaptic plasticity and memory consolidation, just two studies have looked 
at the causal role of Arc in a paradigms relevant to drug abuse and addiction. 
Hearing and colleagues (2011) trained rats to self-administer cocaine, and then 
the rats underwent two weeks of abstinence. Three hours before rats were run in 
a context-induced reinstatement session under extinction conditions (i.e., lever 
present in chamber, but no cocaine infused), Arc antisense was infused into the 
dorsolateral (DL) striatum. While knockdown of Arc did not prevent the context-
induced reinstatement, it did impair extinction learning, as evidenced by more 
lever presses by antisense-infused rats on the second day of reinstatement 
testing. In the second study, Lv and colleagues (2011) examined the role of Arc 
in the nucleus accumbens (NAc) core and shell in morphine-induced conditioned 
place preference (CPP). For each test, an Arc antisense oligonucleotide was 
infused into either NAc core or shell three hours prior to testing. Arc antisense in 
NAc core prevented the development of morphine-induced CPP when Arc 
antisense was infused each day, the expression of morphine-induced CPP when 
Arc antisense was infused only on the day of the preference test, and 
reinstatement of morphine CPP after eight days of extinction. Arc antisense in 
the NAc shell prevented expression of morphine CPP, but had no impact on 
either development of CPP or its reinstatement. It is clear from these two studies 
that Arc is critical in drug cue-related memories in both DL striatum and NAc. 
 The findings of Hearing and colleagues detailed above highlight the need 
to carefully consider task design when assessing the role of Arc in a behavior 
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and in interpreting the results of the Arc disruption in terms of the neural circuitry 
contributing to a particular behavior. In this example, if activation of a memory 
trace in DL striatum were necessary for the context-induced reinstatement of 
cocaine seeking, then presumably that memory trace would become labile when 
the rats were exposed to the context. Based on the evidence from the fear-
conditioning studies reviewed above, knockdown of Arc would thus have 
prevented that memory from being reconsolidated, and rats should not have 
lever-pressed at all the following day when exposed again to the context, as the 
context-induced cocaine-seeking memory encoded in DL striatum would be 
gone. In actuality, however, the Arc antisense-infused rats pressed more than 
controls on the second day. These findings suggest that consolidation of new 
learning occurring on the first reinstatement test day—that is, lever presses now 
no longer deliver cocaine—was contributing to the behavior observed on the 
second day and was disrupted by the loss of Arc during the first day of context-
induced reinstatement. Interestingly, the rats infused with Arc antisense, while 
pressing more than controls on the second day of context-induced reinstatement, 
did not press as much as they did on the first day, as might be expected if only 
consolidation of the new extinction learning were blocked. It is thus possible that 
the intermediate phenotype of the animals infused with Arc antisense reflects 
opponent roles of Arc in the consolidation of the new extinction learning and the 
reconsolidation of the context with the drug-seeking behavior, which was 
activated and made labile during the first day of context-induced reinstatement 
testing. Clearly, when interrogating the role of Arc in learning and memory 
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functions, behavioral paradigms and tasks need to be carefully crafted and 
controlled to isolate the particular process in question. 
The meaning of a correlation between Arc mRNA expression in a brain 
region and behavioral performance. Many studies have used Arc mRNA 
expression as a marker to show activation of neurons or brain regions (e.g., 
Guthrie et al., 2000; Gusev et al., 2005; Zavala et al., 2008; Robinson et al., 
2012; Antoine et al., 2014). However, Guzowski and colleagues (2001) 
previously argued that it is not simply an increase in Arc expression in a brain 
region that indicates a critical involvement of that brain region in the task being 
examined. Rather, the work of Guzowski and colleagues, as well as an 
increasing body of research, suggests that it is the correlation between Arc 
expression and behavioral performance that signifies that task-relevant encoding 
processes in that brain region are critical for the behavior being observed. For 
example, as reviewed above, Arc is critical for long-term spatial memory 
formation in the hippocampus (Guzowski et al., 2000; Martínez et al., 2012). 
Guzowski and colleagues measured Arc mRNA expression in dorsal 
hippocampus of rats sacrificed after training on the spatial version of the Morris 
water maze and found that rats learning more quickly (i.e., those that found the 
platform more quickly) had more Arc mRNA in the hippocampus than rats that 
learned more slowly, resulting in a significant correlation between Arc mRNA 
expression in the hippocampus and learning of the spatial location of the platform 
(2001). Importantly, in rats trained on a cued version of the maze—a task 
dependent on striatal rather than hippocampal function—Arc mRNA expression 
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was still elevated in the hippocampus, but the degree of expression did not 
correlate with learning on the cued task. The critical meaning of the correlation 
between Arc expression and behavioral performance has received additional 
support from studies by Keefe and colleagues, who examined whether a 
correlation exists between Arc mRNA expression in striatum and learning on a 
basal ganglia-mediated learning and memory task; namely, response-reversal 
learning on a T-maze, a task known to be critically dependent on the function of 
the dorsomedial (DM) striatum (Ragozzino et al., 2002). In a study by Daberkow 
et al. (2007), rats that reached criterion on the reversal task in fewer trials had 
more Arc mRNA expression in DM striatum than rats that took more trials to 
reach criterion. Importantly, there were significant increases in Arc mRNA 
expression in the DL striatum and the hippocampus of these rats as well, but 
there were no correlations between expression in those brain areas and trials to 
criterion on the task. These findings therefore paralleled those of Guzowski and 
colleagues (2001) in that there was a significant correlation between Arc mRNA 
expression in the critical brain region (DM striatum) and the measure of learning 
on the task. To further verify that the correlation was indicative of the DM striatum 
being engaged for this response-reversal learning, Arc antisense was infused 
into DM striatum two hours before rats were trained on the reversal task 
(Pastuzyn et al., 2012; Chapter 2). Antisense-infused rats had impaired long-term 
memory consolidation, as shown by their taking more trials to reach criterion than 
control rats when retested on the reversal direction 24 hr later. Thus, these 
findings again suggest that it is the correlation between Arc expression in a brain 
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region and the measure of learning, and not simply the induction of Arc mRNA in 
a brain region, that implicates processes occurring in that brain region as being 
critical to solving the task being completed. Finally, rats that had been pretreated 
with a binge regimen of methamphetamine (METH) were also trained on the 
response-reversal learning task. Although METH-pretreated rats performed as 
well as saline-pretreated controls, reaching criterion on the reversal task in a 
similar number of trials, METH-pretreated rats lacked the correlation between Arc 
mRNA expression in DM striatum and trials to criterion (Daberkow et al., 2008; 
Pastuzyn and Keefe in press; Chapter 3). Rather, in the METH-pretreated rats, a 
significant correlation between Arc mRNA expression in NAc shell and trials to 
criterion on the task was found which did not exist in controls (Pastuzyn and 
Keefe in press; Chapter 3). Further, knockdown of Arc expression via infusion of 
an Arc antisense oligonucleotide into NAc shell of the METH-, but not the saline-, 
pretreated rats two hours prior to the reversal learning impaired retention of the 
learned reversal when examined the following day. Taken together, this growing 
body of evidence strongly suggests that rather than simply Arc induction, it is the 
correlation between Arc mRNA expression and the measure of learning on the 
task that is indicative of encoding processes occurring in that brain region being 
critical for solving the task. 
Arc conclusions. The studies reviewed herein have revealed that Arc 
expression is more than just a marker for neuronal activity. Instead, it is critical 
for memory consolidation and reconsolidation in behavioral tasks across multiple 
brain regions. Although Arc expression is increased in multiple brain regions 
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when animals are engaged in a learning and memory task, the brain region in 
which Arc-regulated plasticity processes are critical for solving the task depends 
on the behavioral task. This critical involvement of Arc-mediated processes in a 
brain region in the learning and memory that is occurring appears to be reflected 
in the correlation between the degree of Arc mRNA expression and the measure 
of learning/memory being examined. It seems plausible to suggest that this 
correlation could be used in future studies to map, with greater precision than 
simply examining Arc induction, the brain circuitry in which plastic changes 




The dopaminergic neurons projecting from the ventral tegmental area and 
the substantia nigra fire in either a phasic or tonic mode (Grace, 2000; Goto and 
Grace, 2005; Grace et al., 2007; Schultz, 2007). Phasic DA neurotransmission is 
a bursting pattern of firing of DA neurons and appears to be responsible for 
mediating reactions to rewards and/or cues. The other mode of DA neuron firing, 
tonic, is a steady-state firing responsible for the basal levels of DA in the brain 
(Schultz, 2007). Phasic DA neurotransmission is essential for learning (Zweifel et 
al., 2009), encoding reward prediction errors (Schultz, 1998, 2007, 2013), and 
assigning incentive salience to cues (Berridge, 2007). The manner in which DA is 
released onto the postsynaptic neurons in the striatum modulates the output of 
basal ganglia components. This review will focus on phasic DA signaling, how it 
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goes awry as a result of METH-induced neurotoxicity, and what impact this 
disruption in DA signaling may have on striatal function. 
The role of phasic dopamine. There are several hypotheses as to the role 
phasic DA might be playing in the brain, which are also reviewed elsewhere 
(Berridge, 2007; Schultz, 2007; Berridge et al., 2009; Schultz, 2013). One idea is 
that phasic DA acts as a reward prediction error signal (Schultz, 1998, 2007, 
2013). In this case, phasic DA release to an unexpected or better-than-expected 
natural reward creates a positive prediction error and helps strengthen the 
association between cue and reward. If the reward is completely expected, there 
is no phasic DA signal, because the animal is not learning anything new. If the 
reward is expected but does not appear, there is a dip in DA release, creating a 
negative prediction error theorized to aid in extinction of responding. Studies 
training rats to work for natural food rewards have demonstrated that phasic DA 
release initially occurs when the reward is given. This response to the reward 
diminishes over time and shifts to one occurring in response to the cue as the 
animal learns that the cue predicts the reward (Day et al., 2007; Brown et al., 
2011). Further, a recent paper using optogenetics to artificially cause phasic DA 
release when there normally would be none resulted in rats forming a cue-reward 
association that did not occur in controls, providing, for the first time, evidence of 
phasic DA acting causally as a reward prediction error (Steinberg et al., 2013). 
 Phasic DA release has also been shown to be involved in behaviors 
related to drug abuse and addiction. Fast-scan cyclic voltammetry revealed 
phasic DA release in the nucleus accumbens when rats initiated cocaine-
 19 
seeking, as well as in response to a cue, once the rats had learned that the cue 
predicted cocaine availability (Phillips et al., 2003). Once the rat self-
administered cocaine for a period of time, this phasic DA signal to the cue shifts 
from occurring in nucleus accumbens to dorsolateral striatum (Willuhn et al., 
2012), possibly via a dopaminergic “spiral” pathway between nucleus 
accumbens, substantia nigra, and dorsolateral striatum (Haber et al., 2000; 
Ikemoto, 2007). Thus, as with natural rewards, phasic DA release to drugs of 
abuse at first signals the unexpected reward (the drug), and then over time fires 
to the cue, and not to the primary reinforcer fully predicted by the cue. 
 Phasic DA release to the cue relates to another hypothesis regarding the 
role of phasic DA: that of incentive salience, in which the reward-paired cue 
acquires motivational properties (Berridge, 2007). DA, specifically in the nucleus 
accumbens core (Saunders and Robinson, 2012), has been shown to be 
necessary for rats to assign incentive salience to a reward-paired cue (Flagel et 
al., 2011). Additionally, genetically disrupting phasic DA signaling by deleting 
NMDA receptors on DA neurons, while leaving tonic DA signaling intact, led to 
mice being significantly impaired in learning cued behaviors (Zweifel et al., 2009). 
This evidence suggests that the role of phasic DA is complex and appears to be 
necessary for learning about both rewards and cues. 
Medium spiny neuron gene expression and the effects of METH-induced 
neurotoxicity. Two populations of GABAergic medium spiny neurons make up 
~95 percent of the neurons in the striatum: striatonigral neurons, known as the 
“direct pathway,” which express D1 DA receptors and the neuropeptides 
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substance P (from preprotachykinin, or ppt) and dynorphin (from 
preprodynorphin) (Gerfen et al., 1990; Surmeier et al., 1996; Gerfen and 
Surmeier, 2011); and striatopallidal neurons, known as the “indirect pathway,” 
which express D2 DA receptors and the neuropeptide enkephalin (from 
preproenkephalin, or ppe) (Gerfen et al., 1990; Le Moine et al., 1990; Surmeier et 
al., 1996; Gerfen and Surmeier, 2011). The basal ganglia are hypothesized to act 
in action selection: the direct pathway, depending on DA levels and signaling 
type, allows an animal to initiate an action, while the indirect pathway inhibits 
actions (for review, see Da Cunha et al., 2012). Action selection in each pathway 
is proposed to occur through the signaling pathways that extend from activation 
of the D1 DA receptor on direct pathway neurons and the D2 DA receptor on 
indirect pathway neurons (for review, see Surmeier et al., 2007). Thus, the two 
main output pathways of the striatum are quite segregated and specialized. 
 As discussed above, METH-induced neurotoxicity results in long-lasting 
damage to DA systems in the brain, manifesting in part as a partial loss of DA 
availability in striatum. Associated with partial DA loss, whether induced by 
METH (Chapman et al., 2001; Johnson-Davis et al., 2002; Howard et al., 2013a; 
Chapter 4) or by 6-hydroxydopamine (6-OHDA; Nisenbaum et al., 1996), is a 
decrease in ppt mRNA expression in direct pathway/striatonigral neurons. 
Conversely, partial DA loss has no effect on ppe mRNA expression (Nisenbaum 
et al., 1996; Chapman et al., 2001; Johnson-Davis et al., 2002; Howard et al., 
2013a; Chapter 4). Rather, ppe mRNA expression only changes—increases—
after extensive (80-90%) DA neuron loss (Gerfen et al., 1991; Nisenbaum et al., 
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1996), similar to the extent of loss seen in late-stage Parkinson’s disease. This 
selective effect of METH-induced neurotoxicity on ppt expression was the first 
suggestion that the DA loss associated with METH-induced neurotoxicity might 
be primarily affecting direct pathway/striatonigral neurons. METH-induced 
neurotoxicity also affects expression of the immediate-early activity-regulated 
cytoskeleton-associated (Arc) gene. In normal animals, basal levels of Arc in 
striatum are quite low (Daberkow et al., 2007, 2008; Barker-Haliski et al., 2012), 
since Arc mRNA transcription is induced by activity (Link et al., 1995; Lyford et 
al., 1995; Steward et al., 1998). However, basal Arc in METH-pretreated rats is 
not only higher than in normal rats, but striatal Arc mRNA levels also fail to 
increase in response to exposure to a novel environment as they do in normal 
rats (Barker-Haliski et al., 2012). While basal Arc transcription is aberrantly 
regulated in both striatonigral and striatopallidal neurons, the numbers of 
striatonigral neurons with Arc mRNA in the cytoplasm correlates with the degree 
of METH-induced DA loss, suggesting that METH-induced neurotoxicity 
significantly disrupts signaling in striatal efferent neurons, particularly striatonigral 
neurons (Keefe and Horner, 2010; Barker-Haliski et al., 2012). 
Impact of METH-induced neurotoxicity on dopamine signaling. 
Surprisingly, DA released in a phasic pattern appears to signal selectively 
through DA D1 receptors on striatonigral/direct pathway neurons. For example, 
stimulation of the medial forebrain bundle (MFB) (through which DA neuron 
axons project to striatum) in a phasic-like manner results in immediate-early gene 
(IEG) expression in D1 DA receptor-containing striatonigral neurons (Chergui et 
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al., 1997; Gonon, 1997; Onn et al., 2000; Howard et al., 2013a; Chapter 4). 
Studies have also proposed that DA released in a tonic, steady-state firing 
pattern preferentially affects D2 receptors on striatopallidal/indirect pathway 
neurons. Computer modeling using values available in the literature suggests 
that high-affinity D2 receptors are saturated at basal levels of extracellular DA 
established by DA neurons firing in a tonic manner (Dreyer et al., 2010). When 
the DA neurons fire phasically, the sudden large increase in DA concentration 
results in significant increases in DA binding to lower-affinity D1 receptors. Thus, 
the manner in which DA is released from the presynaptic neuron in striatum 
controls which receptors are preferentially bound by the DA being released and, 
therefore, which striatal efferent neurons are preferentially affected. 
Because the data reviewed in this section suggest that METH-pretreated 
rats may have more deficits in functioning of the striatonigral/D1-containing 
pathway, we hypothesized that the METH-induced partial DA loss might 
negatively impact phasic DA neurotransmission more than tonic DA 
transmission. Furthermore, prior work had suggested that partial DA loss is 
associated with selective impairment of phasic DA signaling (Bergstrom and 
Garris, 2003). Likewise, microdialysis studies have shown that METH-induced 
neurotoxicity is not associated with altered tonic/basal DA levels in striatum 
(Robinson et al., 1990; Cass and Manning, 1999), but is associated with a deficit 
in phasic DA transmission as assessed using fast-scan cyclic voltammetry 
(Howard et al., 2011; Loewinger et al., 2012; Howard et al., 2013b; Chapter 5). 
Specifically, recent work from Garris and colleagues has shown that less DA is 
 23 
released in the striatum of METH-pretreated rats, relative to saline-pretreated 
controls, when the MFB is stimulated in a phasic-like manner (Howard et al., 
2011). Conversely, the amount of DA released in response to tonic-like 
stimulation of the MFB is the same in METH-pretreated rats relative to controls. 
These findings were then replicated in awake, freely-moving rats exploring a 
novel environment in which spontaneously occurring phasic DA transients were 
recorded in striatum (Howard et al., 2013b). That is, METH-pretreated rats had 
smaller amplitude phasic transients than normal rats and the transients were also 
less frequent. Duration of the transients also increased due to the METH-induced 
loss of DA transporter-containing terminals which normally clear DA from the 
extracellular space (Howard et al., 2013b). These experiments suggest that the 
METH-induced partial loss of DA terminals in striatum does not alter tonic DA 
signaling, but does impair phasic DA signaling. 
Phasic dopamine and medium spiny neuron gene expression. Since 
phasic DA signaling appears to selectively act at D1 DA receptors, it follows that 
phasic DA signaling could have effects on striatonigral neurons that are not 
mirrored in striatopallidal neurons. As noted, Chergui and colleagues (1997) 
demonstrated that phasic-like stimulation of the MFB increased expression of the 
IEG zif268 preferentially in D1-containing medium spiny neurons, whereas tonic-
like stimulation of the MFB did not alter striatal zif268 expression. Recently, we 
put forth the hypothesis that METH-induced deficits in gene expression and, 
possibly, behavioral outcomes are due to impairments of phasic DA 
neurotransmission in these rats (Keefe and Horner, 2010; Barker-Haliski et al., 
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2012). Therefore, to further test this hypothesis, Howard et al. (2013a; Chapter 4) 
determined whether phasic-like stimulation of the MFB could restore the impaired 
striatal gene expression observed in METH-pretreated rats (as discussed). In 
these studies, the MFB of anesthetized rats was stimulated in a phasic- or tonic-
like manner for 45 min, at which point the rats were sacrificed. In situ 
hybridization histochemical analysis of the IEGs Arc and zif268, as well as the 
neuropeptide precursors ppt and ppe, was then completed. As hypothesized, 
phasic-like stimulation of the MFB restored ppt mRNA expression in METH-
pretreated rats back to normal levels, whereas tonic-like stimulation did not 
change ppt mRNA expression. Further confirming the prior findings of Chergui 
and colleagues (1997), phasic-like stimulation increased zif268 and Arc mRNA 
expression, whereas tonic-like stimulation did not. Interestingly, in the case of the 
IEGs, the mRNAs were induced to the same level in both normal and METH-
pretreated rats, despite the fact that METH-pretreated rats are lacking 25-50% of 
their striatal DA terminals, and thus might be expected to be unable to induce 
mRNA transcription in as many medium spiny neurons as normal rats. Finally, 
ppe mRNA expression was unchanged by either phasic- or tonic-like stimulation. 
These findings suggest that restoration of phasic DA neurotransmission in the 
striatum of METH-pretreated rats can rescue impaired striatal gene expression 
and, by extension, possibly normalize striatal function in these rats. 
Pharmacological rescue of METH-induced deficits. The evidence 
presented above suggests that impairment of phasic DA neurotransmission in 
METH-pretreated rats may contribute to at least some of the cellular deficits seen 
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with METH-induced neurotoxicity. Because human METH abusers and animal 
models of METH exposure also show cognitive deficits (see Section 1.1), it 
stands to reason that such cognitive/behavioral deficits could also be a result of 
decreased phasic DA neurotransmission, given that phasic DA transmission has 
been shown to be critical for certain behaviors (see Section 3.1). Thus, if phasic 
DA transmission can be restored in a therapeutic fashion, it may be possible to 
improve cognitive function in individuals with a history of METH abuse and, 
therefore, improve rehabilitation outcomes. 
 L-3,4-dihydroxyphenylalanine (L-DOPA), the most common drug used to 
manage symptoms of Parkinson’s disease, is the biochemical precursor of DA. 
Because the L-aromatic amino acid decarboxylase responsible for converting L-
DOPA to DA is not saturated, administration of L-DOPA results in increased DA 
production in the brain. L-DOPA has been shown to increase vesicular DA 
content and quantal size of DA release in vitro (Pothos et al., 1996; Pothos et al., 
1998). Furthermore, L-DOPA increases DA release in vivo as measured by fast-
scan cyclic voltammetry (Keller Jr. et al., 1988; Wightman et al., 1988; Garris et 
al., 1994) or amperometry (Rodríguez et al., 2007). These studies used rather 
large doses of L-DOPA (100-250 mg/kg) and produced significant increases in 
gross extracellular DA levels. However, there is some intriguing evidence in the 
literature to suggest that L-DOPA might preferentially affect only phasic DA 
neurotransmission if the correct dose is used. For example, in intact humans or 
primates, L-DOPA does not alter DA receptor binding under resting conditions as 
measured by PET scanning (Antonini et al., 1994; Tedroff et al., 1996b; Tedroff 
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et al., 1996a; Flöel et al., 2008). However, if the subject is completing a task, 
administration of L-DOPA increases DA signaling (Flöel et al., 2008). 
Furthermore, L-DOPA was recently shown to restore reward prediction error in 
elderly subjects (Chowdhury et al., 2013)—as reviewed here, phasic DA 
transmission is thought to signal reward prediction error. Thus, we have 
examined whether striatal functioning in METH-pretreated rats can be restored 
by specifically rescuing phasic DA transmission via administration of L-DOPA. 
 In this dissertation (Chapter 5), rats were anesthetized, and the MFB was 
stimulated in a phasic-like pattern once every five minutes. After establishing 
baseline levels of phasic-like DA release, rats were given 50 mg/kg L-DOPA. 
Consistent with our prior observations (Howard et al., 2011), phasic-like DA 
transmission was decreased in METH-pretreated rats relative to saline-
pretreated controls under baseline conditions. However, within 20 min of 
administration of L-DOPA, phasic-like DA release in the METH-pretreated rats 
was restored to levels seen under baseline conditions in saline-pretreated 
controls (Chapter 5). Furthermore, by parsing out the components of the 
voltammogram using principal component regression (Keithley et al., 2009; 
Keithley and Wightman, 2011), we determined that 50 mg/kg L-DOPA selectively 
increased phasic DA neurotransmission in both METH- and saline-pretreated 
rats without altering basal DA transmission. These findings suggest that just one 
dose of L-DOPA is sufficient to acutely rescue evoked phasic-like DA release in 
METH-pretreated rats. 
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Phasic DA conclusions. The evidence presented in this chapter suggests 
that METH-pretreated rats have a specific impairment in phasic DA release, 
which contributes, at least in part, to the deficits in gene expression seen in 
METH-pretreated rats, and by extension, perhaps to the cognitive deficits 
observed as well. Since administration of L-DOPA restored phasic-like DA 
neurotransmission in METH-pretreated rats, this treatment may be useful in 
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ALTERED LEARNING AND ARC-REGULATED CONSOLIDATION OF 
 







Methamphetamine (METH) causes partial depletion of central monoamine 
systems and cognitive dysfunction in rats and humans. We have previously 
shown that the positive correlation between expression of the immediate-early 
gene Arc (activity-regulated, cytoskeleton-associated) in dorsomedial (DM) 
striatum and learning on a response reversal task is lost in rats with METH-
induced striatal DA loss, despite normal behavioral performance and unaltered 
N-methyl-D-aspartate (NMDA) receptor-mediated EPSCs, suggesting intact 
excitatory transmission. This discrepancy suggests that METH-pretreated rats 
may no longer be using the dorsal striatum to solve the reversal task. To test this 
hypothesis, male Sprague-Dawley rats were pretreated with a neurotoxic 
regimen of METH or saline. Guide cannulae were surgically implanted bilaterally 
into DM striatum. Three weeks after METH, rats were trained on a motor 
response version of a T-maze task, and then underwent reversal training. Before   
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reversal training, the NMDA receptor antagonist DL-2-amino-5-
phosphonopentanoic acid (AP5) or an Arc antisense oligonucleotide was infused 
into DM striatum. Acute disruption of DM striatal function by infusion of AP5 
impaired reversal learning in saline-, but not METH-, pretreated rats. Likewise, 
acute disruption of Arc, which is implicated in consolidation of long-term memory, 
disrupted retention of reversal learning 24 hr later in saline-, but not METH-, 
pretreated rats. These results highlight the critical importance of Arc in striatum in 
consolidation of basal ganglia-mediated learning and suggest that long-term 
toxicity induced by METH alters the cognitive strategies/neural circuits used to 




Methamphetamine (METH) abuse is a significant problem worldwide. 
METH causes partial loss of dopamine (DA) and serotonin systems in the brain 
(Seiden et al., 1976; Morgan and Gibb, 1980; Ricaurte et al., 1980; Wagner et 
al., 1980). In humans, METH-induced neurotoxicity is evident as decreases in DA 
transporter (DAT) binding in caudate-putamen that can last for up to 11 months 
(Wilson et al., 1996; McCann et al., 1998; Volkow et al., 2001b; Volkow et al., 
2001a). METH-induced toxicity is also evident as decreases in serotonin 
transporter (SERT) binding across multiple brain regions, including caudate-
putamen and frontal cortex (Sekine et al., 2006; Kish et al., 2009), as well as loss 
of glutamatergic neurons in somatosensory cortex (Pu et al., 1996; Eisch et al., 
1998). Cognitive impairments have also been seen in association with METH-
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induced neurotoxicity, and include deficits in motor sequence learning (Chapman 
et al., 2001), object recognition (Schröder et al., 2003; Belcher et al., 2005; 
Herring et al., 2008), visual discrimination and attentional set-shifting (Izquierdo 
et al., 2010), and novel odor recognition (O'Dell et al., 2011). 
In some tasks, however, behavioral impairments associated with METH-
induced neurotoxicity are not apparent. Such tasks include those examining 
conditioned placed aversion (Achat-Mendes et al., 2005), spatial learning on the 
Morris water maze (Schröder et al., 2003; Herring et al., 2008), and motor 
response reversal learning on a T-maze (Daberkow et al., 2008). With regards to 
the response reversal learning task on the T-maze, expression of Arc (activity-
regulated cytoskeleton-associated gene), an immediate-early gene important in 
consolidation of learning, in dorsomedial (DM) striatum is correlated with number 
of trials to criterion on the reversal learning task in saline-pretreated rats, but not, 
interestingly, in METH-pretreated rats (Daberkow et al., 2007, 2008). Thus, 
although METH-pretreated rats behaviorally appear to be normal on this task, the 
relation between Arc expression in striatum and behavior is lost. Guzowski and 
colleagues (2000; 2001) previously suggested that the correlation between Arc 
expression and learning reflects the involvement of a brain region in a task. 
Whether Arc in DM striatum is necessary for consolidation of response reversal 
learning has not heretofore been examined; furthermore, whether the loss of 
correlation in METH-pretreated rats indicates a change in the brain regions 
engaged during the task is unknown. 
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Therefore, the goal of the present studies was to test whether Arc in DM 
striatum is critical for consolidation of response reversal learning and whether the 
loss of the correlation in METH-pretreated rats reflects a loss of dependence of 
the reversal learning on DM striatal function. We locally infused an Arc antisense 
oligonucleotide (Guzowski et al., 2000; Hearing et al., 2011) or the NMDA 
receptor antagonist AP5 into DM striatum prior to rats engaging in motor 
response reversal learning on the T-maze task. The results indicate that Arc 
signaling in DM striatum is necessary for consolidation of the reversal learning 
and that METH-induced neurotoxicity is associated with a change in the neural 
substrates mediating such reversal learning. 
 
 
Materials and Methods 
Animals. Male Sprague-Dawley rats (Charles River Laboratories, Raleigh, 
NC; 275-300g) were singly housed in tub cages on a 14:10-hr light cycle. Animal 
care and experimental procedures followed the Guide for the Care and Use of 
Laboratory Animals and were approved by the Institutional Animal Care and Use 
Committee at the University of Utah. 
Methamphetamine pretreatment. Rats were treated with a neurotoxic 
regimen of (±)-METH-HCl (4x10mg/kg free base, s.c.; NIDA, Research Triangle 
Park, NC) over 6-one day as previously described Daberkow et al., 2008. One 
hour after the final injection, rats were returned to their home cages and given 
free access to food and water until behavioral training began (METH-pretreated, 
n=25; saline-pretreated, n=29). 
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Surgery. Two weeks after pretreatment, rats were anesthetized with 
ketamine/xylazine (90/10mg/kg, i.p.) and placed in a stereotaxic apparatus. A 
dual, 21-gauge guide cannula (Plastics One, Roanoke, VA) was lowered to end 
just dorsal to DM striatum (mm from Bregma: AP+0.2; ML±1.9; DV-3.2). The 
guide was secured with skull screws and dental acrylic, and dummy cannulae 
inserted. Subsequent infusions were made through 33-gauge infusion cannulae 
extending 1.8mm beyond the guides. Infusion cannulae remained in place for 
one min after the infusion before being withdrawn. 
Reversal learning task. Response reversal learning on the T-maze was 
conducted as previously described (Daberkow et al., 2007). Beginning one week 
after surgery, rats were food restricted and habituated to the food reward and 
maze. The turn bias of each rat was determined, followed by acquisition training 
for three days and then reversal learning. During the reversal-learning task, rats 
had to turn in the opposite direction from acquisition to receive the reward. The 
criterion for learning on both acquisition and reversal tasks was 9/10 correct turns 
in a row. 
Acute pharmacological manipulations. On the day of reversal training, rats 
were infused through their cannulae with either AP5 (0.5 µL/2 min, 25 nmol in 
0.1M PBS, pH 7.4; Tocris Bioscience, Ellisville, MO) Palencia and Ragozzino, 
2004 or an Arc antisense oligonucleotide. The Arc antisense oligonucleotide was 
a chimeric phosphorothioate/phosphodiester oligonucleotide against bases 209-
228 of the Arc gene (Guzowski et al., 2000). The nonsense/control 
oligonucleotide was comprised of the same bases, but in a scrambled sequence. 
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One µL of oligonucleotide (1 nmol/µL, 0.1M PBS, pH 7.4) (Guzowski et al., 2000) 
or PBS vehicle was infused (0.39 µL/min) into each DM striatum. After infusions 
into DM striata, rats were returned to their home cages for five minutes (AP5) or 
two hours (Arc antisense) prior to reversal training. Five minutes after criterion 
was reached, rats infused with AP5 and corresponding PBS-infused controls 
were sacrificed, and the brains removed and frozen in isopentane chilled on dry 
ice. Rats infused with the Arc antisense oligonucleotide and corresponding 
controls (PBS or Arc nonsense oligonucleotide) were returned to their home 
cages upon reaching criterion. The following day, these rats were tested on 
reversal retention to determine the number of trials needed to again reach 
criterion on the reversal direction learned the previous day. Five minutes after 
reaching criterion, rats were sacrificed and brains removed and frozen. 
DAT and SERT autoradiography. Fresh-frozen brains were sectioned (12-
µm), thaw-mounted onto Superfrost Plus (VWR, Aurora, CO) slides, and then 
stored at -20°C. Infusion sites were verified during sectioning (Figure 2.1). DAT 
levels in striatum were determined with [125I]RTI-55 (PerkinElmer, Waltham, MA) 
binding, as previously reported (Boja et al., 1992; O'Dell et al., 2011). SERT 
binding in prefrontal cortex was similarly performed except that fluoxetine was 
omitted.  Prefrontal cortex slides incubated in buffer containing fluoxetine showed 
no binding (data not shown). Slides were apposed to film (Biomax MR; Eastman 
Kodak Co., Rochester, NY) for 24 hr and developed. Images were digitized and 
densitometric analysis accomplished using NIH ImageJ, yielding average, 
background-subtracted gray values in DM and dorsolateral (DL) striatum and six 
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prefrontal cortical regions. Two rostral and two middle striatal sections and four 
prefrontal cortical sections were analyzed per rat. DAT and SERT binding in 
METH-pretreated rats were then converted to percent of average levels in saline-
pretreated rats. 
Error analysis. The number of perseverative and regressive errors made 
during reversal learning by METH- and saline-pretreated rats was calculated as 
defined by Palencia and Ragozzino (2004), with modification due to the task 
differences. Wrong turns were counted as perseverative errors if they occurred 
before a rat made more than three turns in the reversal direction. Incorrect turns 
occurring after the rat had made more than three turns in the new correct 
direction were counted as regressive errors. 
In situ hybridization histochemistry. The left hemisphere from animals 
used for electrophysiological experiments (see below) was frozen, sectioned (12-
µm) and processed for in situ hybridization histochemical determination of Grin2a 
NMDA receptor subunit expression as previously described (Ganguly and Keefe, 
2001) using a full-length ribonucleotide probe synthesized from the cDNA (kind 
gift from Dr. Peter Seeburg) using 35S-UTP and T7 RNA polymerase (Roche, 
Indianapolis, IN). Slides were hybridized overnight in humid chambers at 55°C, 
washed, treated with Ribonuclease A (5 µg/mL), washed, dried, and then 
apposed to X-ray film for one week. Images from films were digitized and 
densitometric analysis accomplished using ImageJ, yielding average, 
background-subtracted gray values in DM, DL, and ventromedial striatum. 
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Determination of striatal DA content. DA content was determined in striatal 
tissue punches collected during sectioning of frozen brain hemispheres for in situ 
hybridization (Chapman et al., 2001).  A blunt-tip, 18-gauge needle was used to 
collect 1-mm3 punches from both medial and lateral striatum (+0.3 mm anterior to 
Bregma). Punches were sonicated in tissue buffer (0.05 M sodium 
phosphate/0.03 M citric acid buffer, 25% methanol (v/v), pH 2.5) and centrifuged. 
Twenty µL of supernatant were injected onto a high-pressure liquid 
chromatography system coupled to an electrochemical detector (EOx = +0.6 V) 
for separation and quantification of DA levels. Values were expressed per mg of 
protein. Protein content was determined with the Lowry protein assay. 
Striatal slice preparation. Acute brain slices were obtained, as previously 
described (Chapman et al., 2003), from adult rats (375-460 g) sacrificed three-
five weeks after pretreatment with saline or METH. Rats were anesthetized 
(pentobarbital, 50 mg/kg) and decapitated. Brains were removed and placed into 
ice cold, oxygenated (95% O2-5% CO2) sucrose Ringer solution, pH 7.4, 
containing (in mM): sucrose (200), KCl (3), NaH2PO4 (1.4), MgSO4 (2), NaHCO3 
(26), glucose (10), and CaCl2 (2). The brain was divided along the midline, and 
the right hemisphere was glued caudal-side down to a Vibraslicer chuck 
(Campden Instruments). Coronal sections (300-350µm) containing striatum were 
placed in a holding chamber at room temperature containing oxygenated Ringer 
solution with 126 mM NaCl in place of sucrose, pH 7.37-7.41. Sections remained 
in the Ringer solution (osmolality 295-305mOsm) for ≥1 hr before recording. 
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Patch clamp recordings. Slices were transferred into the recording 
chamber perfused with fresh, oxygenated, Mg2+-free Ringer solution at room 
temperature (~22°C) via a gravity-feed system (4 mL/min). Whole-cell patch-
clamp was used to record from single striatal neurons, using previously 
described inclusion criteria and data acquisition (Chapman et al., 2003). 
Borosilicate glass microelectrodes (3-6 MΩ resistance) were pulled using a P-87 
micropipette puller (Sutter Instruments). The internal recording solution contained 
(in mM): K gluconate (130), KCl (10), HEPES (10), EGTA (1), CaCl2 (0.1), ATP 
(2), GTP (1) and glutathione (1). The external solution was the same as that in 
the holding chamber. 
 Excitatory postsynaptic currents (EPSCs) were elicited using local, 
minimal stimulation to mitigate voltage- and space-clamp errors (Stevens and 
Wang, 1994; Wilcox et al., 1996). A bipolar stimulating electrode was placed near 
the recording electrode (<300 µm). The stimulating electrode was used to deliver 
current pulses (100-µsec duration) of sufficient amplitude to produce the smallest 
EPSC (25-40 pA) that could be reliably evoked at low frequency (0.1 Hz). To 
isolate and maximally activate NMDA receptor-mediated EPSCs, the Ringer 
solution contained 10 µM 6-cyano-7-nitroquinoxaline-2,3-dione, 50 µM picrotoxin, 
and 10 µM glycine. Data were acquired with an Axopatch ID amplifier and the 
CLAMPEX8 software package interfaced to a Digidata 1200 acquisition board 
(Axon Instruments). Signals were filtered at 5 KHz and sampled at 10 KHz. 
 Only recordings not exhibiting substantial changes in holding current or 
resistance at the electrode tip were used for analysis. All cells required <100pA 
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to be clamped to -70mV. Cells with resting membrane potentials above -55mV 
were omitted from analysis. The following parameters were determined for 
averaged NMDA receptor-mediated EPSCs: rise times, peak amplitudes, decay 
time constants, and weighted τ (τw). The decay time constants were fit with a 
double exponential equation: I(t)=Ifexp(-t/τf)+Isexp(-t/τs), where If is the amplitude 
of the fast component, Is is the amplitude of the slow component, and τf and τs 
are the fast and slow time constants, respectively. Weighted time constants were 
calculated using the equation: τw=[If/(If+Is)]τf+[Is/(If+Is)]τs (Stocca and Vicini, 1998). 
All data are presented as mean±SEM. 
Statistical analysis. Dependent measures from animals used in the 
behavioral studies were compared across pretreatment and treatment groups 
using two-way ANOVAs and post hoc t-tests (JMP v.9.0). Dependent measures 
from animals used for electrophysiological studies were analyzed using unpaired 




DAT and SERT autoradiography. Pretreatment of rats used for the 
behavioral studies with a “binge” regimen of METH resulted in significant 
decreases in striatal DAT binding. METH-pretreated rats in the AP5 experiment 
had significantly less DAT binding than saline-pretreated rats in striatum (Fig. 
2.2a; DM striatum, mean±SEM, 54.6±6.4% of saline, F(1,22)=12.8, p<0.01; DL 
striatum 61.1±6.1%, F(1,22)=12.2, p<0.01). A similar decrease in DAT binding was 
seen in METH-pretreated rats in the Arc antisense experiment (graph not shown; 
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DM striatum, 58.4±6.9% of saline, F(1,29)=18.4, p<0.001; DL striatum 66.4±6.6%, 
F(1,29)=14.2, p<0.001). METH-pretreated rats also had significantly decreased 
SERT binding relative to saline-pretreated controls in all prefrontal regions 
examined (Fig. 2.2b): prelimbic, (57.8±9.5% of saline, F(1,17)=14.3, p<0.01), 
infralimbic (73.6±7.3%, F(1,17)=14.5, p<0.01), medial orbitofrontal (58.9±9.9%, 
F(1,17)=13.8, p<0.01), ventral orbitofrontal (47.3±9.2%, F(1,17)=25.6, p<0.0001), 
lateral orbitofrontal (49.4±9.4%, F(1,17)=20.0, p<0.001), and cingulate 
(44.7±10.9%, F(1,17)=19.7, p<0.001) cortices. 
Effects of acute NMDA receptor blockade in DM striatum. As previously 
reported by our lab (Daberkow et al., 2008), METH-pretreated rats appear to be 
behaviorally normal in terms of motor response reversal learning on the T-maze 
relative to saline-pretreated rats (Fig. 2.3). However, acute disruption of striatal 
function via bilateral infusion of AP5 into DM striatum revealed differences in DM 
striatal involvement in this learning. Analysis revealed a significant overall 
interaction (pretreatment×infusion; F(1,1)=4.6, p<0.05), as well as significant main 
effects of pretreatment (F(1,1)=5.2, p<0.05) and infusion (F(1,1)=7.6, p<0.05). 
Saline-pretreated rats that were infused with AP5 (n=5) required significantly 
more trials to reach criterion than did saline-pretreated, PBS-infused rats (Fig. 
2.3; n=8; t(23)=-3.4, p<0.01). METH-pretreated rats (n=5), on the other hand, were 
unaffected by infusion of AP5, and thus were significantly different from saline-
pretreated, AP5-infused rats (t(23)=2.8, p<0.05), but not METH-pretreated, PBS-
infused (n=9; t(23)=-0.4, p=0.7) or saline-pretreated, PBS-infused (t(23)=-0.3, 
p=0.7) rats. 
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Effects of acute Arc disruption in DM striatum. Consistent with prior 
reports making use of Arc antisense in different brain regions and in different 
learning and memory paradigms (Guzowski et al., 2000; Hearing et al., 2011), we 
observed no effects of Arc antisense infusion into DM striatum on initial reversal 
learning in either saline- or METH-pretreated rats (Fig. 2.4a). Two-way ANOVA 
on trials to criterion on the reversal learning task revealed no main effects of 
pretreatment (F(1,30)=0.01, p=0.9) or infusion (F(1,30)=0.69, p=0.5) and no 
interaction (F(1,2)=0.09, p=0.9). However, again consistent with prior reports 
(Guzowski et al., 2000; Hearing et al., 2011), analysis of retention of the reversal 
learning 24 hr after the initial reversal learning task revealed a significant overall 
interaction (F(1,2)=4.07, p<0.05), but no main effects of pretreatment (F(1,30)=0.9, 
p=0.3) or infusion (F(1,30)=1.22, p=0.3). Saline-pretreated rats infused with Arc 
antisense (n=13) took significantly more trials to reach criterion on the retention 
test (Fig. 2.4b) than controls (saline-pretreated, Arc nonsense-infused: n=4, t(30)=-
1.8, p<0.05; saline-pretreated, PBS-infused: n=4, t(30)=-2.8, p<0.01) and METH-
pretreated, Arc antisense-infused rats (n=8, t(30)=3.7, p<0.001). METH-
pretreated, Arc antisense-infused rats, however, were not significantly different 
from control groups (METH-pretreated, Arc nonsense-infused: n=4, t(30)=1.6, 
p=0.1; METH-pretreated, PBS-infused: n=3, t(30)=0.4, p=0.7). These results 
indicate that Arc in DM striatum is necessary for consolidation of response 
reversal learning under normal conditions, but not in rats with METH-induced 
neurotoxicity. 
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Error analysis. As demonstrated previously (Daberkow et al., 2008) and 
again in this study (Fig. 2.3), METH-pretreated rats perform as well as normal 
rats on response reversal learning on the T-maze. We also analyzed the types of 
errors (Palencia and Ragozzino, 2004) made by METH- or saline-pretreated, 
PBS-infused rats to determine whether the METH-induced monoamine 
depletions altered behavioral flexibility. Consistent with the lack of effect on trials 
to criterion, we found no differences between METH- and saline-pretreated rats 
in numbers of perseverative (saline-pretreated, 25.5±7.4; METH-pretreated, 
28.7±6.5; t(15)=-0.3, p=0.8) or regressive (saline-pretreated, 35.9±8.8; METH-
pretreated, 45.7±11.0; t(15)=-0.7, p=0.5) errors. 
In situ hybridization histochemistry for striatal Grin2a subunit. The 
pharmacological properties of NMDA receptors are determined to a large extent 
by the subunit composition of the receptors, with the NR2 subunits being of 
critical importance in this regard. In particular, prior work has shown that NR2a 
subunit incorporation yields NMDA receptors with higher affinity for competitive 
antagonists such as AP5 (Buller et al., 1994). Therefore, to assess the possibility 
that the lack of effect of AP5 infusion into DM striatum reflects a change in the 
pharmacological properties of NMDA receptors in DM striatum in METH-
pretreated rats, we examined the expression of the NR2a subunit of the NMDA 
receptor in striatum of saline- and METH-pretreated rats. In this experiment, the 
METH-pretreated rats had significant depletions of striatal DA (Table 2.1). These 
depletions, as determined by HPLC-ECD analysis of tissue DA content in the 
striatum, are slightly larger than those observed in the cohorts of rats used for the 
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behavioral experiments described above. Other work in our laboratory 
(unpublished observations) indicates that the magnitude of the DA depletions 
estimated by DAT binding is typically less than the magnitude measured via 
determination of DA tissue content, although the two measures are very highly 
and significantly correlated (r2 values of 0.8-0.9). Thus, although the magnitude 
of the depletions in this cohort of animals used for the determination of NMDA 
receptor expression and function after METH treatment appears to be greater, 
we think that they are roughly equivalent degrees of depletion and that any 
difference simply reflects subtle differences in the actual magnitude of depletion 
induced in different cohorts of animals treated with METH at different times and 
by different investigators. Analysis of film autoradiograms for Grin2a mRNA 
expression in striatal sections (+0.7mm from Bregma) from these saline- and 
METH-pretreated rats revealed a main effect of region (F(2,39)=6.74, p<0.01), but 
no main effect of pretreatment (F(1,39)=0.2, p=0.7) and no significant interaction 
(F(1,2)=0.05, p=0.95) (Fig. 2.5g). Post hoc analysis confirmed previous reports 
(Buller et al., 1994; Standaert et al., 1999; Ganguly and Keefe, 2001) of greater 
Grin2a mRNA expression in both DM (t(39)=-2.1, p<0.05) and DL (t(39)=-3.7, 
p<0.001) striatum relative to VM striatum. 
Electrophysiological properties of NMDA receptor-mediated EPSCs. To 
further assess whether there might be changes in the properties of NMDA 
receptors in striatal efferent neurons induced by METH exposure and whether 
this might underlie the differential sensitivity of the METH-pretreated rats to AP5 
and Arc antisense oligonucleotide infusion, we compared NMDA receptor-
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mediated EPSCs from both the DL and VM aspects of the striatum of both saline- 
and METH-pretreated rats, since there are regional differences in NMDA 
receptor function in the adult striatum (Chapman et al., 2003). As we have 
previously reported (Chapman et al., 2003), the kinetics of the NMDA receptor-
mediated EPSCs were faster in the DL than the VM striatum; however, prior 
exposure to a neurotoxic regimen of METH did not change the kinetics (Fig. 2.5, 
2.6). That is, the rise times (Fig. 2.6a; main effect of region, F(1,72)=9.64, p<0.01), 
τf (Fig. 2.5, 2.6b; main effect of region, F(1,78)=11.27, p=0.001), and τw (Fig. 2.5, 
2.6d; main effect of region, F(1,78)=72.66, p<0.0001) were significantly faster in DL 
striatum, consistent with the greater expression of the Grin2a subunit of the 
NMDA receptor in that region of striatum. There was also a trend for the τs to be 
faster in DL striatum, although the main effect of region was not statistically 
significant (F(1,78)=1.13, p=0.3). However, for none of these kinetic parameters 
was there a significant main effect of pretreatment (rise times, F(1,72)=0.0001, 
p=0.99; τf, F(1,78)=0.03, p=0.9; τs, F(1,78)=0.02, p=0.9; τw, F(1,78)=0.2, p=0.7) or a 
significant interaction (rise times, F(1,72)=1.2, p=0.3; τf, F(1,78)=0.4, p=0.5; τs, 
F(1,78)=2.1, p=0.2; τw, F(1,78)=1.0, p=0.3), indicating that METH-induced 
neurotoxicity was not associated with changes in the fundamental subunit 










 This study confirms previous observations that DM striatum is involved in 
motor response reversal learning (Palencia and Ragozzino, 2004) and that 
METH-pretreated rats appear behaviorally normal on this task (Daberkow et al., 
2008). However, the present results extend these prior observations in three 
important ways. First, the present results establish a critical role for Arc in DM 
striatum in consolidation of reversal learning in normal rats. Second, they provide 
additional support, in a novel brain area, for the hypothesis put forth by Guzowski 
and colleagues (2001) that the correlation between Arc mRNA in a brain region 
and behavioral performance reflects task-relevant encoding processes occurring 
in that brain area. Finally, the present results provide the first direct evidence that 
METH-induced neurotoxicity is associated with a change in the neural substrates 
engaged to solve a behavioral task normally dependent on DM striatum. These 
results therefore highlight the critical importance of striatal Arc for consolidation 
of basal ganglia-mediated learning and suggest that long-term toxicity induced by 
METH alters neural circuits and/or cognitive strategies used to solve tasks 
normally mediated by dorsal striatum. 
 The present data provide the first direct evidence that Arc is a critical 
mediator of consolidation of reversal learning mediated by DM striatum. This 
brain region has previously been implicated in cognitive flexibility, including that 
required for motor response reversal learning. In particular, Ragozzino and 
colleagues have previously established that acute blockade of cholinergic 
muscarinic or glutamatergic NMDA receptors in DM striatum impairs response 
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reversal learning (Ragozzino et al., 2002; Palencia and Ragozzino, 2004). 
Additionally, depletion of DA, but not serotonin, in DM striatum impairs reversal 
learning (O'Neill and Brown, 2007; Clarke et al., 2011). Furthermore, we have 
previously demonstrated that, in normal animals, there is a correlation between 
Arc mRNA in DM, but not DL, striatum and trials to criterion on a response 
reversal learning task (Daberkow et al., 2007). Guzowski and colleagues (2001) 
initially reported such a correlation between Arc expression in hippocampus and 
spatial learning on the Morris water maze, leading them to speculate that such 
correlations reflect the involvement of encoding processes in that particular brain 
region in the consolidation of spatial learning. Therefore, we proposed 
(Daberkow et al., 2007) that the correlation between Arc mRNA in DM striatum 
and trials to criterion on the reversal learning task reflected the fact that this 
reversal is normally dependent on DM striatal function, and that Arc must be a 
critical mediator of plasticity in DM striatum underlying consolidation of reversal 
learning. The present results support this hypothesis, as infusion of an Arc 
antisense oligonucleotide, but not a scrambled oligonucleotide or vehicle, into 
DM striatum impaired performance in normal rats on a reversal retention test 
given 24 hr later. Taken together with prior results showing that Arc antisense 
oligonucleotide infusions into DL striatum disrupt consolidation of extinction 
learning occurring during context-induced reinstatement of cocaine-seeking 
behavior (Hearing et al., 2011), the data strongly implicate Arc as a general, 
critical mediator of encoding processes underlying striatally-based learning and 
memory functions. 
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 Our previous studies on rats with METH-induced neurotoxicity have 
shown that although these rats appear to be behaviorally normal with respect to 
response reversal learning, Arc induction in DM striatum is attenuated and no 
longer correlates with trials to criterion, leading us to hypothesize that METH-
induced neurotoxicity promotes a shift in the neural substrates mediating this 
behavior (Daberkow et al., 2008). The present findings support this hypothesis: in 
rats with METH-induced neurotoxicity, acute disruption of DM striatal function by 
infusion of the NMDA receptor antagonist AP5 or an Arc antisense 
oligonucleotide fails to alter response reversal learning or its retention. Thus, 
although rats with METH-induced neurotoxicity appear to be normal on the 
surface, the neural substrates mediating the behavior have changed. These 
findings are similar to those reported, for example, in Parkinson’s disease 
patients, in which behavior appears unimpaired relative to controls, but functional 
imaging reveals a change in brain regions engaged during the task (Moody et al., 
2004). These findings highlight the need for studies assessing the impact of 
neurotoxicity on learning and memory to examine not simply behavioral 
measures of the learning, but also the processes and brain regions mediating the 
behavior, before concluding that there is a lack of effect of such toxicity on a 
particular behavior. 
 It is conceivable that the lack of effect of acute disruption of NMDA 
receptor and Arc function in DM striatum on reversal learning and its 
consolidation reflects a decrease in sensitivity of DM striatum to these 
manipulations, rather than a reorganization of the neural circuitry mediating the 
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behavior. However, we think that these former possibilities are unlikely, as in situ 
hybridization histochemical analysis of Grin2a mRNA expression and 
electrophysiological determination of the biophysical properties of striatal NMDA 
receptors failed to reveal any METH-induced changes in these NMDA receptor 
subunits or properties. The pharmacology of NMDA receptors is heavily 
influenced by Grin2 subunit incorporation into the receptor (Buller et al., 1994; 
Traynelis et al., 2010), as are the rise-time and decay kinetics of the NMDA 
receptor-mediated current, with Grin2a-containing receptors showing the fastest 
kinetics (Dingledine et al., 1999). Striatal efferent neurons, which are the striatal 
neurons in which Arc is expressed (Vazdarjanova et al., 2006), express the 
Grin2a and Grin2B subunits (Standaert et al., 1999). The present results confirm 
our prior observations and those of others that there is greater expression of 
Grin2a subunits in DL than VM striatum (Buller et al., 1994; Standaert et al., 
1999; Ganguly and Keefe, 2001), and that the rise times and decay kinetics of 
these currents are correspondingly faster in DL than in VM striatum (Chapman et 
al., 2003). These results illustrate our ability to detect differences in subunit 
composition of the NMDA receptor using this electrophysiological approach. 
Importantly, METH-induced neurotoxicity was not associated with changes in 
Grin2a subunit mRNA expression or in the biophysical properties of the NMDA 
receptors in the dorsal striatum, strongly suggesting that METH-induced 
neurotoxicity is not associated with changes in the subunit composition, and thus 
the pharmacology, of striatal NMDA receptors.  It therefore seems unlikely that a 
change in the sensitivity of NMDA receptors in METH-pretreated rats to AP5 or 
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endogenous glutamate underlies the lack of efficacy of acute AP5 infusion or Arc 
antisense infusion in those animals in the present studies. Rather, the data 
suggest that the lack of effect of these agents more likely reflects a change in the 
neural circuitry engaged in the reversal learning task. 
 The consequences of METH exposure that lead to this apparent shift in 
behavioral control are currently unknown; however, the METH-induced partial 
loss of DA in DM striatum may be the basis. As is typical (Chapman et al., 2001; 
Hanson et al., 2009), the binge regimen of METH resulted in an approximately 
40% loss of DA tissue content, as measured by DAT levels, in DM striatum at the 
end of the behavioral training. Although METH also induces a loss of serotonin in 
DM striatum (Haughey et al., 1999), as noted, DA, not serotonin, 
neurotransmission in DM striatum appears to mediate reversal learning (O'Neill 
and Brown, 2007; Clarke et al., 2011; Darvas and Palmiter, 2011). Thus, one 
strong possibility is that it is the partial loss of DA in DM striatum that results in 
the change in sensitivity of response reversal learning to acute manipulations of 
DM striatal function in METH-pretreated rats. 
 An alternative possibility is that METH-induced damage to extrastriatal 
serotonin systems disrupts the function of afferents to DM striatum or other 
neural substrates necessary for reversal learning, thereby altering the circuitry 
engaged during the reversal learning. The neurotoxic regimen of METH used in 
the present study also induces a loss of serotonin in prefrontal cortex (Hotchkiss 
and Gibb, 1980; Ricaurte et al., 1980), including an approximately 50% loss of 
SERT binding in orbitofrontal cortex (OFC) reported herein. Serotonin function in 
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OFC is known to be critical for reversal learning (Clarke et al., 2005; Clarke et al., 
2007; Robbins and Arnsten, 2009). Thus, changes in the function of OFC as a 
consequence of METH-induced neurotoxicity to that region may contribute to the 
changes in reversal learning observed in the present study. However, OFC tends 
to provide afferent innervation to the central and lateral aspects of dorsal 
striatum, as well as nucleus accumbens, and largely does not provide afferents 
to DM striatum (Schilman et al., 2008). On the other hand, prelimbic cortex does 
project strongly to DM striatum (Lévesque and Parent, 1998; Vertes, 2006). As 
presented herein, a neurotoxic regimen of METH results in about a 40% loss of 
SERT in prelimbic cortex. Furthermore, the prelimbic cortex plays a role in 
reversal learning, although the role is more in controlling complex, higher-order 
set-shifting tasks, rather than simple one-dimensional reversal learning such as 
the T-maze task used in this study (Ragozzino et al., 1999; Birrell and Brown, 
2000; Ragozzino, 2003).  Finally, the centromedian and paracentral nuclei of the 
thalamus provide excitatory innervation to the DM striatum (Van der Werf et al., 
2002). These thalamic nuclei receive relatively dense serotonergic innervation 
(Vertes et al., 2010), and data obtained from abstinent human METH abusers 
suggest decreased SERT binding in the thalamus (Sekine et al., 2006). Thus, 
METH-induced alterations in the function of excitatory afferents from intralaminar 
cell groups to DM striatum might also play a role in the disruption of DM striatal 
control over reversal learning observed in the present studies. However, the 
extent to which neurotoxic regimens of METH damage the intralaminar nuclei of 
the thalamus in rodents has not heretofore been reported. Clearly, further studies 
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examining the effects of selective DA depletions induced by substituted 
amphetamines vs. the effects of combined DA/serotonin depletions will be 
necessary to conclusively rule out a contribution of serotonin loss to the changes 
in behavioral control observed in the METH-pretreated rats. 
 An interesting aspect of the present findings is that METH-pretreated rats 
appear to be behaviorally normal, both in terms of trials to criterion and in the 
types of errors made during reversal learning. The neural substrates capable of 
supporting apparently normal reversal learning despite altered DM striatal 
function remain to be determined. One possibility for an alternate neural 
substrate is the nucleus accumbens core, which has been implicated in 
behavioral flexibility (Goto and Grace, 2005; Haluk and Floresco, 2009; Darvas 
and Palmiter, 2011). The “binge” regimen of METH exposure often does not 
induce as much monoamine loss in nucleus accumbens as in dorsal striatum 
(Eisch et al., 1992; Haughey et al., 1999), and DA signaling in accumbens plays 
a role in simple reversal learning (Haluk and Floresco, 2009; Darvas and 
Palmiter, 2011). Future studies thus will be necessary to determine the role of 
nucleus accumbens in reversal learning in METH-pretreated rats, the 
circumstances under which DM striatal vs. nucleus accumbens DA signaling 
normally supports behavioral flexibility, and the cognitive cost associated with a 
loss of DM striatal control over behavioral flexibility. 
 In summary, the present study provides the first evidence that Arc in DM 
striatum is a critical mediator underlying consolidation of motor response reversal 
learning, thereby further validating its importance as a molecular substrate of 
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learning and memory function. Furthermore, the present results are the first to 
show that METH-induced neurotoxicity is associated with a change in neural 
substrates underlying basal ganglia-mediated learning and memory, despite the 
fact that behavioral indices of that learning appear to be normal. These findings 
suggest that METH-induced neurotoxicity may have important ramifications for 
the ability of individuals with a history of METH abuse to engage in cognitive 
behavioral therapies for management of drug addiction, as well as the extent to 
which they can function optimally in tasks related to their employment and 
personal lives. Further studies are therefore needed to fully understand the 
molecular, cellular, and systems level substrates mediating learning and memory 
processes in corticostriatal circuits that are compromised by METH-induced 
monoamine loss and to design approaches to mitigate such effects. 
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Figure 2.1. Infusion sites in dorsomedial striatum. Black dots indicate 
placement of infusion sites in DM striatum of rats in AP5 and Arc experiments. 






Figure 2.2. DAT and SERT binding. (A) DAT decreases (mean±SEM), 
expressed as percent of average values in saline-pretreated controls, in rats 
pretreated with (±)-METH (4x10 mg/kg, two-hour intervals; n=25) or saline (SAL; 
n=29) approximately seven weeks prior to sacrifice. (B), SERT decreases 
(mean±SEM), expressed as percent of average values in saline-pretreated 
controls, in rats pretreated with METH (n=12) or saline (n=11) approximately 
seven weeks after METH pretreatment. *Significantly different from SAL-
pretreated values for same brain region, p<0.01. Cg, cingulate cortex; PLC, 
prelimbic cortex; ILC, infralimbic cortex; mOFC, medial orbitofrontal cortex; 


















Figure 2.3. Effects of acute NMDA receptor blockade in DM striatum. Mean 
trials to criterion (9/10 correct consecutive trials; ±SEM) on a motor response-
reversal task. Rats were given bilateral infusions of AP5 or PBS 5 min prior to the 
beginning reversal learning. *Significantly different from SAL-pretreated, PBS-












Figure 2.4. Effects of acute Arc disruption in DM striatum. Mean trials to 
criterion (±SEM) on the motor response-reversal task (A) and the reversal-
retention tasks (B). (A), Rats were given bilateral infusions of an Arc antisense 
oligonucleotide, Arc nonsense oligonucleotide, or PBS two hours prior to 
beginning reversal training. No significant interactions or main effects of 
pretreatment or infusion were found. (B), Rats were tested on retention of the 
previous day’s reversal learning. No further infusions were made. *Significantly 
different from SAL-pretreated, Arc nonsense oligonucleotide and PBS controls 

























Figure 2.5. Grin2a mRNA expression and decay kinetics of NMDA receptor-
mediated EPSCs. (A-F), Local, minimal stimulation of striatum in proximity (<300 
µm) to the recorded cell elicits a long-lasting, NMDA receptor-mediated EPSC in 
striatum. The average of 35 EPSCs evoked at 0.1 Hz are shown. Representative 
traces showing the decay-time kinetics of NMDA receptor-mediated EPSCs in 
dorsolateral (A, C, E) and ventromedial (B, D, F) striatum of saline- (A, B) and 
METH- (C, D) pretreated rats are shown, as are normalized, superimposed 
traces from DL (E) and VM (F). (G), Grin2a mRNA expression in DL, DM, and 
VM striatum from the hemisphere opposite to that used for electrophysiological 
recordings. Data are average gray values (±SEM) from densitometric analysis of 
film autoradiograms. *Both DM and DL striatum are significantly different from 











Figure 2.6. Kinetic properties of striatal NMDA receptor-mediated EPSCs in 
saline- and methamphetamine-pretreated rats. Values are average kinetic 
parameters (±SEM) calculated from whole-cell, patch-clamp recordings of NMDA 
receptor-mediated EPSCs in the dorsolateral and ventromedial striata of rats 
pretreated with saline (SAL-pretreated; n=10 for DL, n=12 for VM) or a neurotoxic 
regimen of METH (METH-pretreated; n=25 for DL, n=19 for VM). (A), 10-90% 
rise time. The decay of the EPSCs were fit with a double exponential equation, 
I(t)=Ifexp(-t/τf)+Isexp(-t/τs), yielding fast (B; τ fast) and slow (C; τ slow) time 
constants. Weighted time constants (D; weighted τ) were calculated using the 
equation: τw=[If/(If+Is)]τf+[Is/(If+Is)]τs (Stocca and Vicini, 1998). *Significant main 







Table 2.1. Striatal DA tissue content three weeks after a neurotoxic regimen 
of METH. Values are average (±SEM) DA content (ng DA/mg protein) in striatal 
tissue determined via HPLC-ECD analysis of 1-mm3 tissue punches from 
dorsolateral or ventromedial striatum. Values are ng DA/mg protein. *Significantly 
different from saline (p<0.05). 
 
Treatment Striatal DA Tissue Content 
 Dorsolateral 
Saline (n=8) 314±26 
METH (n=8) 98±15* 
 Ventromedial 
Saline (n=8) 282±26 











CHANGES IN NEURAL CIRCUITRY REGULATING RESPONSE-REVERSAL  
 
LEARNING AND ARC-MEDIATED CONSOLIDATION OF LEARNING IN 
 







Methamphetamine-induced neurotoxicity results in long-lasting depletions 
of monoamines and changes in basal ganglia function. We previously reported 
that rats with methamphetamine-induced neurotoxicity no longer engage 
dorsomedial striatum during a response reversal-learning task, as their 
performance is insensitive to acute disruption of dorsomedial striatal function by 
local infusion of an N-methyl-D-aspartate receptor antagonist or an antisense 
oligonucleotide against the activity-regulated cytoskeleton-associated (Arc) gene. 
However, methamphetamine-pretreated rats perform the task as well as controls. 
Therefore, we hypothesized that the neural circuitry involved in the learning had 
changed in methamphetamine-pretreated rats. To test this hypothesis, rats were 
pretreated with a neurotoxic regimen of methamphetamine or with saline. Three 
to five weeks later, rats were trained on the reversal-learning task and in situ 
hybridization for Arc was performed. A significant correlation between Arc 
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expression and performance on the task was found in nucleus accumbens shell 
of methamphetamine-, but not saline-, pretreated rats. Consistent with the idea 
that the correlation between Arc expression in a brain region and behavioral 
performance implicates that brain region in the learning, infusion of an antisense 
oligonucleotide against Arc into the shell impaired consolidation of reversal 
learning in methamphetamine-, but not saline-, pretreated rats. These findings 
provide novel evidence suggesting that methamphetamine-induced neurotoxicity 
leads to a shift from dorsal to ventral striatal involvement in the reversal-learning 
task. Such reorganization of neural circuitry underlying learning and memory 
processes may contribute to impaired cognitive function in individuals with 
methamphetamine-induced neurotoxicity or others with striatal dopamine loss, 




 Methamphetamine (METH) abuse continues to have considerable societal 
impact, with 12 million Americans reporting use in their lifetime (2011 National 
Survey on Drug Use and Health, SAMHSA). METH abuse in humans causes 
decreases in the dopamine transporter (DAT) (Wilson et al., 1996) and serotonin 
transporter (SERT) (Sekine et al., 2006). Further, recent data indicate that people 
with a history of hospitalization for METH abuse are at higher risk of developing 
Parkinson’s disease (Callaghan et al., 2012). 
 The monoamine loss resulting from METH abuse in humans can be 
recapitulated in rodents. METH-induced neurotoxicity causes partial depletions of 
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dopamine (DA) and serotonin (5-HT) (Wagner et al., 1980). As in human METH 
abusers (Dean et al., 2013), this partial monoamine loss is associated with 
cognitive deficits, including impairments in odor and object recognition, 
attentional set-shifting (Marshall and O'Dell, 2012), sequential motor learning 
(Chapman et al., 2001; Daberkow et al., 2005), formation of stimulus-response 
associations (Son et al., 2011), and inhibitory control over behavior (Son et al., 
2013). The deficits in basal ganglia-mediated behaviors may arise secondary to 
impaired phasic DA neurotransmission in the partially denervated striatum 
(Howard et al., 2011; Howard et al., 2013a). 
 Arc (activity-regulated cytoskeleton-associated gene) is an effector 
immediate-early gene involved in synaptic plasticity and memory consolidation 
(Shepherd and Bear, 2011). Hippocampal Arc expression correlates with 
performance and is necessary for memory consolidation on the spatial version of 
the Morris water maze (Guzowski et al., 2000; Guzowski et al., 2001). Similarly, 
our lab has reported correlations between Arc mRNA in dorsomedial striatum 
(DMS) and performance on a striatally-mediated response reversal-learning task 
in normal (Daberkow et al., 2007, 2008), but not METH-pretreated (Daberkow et 
al., 2008), rats, suggesting that although METH-pretreated rats perform as well 
as normal rats on the reversal-learning task, they may rely on different brain 
circuitry to perform the task (Daberkow et al., 2008; Pastuzyn et al., 2012). To 
test this hypothesis, we looked for correlations between Arc mRNA expression in 
different brain regions and reversal learning in METH-pretreated rats relative to 
controls. We found a significant correlation in the nucleus accumbens (NAc) shell 
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in METH-pretreated rats that did not exist in saline-pretreated rats. Further, 
disruption of Arc signaling in the NAc shell of METH-, but not saline-, pretreated 
rats impaired consolidation of the reversal learning. Taken together with our 
previously published observations (Pastuzyn et al., 2012), these data suggest 
that METH-induced neurotoxicity is associated with reorganization of neural 
circuitry engaged in a learning and memory task typically dependent on DMS, 
and that correlations between Arc mRNA expression in brain regions and 
behavioral performance may be a viable ex vivo approach for mapping neural 
circuitry engaged in learning and memory tasks. 
 
 
Materials and Methods 
Animals. Male Sprague-Dawley rats (Charles River Laboratories, Raleigh, 
NC, USA; 275-300 g) were singly housed in tub cages on a 12:12 hr light cycle. 
Animal care and experimental procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Utah and followed the 
Guide for the Care and Use of Laboratory Animals. 
Methamphetamine pretreatment. Rats were treated with a neurotoxic 
regimen of (±)-METH-HCl (4x10 mg/kg, free base, at two-hour intervals, s.c.; 
NIDA, Research Triangle Park, NC, USA) over the course of one day as 
previously described (Daberkow et al., 2008; Son et al., 2013). The day after 
treatment, rats were returned to their home cages and given free access to food 
and water until training began. 
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Dopamine and serotonin transporter autoradiography. DAT and SERT 
autoradiography was performed as detailed previously (Boja et al., 1992; Barker-
Haliski et al., 2012b; Pastuzyn et al., 2012; Son et al., 2013). For striatal 
sections, the buffer contained fluoxetine (Sigma-Aldrich, St. Louis, MO, USA) to 
block binding to the SERT, whereas for prefrontal cortical (PFC) sections, 
fluoxetine was omitted from the buffer, as PFC sections incubated in buffer 
containing fluoxetine showed no staining (data not shown). Slides were apposed 
to film (Kodak Biomax MR film; Eastman Kodak, Rochester, NY, USA) for 24 hr. 
Arc correlations with response-reversal learning: Reversal-learning task. 
Response-reversal learning on a T-maze was conducted as previously described 
(Daberkow et al., 2007; Barker-Haliski et al., 2012a; Pastuzyn et al., 2012). 
Beginning three weeks after METH pretreatment, rats (METH-pretreated, n=9; 
saline-pretreated, n=10) were food restricted and habituated to the food reward 
and maze. The turn bias of each rat was determined, followed by acquisition 
training for three days and then reversal learning. During reversal learning, rats 
had to turn in the opposite direction from acquisition to receive the reward. The 
criterion for learning on both acquisition and reversal tasks was 9/10 correct turns 
in a row. Five minutes after reaching criterion on reversal, rats were exposed to 
CO2 for one minute and then sacrificed by decapitation. Brains were quickly 
removed, flash frozen in 2-methylbutane (Mallinckrodt Baker, Phillipsburg, NJ, 
USA) on dry ice, and stored at -80°C until sectioning. 
Radioactive in situ hybridization histochemistry. Frozen brains were 
sectioned (12-µm; Cryocut 1800; Leica, Wetzlar, Germany). Sections from PFC 
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(mm from Bregma: +3.7 to +2.2), striatum (+1.6 to -0.92 mm), and dorsal 
hippocampus (-2.3 to -3.6 mm) were thaw-mounted onto Superfrost Plus slides 
(VWR, Aurora, CO, USA) and stored at -20°C. Infusion cannula placements were 
determined by eye at this time and recorded on schematic diagrams from a rat 
brain atlas (Paxinos and Watson, 1998). 
 To assess Arc mRNA expression, slides containing striatal, PFC, or 
hippocampal sections were postfixed and delipidated as previously described 
(Ganguly and Keefe, 2001). Detection of Arc mRNA was accomplished using a 
full-length ribonucleotide probe (Daberkow et al., 2007, 2008; Barker-Haliski et 
al., 2012b; Howard et al., 2013b). The plasmid containing the cDNA for Arc 
(Lyford et al., 1995) was linearized with EcoRI. The antisense ribonucleotide 
probe was transcribed using 35S-UTP (striatum) or 33P-UTP (PFC and 
hippocampus) (PerkinElmer, Waltham, MA, USA) and T7 RNA polymerase 
(Roche, Indianapolis, IN, USA). Radioactive in situ hybridization was performed 
as previously described, with slightly modified final washing procedures (Ganguly 
and Keefe, 2001). Slides were apposed to film (Biomax MR) for four-six days. 
Image analysis. Densitometric analysis of digitized film images was 
conducted using NIH ImageJ software, yielding background-subtracted average 
gray values in several brain regions from one hemisphere of each of the four 
sections on the slide. The regions analyzed were: cingulate (Cg1), prelimbic 
(PLC), infralimbic (ILC), ventral orbitofrontal (vOFC), and lateral orbitofrontal 
(lOFC) cortices; DMS and dorsolateral striatum (DLS) and nucleus accumbens 
(NAc) core and shell; CA1, CA3, upper and lower blades of dentate gyrus (DG), 
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and hilus of the dorsal hippocampus. For cortical regions, all cortical layers were 
analyzed. 
Effect of Arc antisense oligonucleotide infusion in nucleus accumbens 
shell. Two weeks after saline (n=11) or METH (n=13) pretreatment, rats were 
anesthetized with ketamine/xylazine (90/10 mg/kg, i.p.) and placed in a 
stereotaxic instrument (Stoelting Co., Wood Dale, IL, USA). A dual 26-gauge 
guide cannula (Plastics One, Roanoke, VA, USA) was lowered to end bilaterally 
just dorsal to NAc shell (mm from Bregma: +2.2 AP; ±1.0 ML; -6.4 DV) and 
secured. Bilateral infusions into NAc shell during behavioral experiments were 
made through 33-gauge infusion cannulae extending 1.1 mm beyond the end of 
the guides into NAc shell. 
The reversal task was the same as described above, except that two 
hours before undergoing reversal learning, either an Arc antisense 
oligonucleotide, Arc nonsense oligonucleotide, or 0.1M PBS (vehicle) was 
infused into NAc shell. The Arc antisense and nonsense oligonucleotides were 
prepared and infused (1 µL of oligonucleotide; 1 nmol/µL in 0.1M PBS, pH 7.4 or 
PBS) at 0.33 µL/min bilaterally into NAc shell, as previously described for DMS 
(Pastuzyn et al., 2012). The design of the oligonucleotides was based on the 
prior work of Guzowski and colleagues (2000). Further, the concentration of 
oligonucleotide and volumes and rates of infusion were also based on that work, 
as well as that of other labs showing restricted delivery of the antisense 
oligonucleotide to specific brain regions, including the nucleus accumbens core, 
lateral amygdala, and anterior cingulate cortex (Ploski et al., 2008; Holloway and 
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McIntyre, 2011; Lv et al., 2011). Postinfusion, rats rested in their home cages for 
two hours, were trained to criterion (9/10 correct trials) on reversal, and were 
returned to their home cages overnight. “Reversal retention” occurred 24 hr later, 
during which rats were rewarded for turning in the reversal direction learned the 
previous day, until criterion (9/10 correct trials) was reached. No further infusions 
were made on the reversal-retention day. 
Statistical analysis. Unpaired t-tests were used to compare RTI-55 
autoradiographic signals and trials to criterion on the reversal-learning task for 
the saline and METH pretreatment groups on which ex vivo analysis of Arc 
mRNA expression was completed. Trials to criterion on the reversal-learning task 
were also correlated with Arc mRNA expression. A two-factor MANOVA 
(pretreatment x day) followed by post hoc analysis with paired t-tests across 
acquisition days was used to assess any effect of METH pretreatment on trials to 
criterion on the three days of response acquisition. A two-way ANOVA was used 
to evaluate the effects of pretreatment (saline or METH) and treatment (infusion 
of Arc antisense, Arc nonsense, or PBS) on trials to criterion on the reversal-
learning and reversal-retention tasks. All statistical tests were run using JMP 




DAT and SERT autoradiography. The administration of METH resulted in 
significant reductions in striatal and NAc DAT binding (Fig. 3.1a). DAT depletions 
did not differ between rats used for ex vivo analysis of Arc mRNA expression and 
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those used to examine the effects of Arc antisense oligonucleotide infusion into 
NAc shell, as two-way ANOVA revealed no main effect of “group” (ex vivo Arc or 
Arc antisense group: DMS, p=0.99; DLS, p=0.7; NAc core, p=0.97; NAc shell, 
p=0.5) and no group x pretreatment (METH or saline) interaction in DMS (p=0.8), 
DLS (p=0.9), NAc core (p=0.97), or NAc shell (p=0.5). There were main effects of 
pretreatment in all four striatal regions. Unpaired, one-tailed t-tests revealed a 
significant decrease in DAT binding in rats pretreated with METH in DMS (t=12.1, 
p=0.0001), DLS (t=9.2, p=0.0001), NAc core (t=5.0, p=0.0001), and NAc shell 
(t=3.3, p=0.002). 
Pretreatment with the binge regimen of METH also resulted in reductions 
in SERT binding in PFC (Fig. 3.1b). As with DAT, SERT depletions were not 
significantly different between the two groups of rats, so the data were collapsed 
for the purpose of this analysis (no effect of group or group x pretreatment 
interaction, respectively, in Cg1 (p=0.5; p=0.5), PLC (p=0.3; p=0.3), ILC (p=0.4; 
p=0.4), vOFC (p=0.6; p=0.6), or lOFC (p=0.4; p=0.4)). Unpaired, one-tailed t-
tests revealed significant decreases in SERT binding in all regions of PFC 
examined in METH-pretreated rats: Cg1, t=9.1, p=0.0001; PLC, t=6.1, p=0.0001; 
ILC, t=3.96, p=0.0003; vOFC, t=10.4, p=0.0001; lOFC, t=8.8, p=0.0001. 
Effect of METH-induced neurotoxicity on trials to criterion for acquisition 
and reversal of response learning. As previously reported (Daberkow et al., 2008; 
Pastuzyn et al., 2012), there was no effect of METH pretreatment on acquisition 
of the response-learning task (F(1,17)=0.2, p=0.6) and no pretreatment x 
acquisition day interaction (F(2,16)=0.3, p=0.7). There was a main effect of 
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acquisition day (F(2,16)=8.4, p=0.03), with the rats overall taking significantly fewer 
trials to reach criterion on the third day of acquisition relative to both the second 
(t=-3.2, p=0.003) and first (t=-3.7, p=0.0008) days (data not shown). Rats with 
METH-induced monoamine depletions also did not differ from saline-pretreated 
controls in the numbers of trials to criterion on the reversal day (t=-0.9, p=0.4; 
data not shown). 
Arc mRNA expression. Analysis of the film autoradiograms revealed no 
significant differences between the levels of Arc mRNA expression in METH- vs. 
saline-pretreated rats in DMS (t=0.2, p=0.8), DLS (t=0.2, p=0.8), NAc core (t=0.5, 
p=0.6), or NAc shell (t=1.6, p=0.1). 
As in striatum, there was no significant effect of METH pretreatment on 
the levels of Arc mRNA expression as reflected in the radioactive in situ 
hybridization signal in Cg1 (t=-1.1, p=0.3), PLC (t=-1.2, p=0.2), ILC (t=0.2, 
p=0.8), vOFC (t=-0.9, p=0.4), or lOFC (t=-0.8, p=0.4). In hippocampal 
subregions, there were also no significant differences between the intensity of 
the Arc mRNA signals in the METH- vs. the saline-pretreated rats in CA1 (t=-1.6, 
p=0.1), upper blade of the DG (t=-1.5, p=0.1), and lower blade of the DG (t=1.1, 
p=0.3). However, the intensity of the Arc mRNA in situ hybridization signal was 
significantly greater in METH- vs. saline-pretreated rats in CA3 (t=-2.5, p=0.02) 
and hilus (t=-4.3, p=0.0007). 
Previous work suggests that although Arc mRNA expression is induced in 
multiple brain regions in animals learning a particular behavior, the degree of that 
induction in a given brain area only correlates with measures of learning if that 
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brain area is involved in the learning (Guzowski et al., 2001; Daberkow et al., 
2007). Consequently, we did not include a caged control group in the present 
studies, because our prior work showed that reversal learning induces Arc 
throughout the brain (Daberkow et al., 2007), and we were testing whether there 
was a correlation between Arc in various brain regions and behavior, not whether 
there simply was an induction of Arc. Furthermore, our prior work suggests that 
rats with METH-induced monoamine depletions no longer rely on “normal” striatal 
circuitry for response-reversal learning (Daberkow et al., 2008; Pastuzyn et al., 
2012). Therefore, we used ex vivo analysis of Arc mRNA expression across 
multiple brain regions that might be involved in reversal learning in an attempt to 
reveal neural substrates being used by the METH-pretreated rats as they learned 
the reversal response. 
Although PFC has been implicated in reversal learning (for review, see 
Ragozzino, 2007), we found no significant correlations in either saline- or METH-
pretreated rats between Arc mRNA expression in PFC regions and trials to 
criterion on the reversal-learning task (Table 3.1). We further speculated that the 
METH-pretreated rats might be relying on a spatial strategy to solve the reversal 
task, and thus looked for correlations between Arc mRNA expression in 
hippocampal subregions and trials to criterion. Again, no significant correlations 
were found in either saline- or METH-pretreated rats (Table 3.1). 
In contrast to the lack of significant correlations in the PFC and 
hippocampus, significant correlations were apparent in striatum, and the region in 
which the correlations were observed varied as a function of METH pretreatment. 
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As previously reported (Daberkow et al., 2007, 2008), Arc mRNA expression in 
DMS, but not DLS, was significantly negatively correlated with trials to criterion 
on the reversal-learning task in saline-pretreated rats (Fig. 3.2). No such 
significant correlation (p=0.9) was apparent for DMS of METH-pretreated rats, 
again consistent with our prior observations (Daberkow et al., 2008). However, in 
NAc shell, there was a significant negative correlation between Arc mRNA 
expression and performance in METH-pretreated rats (R2=0.44, p=0.0497) that 
was not apparent in saline-pretreated rats (p=0.2). Thus, prior exposure to a 
neurotoxic regimen of METH is associated with a change in the brain regions in 
which Arc mRNA expression correlates with behavioral performance, suggesting 
that the METH-pretreated rats might be relying on NAc shell, rather than DM 
striatum, in this task. 
Effect of Arc antisense on response-reversal learning and its retention. 
Prior work from our lab (Pastuzyn et al., 2012) and others (Guzowski et al., 2000; 
Ploski et al., 2008; Czerniawski et al., 2011; Hearing et al., 2011; Holloway and 
McIntyre, 2011; Maddox and Schafe, 2011) has shown that disruption of Arc in a 
brain area known to be involved in completion of a particular learning/memory 
task disrupts consolidation of the memory. Thus, to further examine whether the 
circuitry mediating response-reversal learning and consolidation of that learning 
in METH-pretreated rats had shifted to rely on NAc shell, we determined whether 
local infusion of an Arc antisense oligonucleotide into NAc shell had differential 
effects on retention of the reversal learning in METH- vs. saline-pretreated rats. 
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Figure 3.2 illustrates the locations of the tips of the infusion cannulae in NAc shell 
for each rat. 
 Consistent with our prior observations (Daberkow et al., 2008; Pastuzyn et 
al., 2012), METH- and saline-pretreated rats did not differ in trials to criterion 
during the acquisition days (data not shown). Infusion of an Arc antisense 
oligonucleotide did not alter performance on the day of reversal learning (Fig. 
3.4a), as a two-way ANOVA on pretreatment (saline, METH) x treatment (Arc 
antisense, Arc nonsense, PBS) for trials to reach criterion on the reversal task 
revealed no significant main effect of pretreatment (F(1,1)=0.05, p=0.8) or infusion 
(F(2,2)=1.0, p=0.4) and no significant interaction (F(2,2)=0.1, p=0.9). 
Rats were tested for retention of the reversal learning 24 hr later. Two-way 
ANOVA on pretreatment x treatment for trials needed to reach criterion on the 
reversal-retention test revealed a main effect of pretreatment (Fig. 3.4b; 
F(1,18)=5.29, p=0.03), a trend towards an effect of treatment (F(2,18)=2.81, p=0.09), 
and a significant pretreatment x treatment interaction (F(2,2)=6.2, p=0.009). Tukey 
HSD post hoc analysis of the significant interaction revealed that infusion of Arc 
antisense into NAc shell during the reversal learning did not impair retention of 
the reversal learning in the saline-pretreated rats, as the trials to criterion on the 
retention day were not different from those in the saline-pretreated rats infused 
with a nonsense oligonucleotide (p=0.97) or PBS (p=0.995). Conversely, infusion 
of the Arc antisense oligonucleotide into NAc shell did impair retention of reversal 
learning in the METH-pretreated rats. METH-pretreated rats infused with the Arc 
antisense oligonucleotide during reversal learning took significantly more trials to 
 92 
reach criterion on the retention test the following day relative to METH-pretreated 
rats infused with the nonsense oligonucleotide (p=0.01) or PBS (p=0.03), as well 
as relative to the saline-pretreated rats infused with the Arc antisense 
oligonucleotide (p=0.003). Taken together with our prior results showing that 
infusion of Arc antisense into DMS impairs retention of reversal learning in 
saline-, but not METH-, pretreated rats (Pastuzyn et al., 2012), the accumulating 
evidence suggests that the neural circuitry in which consolidation of reversal 




Previous results suggest that the correlation between Arc mRNA 
expression in a brain region and behavioral performance on a task, rather than 
the simple presence of gene expression, reflects the necessity of synaptic 
modifications in that brain region for learning and its consolidation (Guzowski et 
al., 2001; Daberkow et al., 2007; Hearing et al., 2011; Pastuzyn et al., 2012). The 
present findings provide additional support for this view by showing again that 
disruption of Arc in a brain region impairs consolidation of learning only if a 
significant correlation between Arc expression in that brain region and behavioral 
performance was observed. The present work also confirms earlier results 
showing a loss of the normal correlation between Arc mRNA expression in DMS 
and response-reversal learning in rats with METH-induced neurotoxicity 
(Daberkow et al., 2008). The present study extends those findings by 
demonstrating the appearance of a novel correlation between Arc expression in 
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NAc shell and behavioral performance as a consequence of prior METH 
exposure and subsequent sensitivity of reversal-learning consolidation to infusion 
of an Arc antisense oligonucleotide into NAc shell. These findings suggest that 
prior neural injury—in this case, METH-induced neurotoxicity—leads to 
alterations in the neural circuitry engaged when an animal performs a learning 
and memory task, and that this change in circuitry can be monitored by 
evaluating the correlation between Arc mRNA expression in various brain regions 
and behavioral performance. This approach may therefore serve as an ex vivo 
imaging approach to interrogate neural circuits engaged in learning and memory 
tasks and how those circuits are affected by CNS insult. 
The reversal learning examined in the present study is typically dependent 
on the functional integrity of DMS, as infusion of an NMDA receptor antagonist or 
an antisense oligonucleotide against Arc into DMS in normal animals disrupts 
learning and consolidation of that learning, respectively (Palencia and 
Ragozzino, 2004; Pastuzyn et al., 2012). Despite this apparent specific role of 
DMS in response-reversal learning, in situ hybridization histochemical staining 
revealed expression of Arc mRNA throughout the brain. Thus, as previously 
suggested (Guzowski et al., 2001; Daberkow et al., 2007, 2008), evidence is 
accumulating that it is not simply the presence of Arc mRNA induction in a brain 
region that implicates plasticity processes in that region in the learning/memory 
formation; rather, it appears to be the correlation between Arc and the measure 
of learning that is the hallmark implicating synaptic plasticity processes in a brain 
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region as being critical for the particular learning being examined and its 
consolidation. 
Evidence that the correlation between Arc mRNA expression in a brain 
region and behavioral performance is the critical dependent measure for using 
Arc mRNA expression to identify brain regions involved in the learning/memory 
being examined comes from studies using site-specific infusions of antisense 
oligonucleotides to disrupt Arc function. For example, Guzowski and colleagues 
(2001) reported a significant inverse correlation between hippocampal Arc 
expression and latency to escape in a spatial, but not cued, version of the Morris 
water maze. Antisense-mediated knockdown of Arc in hippocampus during 
learning on the spatial task impaired memory consolidation, as evidenced by 
impaired retention of the previously learned spatial location (Guzowski et al., 
2000). Likewise, prior work by Hearing and colleagues (2008) revealed a 
significant correlation between Arc mRNA expression in DLS and context-
induced lever pressing (cocaine-seeking) during a one-hour extinction test. 
Infusion of an Arc antisense oligonucleotide during that one-hour extinction 
session impaired consolidation, as evidenced by greater lever pressing in the 
antisense-infused rats when assessed 24 and 48 hr later (Hearing et al., 2011). 
We also previously reported that normal rats show a significant inverse 
correlation between Arc mRNA in DMS and trials to criterion on the reversal-
learning task (as reported herein and Daberkow et al., 2007, 2008) and that 
infusion of an Arc antisense oligonucleotide into DMS impairs consolidation of 
reversal learning in those normal animals (Pastuzyn et al., 2012). Importantly, in 
 95 
METH-pretreated rats the correlation between Arc mRNA expression in DMS and 
reversal learning is lost (as reported herein and Daberkow et al., 2007, 2008), 
and infusion of an Arc antisense oligonucleotide into the DMS does not impair 
consolidation of the reversal learning in these METH-pretreated rats  (Pastuzyn 
et al., 2012). Similarly, in the present study, infusion of the Arc antisense 
oligonucleotide into NAc shell of normal animals—a brain region in which Arc 
mRNA expression does not correlate with reversal learning—does not impair 
retention of the learned reversal, even though there is Arc expression in this 
region. Taken together, these findings suggest the interpretation that the 
correlation between Arc in a brain region and the index of learning can be used 
to map, ex vivo, the neural circuitry engaged in the particular learning and 
memory task. 
We have previously reported that the correlation between Arc in DMS and 
reversal learning normally observed in intact rats is lacking in rats with METH-
induced neurotoxicity, despite the fact that they have apparently normal 
response-reversal learning (Daberkow et al., 2008). Therefore, in the present 
work, we performed a broader evaluation of Arc mRNA in different brain regions 
and reversal learning in METH-pretreated rats. We discovered a novel correlation 
in METH-pretreated rats between Arc in NAc shell and reversal learning. In this 
case, infusion of Arc antisense into NAc shell during the reversal learning 
impaired consolidation of that learning. Although we did not directly verify that the 
antisense oligonucleotide-mediated knockdown of Arc remained confined to the 
NAc shell, two lines of evidence suggest that the effect of the antisense 
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oligonucleotide observed in the METH-pretreated rats is likely due to loss of Arc 
function in the NAc shell. First, several prior studies have infused biotinylated Arc 
antisense oligonucleotides into specific brain regions similar in size to the NAc 
shell at concentrations, volumes, and rates of infusion similar to those used here 
and have reported that the infused oligonucleotide remains restricted to the 
region in which it was infused (Ploski et al., 2008; Holloway and McIntyre, 2011; 
Lv et al., 2011). Second, although restriction of infused Arc antisense to the NAc 
shell has not been directly examined, the prior work by Lv and colleagues (2011) 
reported dissociable effects of Arc antisense infusion into the NAc shell vs. core 
on morphine-induced conditioned place preference. Taken together, these data 
suggest that infusion of Arc antisense oligonucleotide in the present study likely 
specifically disrupted Arc function in the NAc shell, thereby disrupting reversal 
learning in the METH-pretreated rats. 
The fact that METH-pretreated rats appear to rely on different striatal 
circuitry to perform the reversal task relative to intact controls is consistent with 
literature showing differences in neural circuitry activated during learning 
paradigms between normal individuals and individuals with CNS injury/disease, 
such as Parkinson’s disease (e.g., Moody et al., 2004; Beauchamp et al., 2008; 
Rieckmann et al., 2010). For example, previous fMRI analysis of Parkinson’s 
disease patients who performed as well as controls on a probabilistic weather 
prediction task revealed that they activated medial temporal lobe during the task, 
whereas controls showed normal activation of basal ganglia circuitry (Moody et 
al., 2004). It is therefore critical to assess not just behavioral performance, but 
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also the neural circuitry underlying behavioral performance, in order to fully 
appreciate the impact of CNS insult, as the neural circuitry mediating the 
behavior may be altered even if gross behavioral performance appears intact. 
In the case of the present studies, the basis for this reorganization of task-
related processing is unknown, but may be secondary to the METH-induced DA 
depletions. As confirmed in the present work, exposure to high doses of METH 
results in partial DA loss (Wagner et al., 1980). This loss is associated with 
impairment of phasic DA signaling (Howard et al., 2011; Howard et al., 2013a), 
along with loss of transcriptional activation and normal subcellular distribution of 
Arc mRNA in dorsal striatum (Barker-Haliski et al., 2012b), both of which are 
critical for synaptic plasticity underlying basal ganglia-mediated learning and 
memory processes (Calabresi et al., 2007; Schultz, 2007). As previously reported 
(e.g., Ricaurte et al., 1980; Haughey et al., 1999; Wallace et al., 1999; Johnson-
Davis et al., 2002), in the present study, METH-induced DA loss in the NAc, 
particularly in the shell, was less extensive. Based on previous evidence from our 
lab, there appears to be a threshold (~40% depletion) necessary for behavioral 
impairments to be evident (Daberkow et al., 2005). Perhaps the ~25% depletion 
in NAc shell observed in the present study was insufficient to prevent this brain 
region from being used by METH-pretreated rats in the behavioral task. While we 
have observed disruption of DA transients in the NAc core of METH-pretreated 
rats (Howard et al., 2013a), whether there is less significant disruption of phasic 
DA signaling in NAc shell at these levels of METH-induced DA loss remains to be 
determined. 
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Both DMS and NAc shell are motor outputs for the basal ganglia, and NAc 
shell is also often touted as being involved in motivated and goal-directed 
behavior (Ikemoto, 2007; Humphries and Prescott, 2010). Therefore, DA-
mediated plasticity may be relatively preserved in NAc shell compared to DMS 
after METH-induced neurotoxicity, allowing DA-mediated synaptic modifications 
there to subserve consolidation of response-reversal learning. Furthermore, 
studies have shown that there are differences in how rostral and caudal NAc 
shell modulate behavior (Reynolds and Berridge, 2001). Our infusions targeted 
the rostral NAc shell, and given the differences in behavioral output of rostral and 
caudal NAc shell, as well as the anatomical inputs/outputs to the two regions 
(e.g., Usuda et al., 1998; Groenewegen et al., 1999), it will be interesting in future 
studies to examine the relative contributions of the rostral vs. caudal NAc shell to 
reversal learning in normal and METH-pretreated rats. 
As noted above, the lack of effect of METH pretreatment on the levels of 
Arc mRNA expression in dorsal striatum in the present study appears to be at 
odds with our prior work showing decreased Arc mRNA in such animals 
(Daberkow et al., 2008; Barker-Haliski et al., 2012b). This apparent difference 
likely arises from the approaches and, more so, the dependent measures, used 
in the different studies. In our former studies, we used fluorescent in situ 
hybridization (FISH) and determined the numbers of striatonigral vs. 
striatopallidal neurons with Arc mRNA signal in different subcellular 
compartments. In the present study, the radioactive in situ hybridization signal 
gives us a broad determination of Arc mRNA expression across both populations 
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of striatal efferent neurons and in all subcellular compartments. Our work with 
FISH has shown that basal Arc mRNA transcription is increased in both striatal 
efferent neuron populations in rats with METH-induced neurotoxicity, but that the 
animals do not further induce Arc mRNA in response to behavioral activation 
(Daberkow et al., 2008; Barker-Haliski et al., 2012b). Further, METH-induced DA 
loss is associated with loss of Arc mRNA specifically in the cytoplasm of 
striatonigral efferent neurons (Daberkow et al., 2008; Barker-Haliski et al., 
2012b). It is this latter effect that is apparent in our prior work (Daberkow et al., 
2008; Barker-Haliski et al., 2012b), as the dependent measure reported is the 
number of neurons with Arc mRNA signal in the cytoplasm. In the present study, 
because the radioactive in situ hybridization approach incorporates signal in both 
populations of neurons and in all subcellular compartments, the METH-induced 
loss of cytoplasmic Arc mRNA signal in one subpopulation of neurons is not 
apparent. That said, what the FISH and radioactive in situ approaches have in 
common is that both reveal the correlation between Arc mRNA expression and 
behavior (findings herein and in Daberkow et al., 2007, 2008). 
 The results of this study suggest that there is a change, following METH-
induced neurotoxicity, in the brain circuitry used in a behavioral task. Further, 
they provide additional support for the proposition that a correlation between Arc 
mRNA expression in a brain region and the measure of learning on a task 
implicates synaptic plasticity processes in that brain region as being critical for 
learning and its consolidation. Since humans with a history of METH abuse also 
can have partial monoamine loss, they may be forced to rely on potentially “less 
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ideal” neural circuits to perform particular cognitive tasks, and this lack of normal 
cognitive processes may contribute to cognitive deficits seen (Dean et al., 2013), 
especially in more complicated tasks that may require engagement of several 
brain regions at once. Better understanding the impact of neurotoxicity on 
synaptic plasticity mechanisms should allow for the development of targeted 
therapies to address impaired cognitive function in individuals with METH-
induced neurotoxicity or others with striatal dopamine loss, such as patients with 
Parkinson’s disease. 
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Figure 3.1. METH neurotoxicity results in decreases in DAT and SERT 
binding. Graphs showing METH-induced decreases in (A) striatal DAT and (B) 
prefrontal cortical SERT as revealed by [125I]RTI-55 binding. Since DAT and 
SERT binding between rats in the Arc correlation experiment and Arc antisense 
infusion experiment were not significantly different, binding values from both sets 
of rats are combined into one graph. Saline (SAL)-pretreated, n=21; METH-










Figure 3.2. Correlations between Arc mRNA in striatal subregions and trials 
to criterion on the response reversal-learning task. Arc mRNA expression 
was determined by densitometric analysis of film autoradiograms using ImageJ 
and is expressed as background-subtracted average gray values (arbitrary units). 
Significant correlations (as indicated by box around R2 and p values) were in DM 
striatum of (A) saline (SAL)-pretreated rats (R2=0.56, p=0.013) and NAc shell of 
(B) methamphetamine (METH)-pretreated rats (R2=0.44, p=0.0497). METH-
pretreated rats were given a neurotoxic regimen of (±)-METH•HCl (4 x 10 mg/kg 
free base, s.c., at two-hour intervals) approximately seven weeks prior to reversal 
learning. DMS, dorsomedial striatum; DLS, dorsolateral striatum; NAcC, nucleus 








Figure 3.3. Placement of infusion sites in nucleus accumbens shell. 
Diagrams (modified from Paxinos and Watson, 1998) showing placement of 
infusion sites (black dots) in the nucleus accumbens shell of rats infused with an 
Arc antisense or Arc nonsense oligonucleotide or with PBS. Numbers indicate 








Figure 3.4. Knockdown of Arc impairs consolidation of reversal learning in 
METH-, but not saline-, pretreated rats. Rats were infused with an Arc 
antisense oligonucleotide, Arc nonsense oligonucleotide, or PBS into NAc shell 
two hours prior to response-reversal learning on a T-maze. (A) None of the 
compounds had any effect on reversal learning in saline- or METH-pretreated 
rats. (B) Rats were tested on reversal retention 24 hr after reversal learning. 
Knockdown of Arc mRNA in NAc shell via an Arc antisense oligonucleotide 
impaired reversal retention in METH-, but not saline-, pretreated rats. Values are 
average trials to criterion (9/10 correct consecutive trials; ±SEM, n=3-6/group) on 
the reversal-learning task (A) or on the reversal-retention test 24 hr later (B). 












Table 3.1. Correlations between Arc mRNA expression in subregions of 
prefrontal cortex and hippocampus and trials to criterion on the response 
reversal-learning task. Values are R2 and respective p values obtained from 
multivariate analysis of the relation between in situ hybridization histochemical 
staining for Arc mRNA in each brain region and trials to criterion on a response 
reversal-learning task for rats pretreated with saline (4 x 1 mL/kg at two-hour 
intervals, n=10) or a neurotoxic regimen of (±)-METH (4 x 10 mg/kg, at 2-hr 
intervals, n=9) at least seven weeks prior to testing and sacrifice. Cg, cingulate 
cortex; PLC, prelimbic cortex; ILC, infralimbic cortex; vOFC, ventral orbitofrontal 
cortex; lOFC, lateral orbitofrontal cortex; CA1, Cornu Ammonis 1; CA3, Cornu 












PHASIC-LIKE STIMULATION OF THE MEDIAL FOREBRAIN BUNDLE  
 









Methamphetamine-induced partial dopamine depletions are associated 
with impaired basal ganglia function, including decreased preprotachykinin 
mRNA expression and impaired transcriptional activation of activity-regulated, 
cytoskeleton-associated (Arc) gene in striatum. Recent work implicates deficits in 
phasic dopamine signaling as a potential mechanism linking methamphetamine-
induced dopamine loss to impaired basal ganglia function. The present study 
thus sought to establish a causal link between phasic dopamine transmission 
and altered basal ganglia function by determining whether the deficits in striatal 
neuron gene expression could be restored by increasing phasic dopamine 
release. Three weeks after pretreatment with saline or a neurotoxic regimen of 
methamphetamine, rats underwent phasic- or tonic-like stimulation of ascending 
dopamine neurons. Striatal gene expression was examined using in situ 
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hybridization histochemistry. Phasic-like, but not tonic-like, stimulation induced 
immediate-early genes Arc and zif268 in both groups, despite the partial striatal 
dopamine denervation in methamphetamine-pretreated rats, with the Arc 
expression occurring in presumed striatonigral efferent neurons. Phasic-like 
stimulation also restored preprotachykinin mRNA expression. These results 
suggest that disruption of phasic dopamine signaling likely underlies 
methamphetamine-induced impairments in basal ganglia function, and that 
restoring phasic dopamine signaling may be a viable approach to manage long-





Methamphetamine (METH) is an addictive psychostimulant that is 
neurotoxic to dopamine (DA) neurons. Markers of DA innervation in both the 
dorsal and ventral striatum are reduced in brains of chronic METH abusers 
(Wilson et al., 1996), and individuals with a history of hospitalization associated 
with METH use are more likely to develop Parkinsonism (Callaghan et al., 2012). 
Thus, it is likely that some proportion of individuals who abuse METH will 
experience a period of partial DA loss as a consequence of their METH abuse 
prior to the development of Parkinsonism. Prior studies have suggested a 
relation between METH-induced DA loss and cognitive impairment in individuals 
with a history of METH abuse, as reduction of dopamine transporter (DAT) 
binding in the caudate-putamen correlates with motor and cognitive impairments 
 113 
in METH users (Volkow et al., 2001). Furthermore, METH use is associated with 
cognitive decline, as executive functions, learning, and memory, which are 
dependent on intact striatal circuitry (Brown et al., 1997; Packard and Knowlton, 
2002), are impaired in METH users (Scott et al., 2007; Dean et al., 2013, but see 
Hart et al., 2012). Similarly, in rodents, exposure to METH causes significant 
striatal DA denervation (Hotchkiss and Gibb, 1980; Ricaurte et al., 1980; Ricaurte 
et al., 1982). Associated with this depletion are learning impairments, including 
impaired recognition of novel stimuli (Schröder et al., 2003; Marshall et al., 2007; 
Herring et al., 2008; O'Dell et al., 2011), impaired motor-sequence learning 
(Chapman et al., 2001; Daberkow et al., 2005), and altered reversal learning 
(Izquierdo et al., 2010; Pastuzyn et al., 2012). Despite the association between 
METH-induced DA denervation and learning impairments, the molecular 
mechanisms linking these phenomena are not fully understood. 
Approximately 95% of striatal neurons are GABAergic medium spiny 
neurons (MSNs), which are found in two roughly equal subtypes. Striatonigral 
(“direct pathway”) MSNs express D1 DA receptors, as well as the neuropeptides 
substance P (and its preprotachykinin (ppt) precursor) and dynorphin (Gerfen et 
al., 1990; Surmeier et al., 1996). Striatopallidal neurons (“indirect pathway”) 
express D2 DA receptors, as well as the neuropeptide enkephalin (and its 
preproenkephalin (ppe) precursor) (Gerfen et al., 1990; Le Moine et al., 1990; 
Surmeier et al., 1996). Partial striatal DA loss induced by either METH or 6-
hydroxydopamine (6-OHDA) results in a reduction in basal ppt expression in 
striatum, but no change in ppe expression (Nisenbaum et al., 1996; Chapman et 
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al., 2001; Johnson-Davis et al., 2002). Furthermore, METH-induced neurotoxicity 
is associated with loss of Arc (activity-regulated, cytoskeleton-associated gene) 
transcription in response to behavioral activation (Daberkow et al., 2008; Barker-
Haliski et al., 2012a), and only the impairment in the numbers of striatonigral 
neurons with Arc mRNA in the cytoplasm correlates significantly with the degree 
of METH-induced striatal DA loss (Barker-Haliski et al., 2012a). Taken together, 
these data suggest that partial DA loss, such as that induced by METH, affects 
striatal efferent neuron function and that this dysfunction may predominantly 
affect striatonigral neurons. 
METH-induced neurotoxicity selectively impairs phasic-like DA signaling 
(Howard et al., 2011), which is thought to preferentially affect striatonigral 
neurons (Chergui et al., 1997; Gonon, 1997; Onn et al., 2000). METH-induced 
partial DA depletion is associated with diminished amplitude of DA signals 
evoked using phasic-like stimulation of the DA neurons ascending through the 
medial forebrain bundle (MFB) (Howard et al., 2011), as well as the amplitude of 
endogenous, spontaneously occurring phasic DA transients (Howard et al., 
2013). On the other hand, tonic DA levels, which are thought to be sufficient to 
activate D2 receptors expressed by striatopallidal neurons (Richfield et al., 1989; 
Dreyer et al., 2010), are not disrupted following METH pretreatment, as assessed 
by microdialysis (Cass and Manning, 1999). Interestingly, enhancing phasic-like, 
but not tonic-like, DA signaling via electrical stimulation of DA neurons results in 
increased zif268 expression in D1 DA receptor-containing striatonigral neurons 
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(Chergui et al., 1997). Therefore, METH-induced dysfunction in direct pathway 
MSNs may be due to impairments in phasic, but not tonic, DA signaling. 
If reduced phasic DA signaling is related to the gene expression deficits 
observed following METH-induced partial DA denervation, then augmenting 
phasic DA signaling should restore normal gene expression in the partially DA 
denervated striatum. We tested this hypothesis by pretreating rats with a 
neurotoxic regimen of METH and then, three weeks later, stimulating DA neurons 
ascending through the MFB in either a phasic- or tonic-like pattern. We then 
assessed striatal expression of ppt and ppe and the immediate-early genes 
(IEGs) Arc and zif268. We show that phasic-like stimulation increases IEG 
expression in both METH- and saline-pretreated rats and that the increase in Arc 
mRNA expression is preferentially in direct pathway neurons. Furthermore, the 
phasic-like stimulation restores ppt expression in METH-pretreated rats without 
altering ppe expression. These findings suggest that restoring phasic DA 
signaling may ameliorate basal ganglia dysfunction arising consequent to partial 
DA depletion, such as that induced by METH. 
 
 
Materials and Methods 
Animals. Adult male Sprague-Dawley rats (n=30, 240-350 g at time of 
pretreatment) were purchased from Harlan (Indianapolis, IN, USA) and housed in 
a light- and temperature-controlled vivarium. Access to food and water was 
provided ad libitum. All procedures conformed to the NIH Guide for the Care and 
 116 
Use of Laboratory Animals and were approved by the Institutional Animal Care 
and Use Committee of Illinois State University. 
Drugs. (±)-Methamphetamine hydrochloride was provided by the National 
Institute on Drug Abuse (Rockville, MD, USA). METH doses were calculated as 
free base. All other chemicals were purchased from Sigma Aldrich (St. Louis, 
MO, USA). 
METH pretreatment. The “binge” neurotoxic METH regimen was 
conducted as previously described (Howard et al., 2011). Briefly, animals were 
housed in plastic tub cages (50 cm length X 40 cm width X 20 cm height: four 
rats/cage). METH was dissolved in 0.9% saline and all injections were made 
subcutaneously. Four injections of either METH (7.5 mg/kg) or saline were 
administered at two-hour intervals. Temperature was monitored rectally using a 
Thermalert TH-5 (Physitemp, Clifton, NJ, USA) prior to, immediately after the first 
injection, and every hour thereafter, continuing two hours after the final injection 
of METH. Health was assessed at least every hour, and if rats showed signs of 
overheating, they were placed in a separate tub on ice for ~10 min. 
Electrical stimulation and in vivo voltammetry. Three weeks after METH or 
saline pretreatment, animals to be stimulated were anesthetized with urethane 
(1.5 g/kg, i.p.) and placed in a stereotaxic apparatus (David Kopf Instruments, 
Tajunga, CA, USA). Four holes were drilled into the skull to allow for lowering of 
the stimulating electrode, two carbon fiber microelectrodes (CFM), and a Ag/AgCl 
reference electrode. The twisted, bipolar stimulating electrode (Plastics One, 
Roanoke, VA, USA) was placed dorsal to the MFB (-4.6 AP; +1.4 ML; -7.0 DV) 
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(Paxinos and Watson 1986) and was incrementally lowered until a robust DA 
signal was recorded in the striatum at the CFMs placed in the dorsomedial (DM) 
and dorsolateral (DL) striatum (+1.2 AP; +1.0 and +4.0 ML, respectively; -4.5 DV; 
Paxinos and Watson 1986) at 6o angles to allow side by side ipsilateral 
placement. Changes in DA concentration were recorded using fast-scan cyclic 
voltammetry (FSCV), where a triangular waveform (-0.4 V to 1.3 V and back at 
400 V/s) was applied to the tip of the CFM every 100 ms (Cahill et al., 1996) 
using an EI400 bipotentiostat (Ensman Instruments, Bloomington, IN, USA) that 
was computer-controlled using TH-1 software (ESA, Chelmsford, MA, USA). 
Current recorded at each CFM was converted to concentration using in vitro 
calibration immediately following experiments (Logman et al., 2000). The 
purpose of recording with FSCV at a CFM in this experiment was to identify DA 
neurons ascending through the MFB for stimulation with phasic- and tonic-like 
pulse trains, and to ensure optimal stimulating electrode placement. 
Nonstimulated control rats were anesthetized with urethane, but did not undergo 
surgical manipulations or any stimulation. 
Following optimization of the stimulating electrode placement, no 
stimulation was given for one hour to reduce optimization- and handling-induced 
striatal gene expression (Daberkow et al., 2007). The experimental stimulation 
protocol was then begun. Electrical stimulation was optically isolated (NL 800, 
Neurolog, Medical Systems, Great Neck, NY, USA) and synchronized with FSCV 
recordings. The stimulation protocol was chosen based on previous work noting 
enhanced expression of mRNA for the IEG zif268 following phasic-like (“burst”), 
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but not tonic-like (“regular”), stimulation (Chergui et al., 1997). Stimulation was 
comprised of constant-current, biphasic pulses (2 ms and 300 µA each phase) 
and was delivered in either a phasic-like (5 pulses at 30 Hz repeated every 1 s 
for 60 s; n=5 METH-pretreated; n=5 saline-pretreated) or tonic-like (300 pulses at 
5 Hz; n=5 METH-pretreated; n=5 saline-pretreated) pattern. Stimulation trains 
were 60 s in duration and were repeated a total of 15 times, with 2 min 
separating each stimulation train, for a total stimulation session time of 45 min. 
Immediately following stimulation sessions, animals were euthanized and brains 
were rapidly extracted. Nonstimulated control rats were sacrificed 180 min after 
being anesthetized with urethane (n=5 METH-pretreated; n=5 saline-pretreated). 
Brains were flash frozen in 2-methylbutane (EMD Millipore, Billerica, MA, USA) 
on dry ice and stored at -80oC. 
Dopamine transporter (DAT) autoradiography. To determine the extent of 
METH-induced DA depletions, frozen brains were sectioned (12-µm coronal 
sections) using a cryostat (Cryocut 1800; Leica, Wetzlar, Germany). Sections 
were thaw-mounted onto Superfrost Plus (VWR, Aurora, CO, USA) slides. Slides 
were stored at -20°C until needed. DA transporter (DAT) autoradiography was 
performed as detailed previously by others and us (Boja et al., 1992; O'Dell et al., 
2011; Pastuzyn et al., 2012). Briefly, slides were incubated in buffer containing 
fluoxetine to block radioligand binding to the serotonin transporter in striatum. 
Slides then were incubated in the continued presence of fluoxetine with [125I]RTI-
55 (PerkinElmer, Waltham, MA, USA). Slides were then rinsed, dried under a 
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stream of warm air, and exposed to film (Kodak Biomax MR; Eastman Kodak, 
Rochester, NY, USA) for 24 h before being developed. 
Radioactive in situ hybridization. To assess striatal IEG expression, frozen 
slides containing striatal sections were postfixed and delipidated as previously 
described (Ganguly and Keefe, 2001). As detailed previously, detection of ppt 
(Chapman et al., 2001; Johnson-Davis et al., 2002; Horner et al., 2005), ppe 
(Ganguly and Keefe, 2000; Chapman et al., 2001; Ganguly and Keefe, 2001; 
Daberkow et al., 2007), zif268 (Keefe and Adams, 1998), and Arc (Daberkow et 
al., 2007, 2008; Barker-Haliski et al., 2012a) mRNAs was accomplished using 
ribonucleotide probes. Antisense ribonucleotide probes were transcribed from 
linearized plasmids using 35S-UTP (PerkinElmer) and SP6 (ppe and ppt) or T7 
(zif268 and Arc) RNA polymerases (Roche, Indianapolis, IN, USA). The 
radioactive in situ hybridization was performed as previously described (Ganguly 
and Keefe, 2001) with slight modifications to final washing procedures. The last 
four washes on the second day were either at 55°C (Arc and ppt) or room 
temperature (ppe and zif268). Slides were dipped in ddH2O, air-dried, and 
exposed to film. Exposure times were: ppt, zif268, and Arc, two weeks; ppe, 
three days. 
Fluorescent in situ hybridization. To assess pathway-specific expression 
of Arc mRNA, slides were postfixed and delipidated as for radioactive in situ 
hybridization above. As previously described (Daberkow et al., 2007; Barker-
Haliski et al., 2012a), expression of Arc and ppe mRNAs in striatum was 
determined by performing double-label fluorescent in situ hybridization (FISH) 
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using probes directed against Arc and ppe mRNAs. Arc and ppe antisense 
ribonucleotide probes were synthesized using digoxigenin-UTP (DIG-UTP) and 
fluorescein-UTP (FITC-UTP) with T7 and SP6 RNA polymerases using DIG or 
FITC labeling kits (Roche), respectively. Slides were hybridized and detected as 
previously described (Daberkow et al., 2007, 2008; Barker-Haliski et al., 2012b), 
except that a 1:50,000 solution of SYTOX Green (Molecular Probes; Life 
Technologies, Grand Island, NY, USA) was used as a nuclear stain instead of 
DAPI. As controls, a set of slides was run in parallel either without ribonucleotide 
probes or without antibodies. Lack of signal on these slides was taken as 
evidence of the specificity of the in situ hybridization histochemical labeling. 
Image analysis. Films from DAT autoradiography and radioactive in situ 
hybridization histochemistry were developed, and images were digitized using a 
video camera (CCD72S; Dage-MTI, Michigan City, IN, USA) and fiber optic light 
box. The intensity of the light was adjusted so that it fell within the linear range of 
the camera, as determined by a photographic step tablet (Eastman Kodak Co.). 
Densitometric analysis of the digitized images was then accomplished using NIH 
ImageJ software, yielding average gray values in DM and DL striatum for both 
hemispheres. Two rostral (+1.6 mm from Bregma) and two middle striatal 
sections (+0.7 mm from Bregma) were analyzed per rat. For each hemisphere, 
the average gray value of the corpus callosum was subtracted from the average 
gray value of DM and DL striatum to correct for background staining. Decreases 
in DAT in METH-pretreated rats were calculated as a percent of DAT levels in 
saline-pretreated rats. 
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 FISH images were collected using a Leica DM4000B automated upright 
microscope (63X oil immersion objective) connected to a Leica EL6000 external 
light source with a mercury metal halide bulb and a Leica DFC300 FX digital 
color camera. Surveyor computer software (Objective Imaging Ltd.; Cambridge, 
UK) was used to control the automated stage, perform multichannel scanning, 
and capture the fluorescent images. A 2 x 2 montage (0.38 mm2) was captured in 
the area of striatum with the most Arc expression, as identified from the film 
autoradiograms of Arc mRNA expression. In the case of rats with no apparent 
stimulation-induced Arc mRNA expression on the film autoradiograms, montages 
of FISH staining were captured in DL striatum, as DL striatum was the location 
where the majority of rats stimulated in a phasic-like manner showed Arc 
expression. The total numbers of Arc-positive/ppe-negative (i.e., presumed 
striatonigral neurons) and Arc-positive/ppe-positive (i.e., striatopallidal neurons) 
neurons in each image were counted by an experimenter blinded to the 
treatment groups. Furthermore, the average signal intensity of Arc expression in 
each individual neuronal population (striatonigral and striatopallidal) was 
measured in ImageJ by first individually outlining all Arc-positive/ppe-positive 
neurons in an image and measuring signal intensity in those cells. Then, the Arc-
positive/ppe-negative neurons in the image were outlined and the average Arc 
signal intensity of those neurons was measured. 
Statistical analysis. Rectal temperatures were compared using repeated 
measures MANOVA with pretreatment as a factor and time as a repeated 
measure.  Post hoc one-way ANOVAs with Tukey-Kramer HSD tests were used 
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to further interrogate the significant pretreatment x time interaction for the body-
temperature data. For radioactive in situ hybridization and DAT autoradiography, 
average gray values were compared between pretreatment (METH or saline) and 
stimulation (no stimulation, tonic, or phasic) groups by two-way ANOVA. For 
FISH, the numbers of Arc-positive/ppe-negative and Arc-positive/ppe-positive 
cells were compared between pretreatment and stimulation groups by two-way 
ANOVA. The relative amount of Arc signal in the striatal neuron populations was 
also examined by calculating a “difference score,” which was the average gray 
value of the Arc-positive/ppe-negative population minus the average gray value 
of the Arc-positive/ppe-positive population for each animal. This “difference 
score” was compared between pretreatment and stimulation groups by two-way 
ANOVA. Post hoc Tukey-Kramer HSD tests were performed when ANOVA 
revealed significant interactions or main effects. Statistical tests were performed 




METH pretreatment and DAT autoradiography. A treatment x time 
repeated measures MANOVA revealed that the METH “binge” pretreatment 
paradigm differentially altered body temperature across METH- and saline-
treated rats (Fig. 4.1a; significant effect of time, F(7,30)=4.45, p=0.0032; significant 
effect of treatment F(1,30)=53.43, p<0.0001; significant time x treatment 
interaction, F(7,30)=35.20, p<0.0001). Post hoc analysis revealed that METH-
treated animals were significantly hyperthermic relative to saline-treated animals 
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two hours after METH injection and every hour thereafter (p<0.001 at 120-420 
min after METH). METH pretreatment resulted in significant decreases in striatal 
DAT three to five weeks later, as assessed by [125I]RTI-55 autoradiography (Fig. 
4.1b-c). A two-way ANOVA revealed a main effect of pretreatment (DM striatum, 
F(1,24)=17.1, p<0.001; DL striatum, F(1,24)=20.3, p=0.0001), but no significant main 
effect of stimulation and no significant pretreatment x stimulation interaction 
(p>0.05). 
Effect of phasic- and tonic-like stimulation of the MFB on Arc expression. 
Stimulation of the MFB resulted in changes in striatal Arc expression in both 
saline- and METH-pretreated rats (Fig. 4.2a). A two-way ANOVA (pretreatment x 
stimulation) for Arc mRNA expression in DM striatum revealed a main effect of 
stimulation (Fig. 4.2b; F(2,24)=5.29, p<0.05), but no significant effect of 
pretreatment (p>0.05) and no significant stimulation x pretreatment interaction 
(p>0.05). Post hoc analysis of the main effect of stimulation revealed that phasic-
like stimulation increased Arc mRNA expression in the DM striatum both relative 
to nonstimulated controls (p=0.03) and rats receiving tonic-like stimulation 
(p<0.05). However, Arc mRNA expression in rats receiving tonic-like stimulation 
was not different from the nonstimulated control group (p>0.05). 
Similarly, in DL striatum, there was a main effect of stimulation (Fig. 4.2b; 
F(2,24)=7.24, p<0.01), but no main effect of pretreatment (p>0.05) and no 
significant stimulation x pretreatment interaction (p>0.05). Post hoc analysis 
again revealed that phasic-like stimulation increased Arc mRNA expression 
relative to that seen in nonstimulated controls (p<0.01) and rats receiving tonic-
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like stimulation (p=0.03). As in DM striatum, there was no significant difference in 
Arc mRNA expression in rats receiving tonic-like stimulation relative to 
nonstimulated controls (p>0.05). Thus, regardless of whether rats had partial DA 
loss induced by METH pretreatment, phasic-like activation increased the 
expression of Arc mRNA in DM and DL striatum. 
Effect of phasic- and tonic-like stimulation of the MFB on zif268 
expression. Stimulation of the MFB resulted in changes in striatal zif268 
expression in both saline- and METH-pretreated rats that were similar to those 
observed for Arc (Fig. 4.2c). A two-way ANOVA (pretreatment x stimulation) in 
DM striatum revealed a main effect of stimulation (Fig. 4.2d; F(2,24)=9.46, 
p<0.001), but no effect of pretreatment (p>0.05) and no significant interaction 
(p>0.05). Post hoc analysis of the main effect of stimulation revealed that zif268 
expression was significantly greater in rats receiving phasic-like stimulation 
relative to both rats receiving tonic-like stimulation (p<0.001) or no stimulation 
(p<0.001). The expression of zif268, however, was not different between rats 
receiving tonic-like stimulation and rats receiving no stimulation (p>0.05). 
Likewise, in DL striatum, there was a significant main effect of stimulation 
(Fig. 4.2d; F(2,24)=8.12, p<0.01), but no main effect of pretreatment (p>0.05) and 
no significant interaction (p>0.05). Again, post hoc analysis revealed that zif268 
expression in rats receiving phasic-like stimulation was significantly greater than 
that in rats receiving tonic-like stimulation (p<0.01) or no stimulation (p<0.01). 
The expression of zif268 was not significantly different between rats receiving 
tonic-like stimulation and nonstimulated controls (p>0.05). Thus, as was the case 
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for Arc, phasic- but not tonic-like stimulation of the MFB increased zif268 
expression in both METH- and saline-pretreated rats. 
Effects of phasic- and tonic-like stimulation of the MFB on ppt expression. 
We and others (Nisenbaum et al., 1996; Chapman et al., 2001; Johnson-Davis et 
al., 2002) have previously reported that partial DA loss, such as that induced by 
METH pretreatment, results in a long-term decrease in ppt expression. 
Consistent with this prior work, in the present study, METH-pretreatment was 
associated with a decrease in ppt mRNA expression (Fig. 4.3a, c, d). Two-way 
ANOVA of ppt mRNA expression in DM striatum revealed a main effect of 
pretreatment (Fig. 4.3c; F(1,24)=4.87, p<0.05), with ppt expression being lower 
overall in METH-pretreated rats. The ANOVA also revealed a main effect of 
stimulation (Fig. 4.3b; F(2,24)=4.6, p<0.05), but no significant interaction (p>0.05). 
Post hoc analysis of the main effect of stimulation revealed that phasic-like 
stimulation significantly elevated ppt mRNA expression in DM striatum relative to 
rats receiving tonic-like stimulation of MFB (p<0.02).  
  In DL striatum, there was a trend towards an effect of pretreatment (Fig. 
4.3d; F(1,24)=3.34; p=0.08) and a main effect of stimulation (Fig. 4.3b; F(2,24)=3.67, 
p<0.05), but no significant interaction (p>0.05). Post hoc analysis revealed strong 
trends indicating that phasic-like stimulation increased ppt expression in DL 
striatum relative to both that seen in rats receiving tonic-like stimulation (p=0.057) 
and control rats that did not receive stimulation (p=0.084). As with the other 
genes, ppt mRNA expression was not different between rats receiving tonic-like 
stimulation vs. no stimulation controls (p=0.98). 
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Effects of phasic- and tonic-like stimulation of the MFB on ppe expression. 
Neither METH pretreatment nor stimulation of the MFB in either a phasic-like or 
tonic-like pattern resulted in any significant changes in striatal ppe mRNA 
expression in saline- or METH-pretreated rats (Fig. 4.3e-f). Thus, in both DM and 
DL striatum, there were no significant main effects of pretreatment or stimulation 
and no significant interactions (all p>0.05). 
Effects of phasic- and tonic-like stimulation of the MFB on Arc expression 
in subpopulations of striatal neurons. Stimulation of the MFB did not cause any 
changes in the numbers of ppe-negative (presumed striatonigral) and ppe-
positive (striatopallidal) neurons positive for Arc mRNA expression (p>0.05; Fig. 
4.4a-b). However, it was clear during blinded image analysis that the relative 
amount of signal for Arc mRNA was different between striatonigral and 
striatopallidal neurons (Fig. 4.4c-f). Thus, we measured the relative average gray 
value of Arc expression in the two efferent neuron populations separately and 
calculated a “difference score” (see Materials and Methods) reflecting the 
difference in the average gray value of the Arc signal in ppe-negative vs. ppe-
positive neurons. Two-way ANOVA of this "difference score" revealed a 
significant main effect of stimulation (F(2,24)=9.3, p=0.001), but no main effect of 
pretreatment (p>0.05) and no significant interaction (p>0.05). Post hoc analysis 
of the main effect of stimulation revealed that greater Arc mRNA expression in 
ppe-negative neurons was induced by phasic-like stimulation relative to either 





Consistent with prior reports in the literature, the present results show that 
partial striatal DA loss, such as that induced by a neurotoxic regimen of METH, is 
associated with decreased ppt mRNA expression in the striatum (Nisenbaum et 
al., 1996; Chapman et al., 2001; Johnson-Davis et al., 2002). Furthermore, the 
present results confirm prior work (Chergui et al., 1997) that phasic-like 
stimulation of the MFB increases zif268 expression in striatum. Additionally, the 
present work extends these previous studies by showing that phasic-like 
stimulation also increases Arc and ppt mRNA expression in striatonigral neurons 
and, importantly, that this effect of phasic-like stimulation is effective in driving 
gene expression in presumed striatonigral efferent neurons even in the setting of 
partial DA loss induced by METH. Thus, the present data reinforce the idea that 
phasic-like DA neuron activity appears to selectively affect the function of 
striatonigral efferent neurons and suggest that sufficient circuitry remains in rats 
with partial striatal DA loss to restore striatal function by enhancing phasic DA 
neurotransmission 
 The present data suggest that augmentation of phasic-like DA 
neurotransmission in animals with partial striatal DA loss may generally restore 
the ability of residual DA neurons to regulate striatonigral efferent neuron gene 
expression. As noted above, partial DA loss, such as that induced by 6-OHDA or 
a neurotoxic regimen of METH, is associated with an impairment of phasic-like, 
but not tonic-like, DA signals (Bergstrom and Garris, 2003; Howard et al., 2011). 
It has been proposed, based on electrophysiological (Onn et al., 2000) and 
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computer modeling (Dreyer et al., 2010) studies, that D1 DA receptors, and thus 
striatonigral efferent neurons (Gerfen and Surmeier, 2011), are most sensitive to 
the higher levels of extracellular DA resulting from phasic DA activity. 
Alternatively, it has been suggested that D2 DA receptors, which are selectively 
expressed by striatopallidal efferent neurons, are largely saturated by DA under 
tonic extracellular DA levels and thus are largely insensitive to phasic increases 
in extracellular DA levels (Dreyer et al., 2010). Taken together, these data 
suggest that the decrease in phasic DA neurotransmission associated with partial 
DA loss selectively impairs D1 receptor activation and, therefore, normal gene 
expression in striatonigral neurons. Our present results further suggest that 
augmenting phasic-like DA neurotransmission can restore the degree of D1 
dopamine receptor activation and, thus, striatonigral neuron function. 
 Consistent with this model, expression of ppe mRNA in D2 DA receptor-
expressing striatopallidal neurons was not altered either by METH-induced 
neurotoxicity or by phasic- or tonic-like stimulation of the MFB in this study. 
Previous studies from our lab and others that found a decrease in ppt expression 
in the setting of partial striatal DA loss also reported no change in ppe mRNA 
expression (Nisenbaum et al., 1996; Chapman et al., 2001; Johnson-Davis et al., 
2002). Interestingly, expression of ppe mRNA in striatopallidal neurons only 
changes (increases) in the setting of extensive (~80-90%) denervation of the 
striatum (Gerfen et al., 1991; Nisenbaum et al., 1996), and this same degree of 
striatal DA denervation is necessary before a decrease in tonic, extracellular 
levels of DA occurs (Abercrombie et al., 1990; Castañeda et al., 1990). Given 
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that METH neurotoxicity resulted in an ~25% striatal DA denervation (Fig. 4.1c), 
METH-induced neurotoxicity is not associated with changes in tonic extracellular 
levels of DA (Robinson et al., 1990; Cass and Manning, 1999). It is therefore not 
surprising that the METH-pretreated rats in this study, as in previous reports, did 
not have changes in ppe expression. 
One confound of the current study is nonselective stimulation of axons in 
the MFB. The MFB is highly heterogeneous and contains nondopaminergic 
neurons that project to both striatum and the cortex (Nieuwenhuys et al., 1982). 
Additionally, the striatum receives glutamatergic afferents from various cortical 
areas (McGeorge and Faull, 1989; Ramanathan et al., 2002), and electrical 
stimulation of the cortex augments striatal IEG expression in monkeys 
(Parasathay and Graybiel, 1997) and rats (Fu and Beckstead, 1992; Liste et al., 
1995). Therefore, it is possible that the gene expression measured here was 
partially induced through a nondopaminergic pathway, potentially relayed through 
the cortex. However, electrical stimulation of MFB released DA in the striatum as 
measured by FSCV (data not shown), the stimulating electrode was optimized 
within the MFB to elicit this DA release, and previous work has demonstrated that 
the D1 antagonist SCH23390 impairs expression of zif268 (NGFI-A) caused by 
MFB stimulation (Chergui et al., 1997). Furthermore, as is apparent in Figures 
4.2 and 4.3, cortical activation of Arc and zif268 expression is notable in animals 
that received phasic- or tonic-like stimulation, whereas only animals receiving 
phasic-like stimulation showed increased striatal IEG expression. We noted no 
correlation between gene expression in striatum and that in the cortex directly 
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overlying striatum in either stimulation group (data not shown), suggesting that 
the cortical and striatal gene expression are not linked. Thus, these data suggest 
that the striatal gene expression is likely induced by electrical stimulation of DA 
neurons ascending through the MFB, although we cannot definitively rule out a 
contribution of other circuits to the effects at present. 
Somewhat analogous to METH-induced neurotoxicity, Parkinson’s 
disease (PD) is characterized in part by loss of striatal DA nerve terminals 
(Hornykiewicz and Kish, 1987) and dysfunction in striatal gene products (Nisbet 
et al., 1995). Importantly, cognitive impairments have been recognized in PD 
patients during the preclinical stage (Abbruzzese et al., 2009). While the 
pathology underlying these cognitive impairments is not understood, theoretical 
models indicate that deficits in D1 receptor signaling may play a role (Frank et 
al., 2004; Guthrie et al., 2009; Wiecki and Frank, 2010). It is thus informative that 
decreases in indices of D1 DA receptor-expressing striatonigral neuron function, 
including transcriptional activation of IEGs essential for consolidation of long-term 
memories (Barker-Haliski et al., 2012a), and deficits in basal ganglia-mediated 
learning and memory functions are apparent in rats with partial DA depletions 
(less than 80%), such as those induced by METH (Chapman et al., 2001; 
Daberkow et al., 2005; Daberkow et al., 2008; Son et al., 2011; Pastuzyn et al., 
2012). Taken together, these data suggest that deficits in phasic DA signaling 
and downstream striatonigral gene expression alterations may be involved in the 
cognitive disabilities apparent in both the setting of METH-induced neurotoxicity 
and the preclinical stages of PD. The present data further suggest that 
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approaches to augment residual phasic DA signaling in the context of partial DA 
denervation or to replicate such signaling in the setting of more extensive DA 
denervation may prove fruitful in managing cognitive deficits associated with 
deficits in DA signaling, such as those observed in individuals with a history of 
METH abuse or PD. 
 Our findings demonstrate that augmenting phasic DA signaling in the 
partially DA denervated striatum enhances striatal gene expression to the same 
extent as in the intact striatum. Deficits in striatonigral neuron gene expression 
induced by large DA-depleting brain lesions are reversed with administration of 
levodopa (L-DOPA) (Zeng et al., 1995; Westin et al., 2001). Given that L-DOPA 
increases vesicular content of DA (Pothos et al., 1996) and electrically evoked 
DA release in intact rats (Garris et al., 1994; Rodríguez et al., 2007), it seems 
likely that it will augment phasic DA signaling in the context of partial striatal DA 
loss. Whether the postsynaptic consequences of partial DA denervation can be 
reversed with L-DOPA treatment or administration of other agents that enhance 
phasic DA signaling, such as amphetamine (Ramsson et al., 2011; Daberkow et 
al., 2013), which is used as a cognitive enhancer in treating attention-deficit 
hyperactivity disorder and drug addiction (Brady et al., 2011; Steiner and Van 
Waes, 2013), is currently being examined. 
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Figure 4.1. Effect of methamphetamine pretreatment on body temperature 
and dopamine innervation in the dorsal striatum. (A) METH treatment 
resulted in significantly increased body temperatures relative saline-treated 
controls. Arrows indicate time of METH injections. Data are average rectal 
temperatures (°C; mean±SEM, n=15 for saline-treated and n=15 for METH-
treated). *Significantly different from saline-treated rats at the same time point. 
BL, baseline; **p<0.001, ***p<0.0001. (B) Representative images of [125I]RTI-55 
striatal DAT binding in a saline- and METH-pretreated rat three to five weeks 
after METH pretreatment. (C) METH pretreatment resulted in partial dopamine 
denervation in both the dorsomedial (DMS) and dorsolateral (DLS) striatum three 
to five weeks after METH pretreatment as assessed by [125I]RTI-55 binding to 
dopamine transporters. Data are presented as percent of saline-pretreated 
values (±SEM, n=15 for saline-pretreated and n=15 for METH-pretreated). 


























Figure 4.2. Effect of MFB stimulation on expression of Arc and zif268 in 
striatum of METH- and saline-pretreated rats. (A, C) Representative images of 
striatal Arc (A) or zif268 (C) mRNA expression in saline- (top row) and METH- 
(bottom row) pretreated rats. Circles on the Arc/saline-pretreated/no stimulation 
image represent the regions of interest (ROIs) measured in both dorsomedial 
(DMS) and dorsolateral (DLS) striatum for all genes in this study. (B, D) 
Quantification of Arc (B) and zif268 (D) expression in stimulation groups 
collapsed across pretreatment group. Data are average gray values (arbitrary 
units; mean±SEM; n=10 for each stimulation group per subregion, per gene 
product). *Significantly different from both no stimulation (No Stim) and Tonic 
groups, p<0.05. **Significantly different from both No Stim and Tonic groups, 




















Figure 4.3. Effect of MFB stimulation on expression of preprotachykinin 
and preproenkephalin in striatum of METH- and saline-pretreated rats. (A) 
Representative images of striatal ppt mRNA expression in saline- (top row) and 
METH- (bottom row) pretreated rats. (B) Quantification of ppt expression in 
stimulation groups collapsed across pretreatment groups. Data are average gray 
values (arbitrary units; mean±SEM, n=10 for each stimulation group per 
subregion). *Significantly different from Tonic group, p<0.05. (C, D) Quantification 
of ppt expression separated by pretreatment group to demonstrate the effect of 
METH pretreatment on ppt expression. Data are average gray values (arbitrary 
units; mean±SEM, n=5 for saline- and METH-pretreated animals per stimulation 
group for both DMS and DLS). #Main effect of pretreatment, p<0.05. (E) 
Representative images of striatal ppe mRNA expression in saline- (top row) and 
METH- (bottom row) pretreated rats. (F) Quantification of ppe expression in 
dorsomedial striatum. Data are average gray values (arbitrary units; mean±SEM, 
n=5 for saline- and METH-pretreated animals per stimulation group). Data from 













































Figure 4.4. Phasic-like stimulation of dopamine neurons increases Arc 
expression in striatonigral neurons. (A-B) Numbers of Arc-positive/ppe-
negative and Arc-positive/ppe-positive cells/0.5 mm2 in the striatum of A) saline 
(SAL)- and B) METH-pretreated rats receiving no stimulation (No Stim) or tonic-
like or phasic-like stimulation of the MFB. (C-F) Representative fluorescent in situ 
hybridization images of Arc mRNA expression in presumed striatonigral neurons 
(Arc-positive/ppe-negative; arrowheads) and striatopallidal neurons (Arc-
positive/ppe-positive; arrows) in rats that received phasic-like (C-D) or tonic-like 
(E-F) stimulation. Arc is orange, ppe is blue, SYTOX nuclear stain is green. 
Images in C and E show all three channels, while images in D and F show only 
the Arc channel. Scale bar=10 µm. (G) Graph showing the “difference score” 
collapsed across pretreatment (p>0.05), defined as the difference between the 
average gray value of Arc-positive/ppe-negative and Arc-positive/ppe-positive 














L-DOPA RESCUES DOPAMINE RESPONSES EVOKED BY PHASIC-LIKE  
 
STIMULATION OF THE MEDIAL FOREBRAIN BUNDLE IN RATS WITH  
 





Methamphetamine (METH) abuse causes long-lasting damage to 
monoamine systems in the brain, which can be modeled in rats using a “binge” 
regimen of METH. METH-pretreated rats display partial depletion of dopamine 
(DA) in the striatum and show abnormal striatal gene expression, altered circuitry 
used in a striatally-mediated task, and decreased striatal phasic DA transmission. 
Recent research has indicated that L-DOPA may restore normal function to the 
striatum after METH-induced neurotoxicity. Here, we investigated whether L-
DOPA could restore phasic DA neurotransmission following METH neurotoxicity. 
Rats were pretreated with a neurotoxic regimen of METH (4x10 mg/kg, s.c., at 
two-hour intervals) or with saline. Three weeks later, rats were anesthetized and 
fast-scan cyclic voltammetry was used to measure DA release in the dorsomedial 
and dorsolateral striatum caused by stimulation of the medial forebrain bundle. 
Rats were injected with benserazide (40 mg/kg, i.p.) and L-DOPA (50 mg/kg, i.p.) 
 148 
and stimulation-induced DA release was recorded for two hours. L-DOPA 
restored phasic-like DA release in METH-pretreated rats to saline-pretreated 
control levels. Surprisingly, response to L-DOPA was not uniform throughout the 
striatum, as some recording sites displayed large activation to L-DOPA and some 
did not, even if recorded simultaneously within the same striatal subregion. Also, 
chemometric analysis indicated no detectable basal DA changes after L-DOPA, 
indicating specific phasic DA activation. These findings suggest that the 
decreased phasic DA release seen in METH-pretreated rats can be partially 
rescued with L-DOPA, which is promising for future translational studies in 




  Methamphetamine (METH) abuse is an ongoing societal issue. In addition 
to the highly addictive nature of METH, users abstaining from the drug also face 
cognitive impairments (Marshall and O'Dell, 2012; Dean et al., 2013), which are 
linked to long-term changes in the brain induced by METH including loss of 
markers of dopamine (DA) innervation in striatum (Wilson et al., 1996; Volkow et 
al., 2001; McCann et al., 2008). “Binge” regimens of METH in rodents cause 
similar DA depletion to those seen in human METH abusers (Seiden et al., 1976; 
Morgan and Gibb, 1980; Ricaurte et al., 1980; Wagner et al., 1980; Marshall and 
O'Dell, 2012). Additionally, METH-induced DA loss is related to diminished 
learning performance in rats on several behavioral tasks (Friedman et al., 1998; 
Chapman et al., 2001; Schröder et al., 2003; Achat-Mendes et al., 2005; Belcher 
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et al., 2005; Daberkow et al., 2005; Izquierdo et al., 2010; O'Dell et al., 2011; 
Reichel et al., 2012), though the mechanisms underlying these impairments are 
not clear. 
 Secondary to monoamine loss is basal ganglia dysfunction, which is 
evidenced by altered basal (Chapman et al., 2001; Johnson-Davis et al., 2002) 
and behavior-induced striatal gene expression (Daberkow et al., 2008; Barker-
Haliski et al., 2012) and changes in circuitry mediating behavior (Son et al., 2011; 
Pastuzyn et al., 2012). While the exact mechanism behind striatal dysfunction is 
unclear, METH-induced reduction in phasic DA signaling (Howard et al., 2011; 
Howard et al., 2013b), a mode of DA neurotransmission important in striatal gene 
expression (Chergui et al., 1997), has been proposed to subserve these 
changes. In fact, enhancing phasic DA signals in METH-pretreated animals 
normalizes gene expression deficits, indicating a link between reduced DA 
signaling and basal ganglia dysfunction (Howard et al., 2013a). 
 Therefore, restoring normal phasic signaling may be a means of 
ameliorating basal ganglia dysfunction following METH neurotoxicity. An obvious 
candidate to restore phasic DA signaling is L-3,4-dihydroxyphenylalanine (L-
DOPA), the biochemical precursor to DA and gold-standard treatment of 
Parkinson’s disease. Chronic L-DOPA reestablishes normal gene expression 
following METH neurotoxicity, indicating a restoration of phasic DA (unpublished 
observations). Additionally, electrochemical measurements in intact (Wightman 
et al., 1988; Garris et al., 1994b; Rodríguez et al., 2007) and severely DA-
depleted rats (Keller Jr. et al., 1988) indicate L-DOPA can augment electrically-
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evoked DA. Therefore, to test whether L-DOPA restores normal phasic DA 
following METH-induced partial DA depletions, L-DOPA (50 mg/kg, i.p.) was 
administered to METH- and saline-pretreated rats, and phasic DA signals were 
electrically evoked and measured using fast-scan cyclic voltammetry. L-DOPA 
restored phasic signals to baseline, control values in METH-pretreated animals. 
Unexpectedly, L-DOPA-mediated increases in phasic signals varied based on 
striatal recording site, even within the same animal and brain region. Additionally, 
chemometric analysis revealed no overt changes in basal DA levels within the 
first hour of L-DOPA treatment in METH- or saline-pretreated rats, despite 
increases in evoked signals. These data indicate that L-DOPA normalizes METH-




Materials and Methods 
Animals. Adult male Sprague-Dawley rats (250-300 g, METH-pretreated, 
n=12, 18 recordings; saline-pretreated n=12, 17 recordings) were purchased 
from Harlan (Indianapolis, IN, USA) and were housed in a light- and temperature-
controlled vivarium. Access to food and water was provided ad libitum. All 
procedures conformed to the NIH Guide for the Care and Use of Laboratory 
Animals and were approved by the Institutional Animal Care and Use Committee 
of Illinois State University. 
Drugs. (±)-Methamphetamine hydrochloride was provided by the National 
Institute on Drug Abuse (Rockville, MD, USA). L-3,4-dihydroxyphenylalanine 
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methyl ester hydrochloride and benserazide hydrochloride were both purchased 
from Sigma-Aldrich (St. Louis, MO, USA) and were dissolved in 0.9% sterile 
saline for injections. 
Methamphetamine pretreatment. Rats were treated with a neurotoxic 
“binge” regimen of METH (4 x 10 mg/kg, s.c., at two-hour intervals) as previously 
described (Howard et al., 2011). Briefly, rats were housed in plastic tub cages 
(50 cm length x 40 cm width x 20 cm height; 4-8 rats/tub). Rectal temperature 
was taken every hour for eight hours during the injection day using a Thermalert 
TH-5 (Phystemp, Clifton, NJ, USA). Rats were rehoused in the vivarium the 
following morning. 
In vivo voltammetry.  Rats were anesthetized with urethane (1.5 g/kg, i.p.) 
and placed in a stereotactic frame (David Kopf Instruments, Tajunga, CA, USA). 
Four holes were drilled to allow insertion of two recording electrodes, a 
stimulating electrode, and a reference electrode. Evoked DA concentration was 
recorded using fast-scan cyclic voltammetry (Cahill et al., 1996) by applying a 
triangular waveform to carbon fiber recording microelecrodes, which were 
fabricated as previously described (Ramsson et al., 2011b). Recording 
electrodes were lowered at a 6o angle ipsilaterally into the dorsomedial (DMS) 
and dorsolateral (DLS) striatum (mm from Bregma: +1.2 AP, +1.0 and +4.0 ML, 
respectively, and -4.5 DV; Paxinos and Watson, 1986). The Ag/AgCl reference 
electrode (Stoelting, Wood Dale, IL, USA) was placed in the contralateral cortex 
relative to the working electrodes. Voltammetry was controlled using TH-1 
software (ESA, Chelmsford, MA, USA) with either an EI400 (Ensman 
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Instruments, Bloomington, IN, USA) or UEI (University of North Carolina at 
Chapel Hill, Department of Chemistry Electronics Facility, Chapel Hill, NC, USA) 
bipotentiostat. Immediately following in vivo experiments, recorded current was 
converted to concentration by in vitro calibration (Logman et al., 2000). 
Electrical stimulation. A twisted bipolar stimulating electrode (Plastics One, 
Roanoke, VA, USA) was placed dorsal to the medial forebrain bundle (mm from 
Bregma: -4.6 AP, +1.4 ML, -7.0 DV; Paxinos and Watson, 1986) and was 
optimized to maximize evoked DA response in the striatum. During experiments, 
DA was evoked using phasic-like stimulus parameters (300 µA, 4 ms biphasic 
pulses, 24 pulses at 60 Hz). Stimulation was optically isolated and controlled 
using constant-current generators (Neurolog NL800, Digitimer Limited, 
Letchworth Garden City, UK). 
Experimental design. Following optimization of recording and stimulating 
electrodes, 24 pulse, 60 Hz stimulation was applied every 5 min for a total of 155 
min. Fifteen minutes following beginning of recordings, the peripheral L-amino 
acid decarboxylase inhibitor benserazide hydrochloride (40 mg/kg, i.p.) was 
administered, followed 20 min later by L-DOPA (50 mg/kg, i.p.) (Abercrombie et 
al., 1990; Rodríguez et al., 2007). Recordings were collected for two hours 
following L-DOPA injection. Maximal DA response at the oxidation potential for 
dopamine was determined, and evoked responses were analyzed for release 
and uptake rates (see following section). Additionally, basal DA was assessed 
using a chemometric approach (see following section). Immediately following 
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experiments, rats were euthanized and brains were rapidly removed and flash 
frozen using 2-methyl butane (EMD Millipore, Billerica, MA, USA) on dry ice. 
DAT autoradiography. Fresh-frozen brains were sectioned (12 µm), thaw-
mounted onto Superfrost Plus slides (VWR, Aurora, CO, USA), and stored at -
20°C. DAT binding in striatum was determined with [125I]RTI-55 (PerkinElmer, 
Waltham, MA, USA; Boja et al., 1992) binding, as previously reported (Barker-
Haliski et al., 2012; Pastuzyn et al., 2012; Son et al., 2013). Slides were apposed 
to film (Biomax MR; Eastman Kodak Co., Rochester, NY, USA) for 24 hr and 
developed. Images were digitized and densitometric analysis accomplished using 
NIH ImageJ, yielding average, background-subtracted gray values in DMS and 
DLS. Two rostral (+1.6 mm from Bregma; Paxinos and Watson, 1986) and two 
middle (+0.7 mm) striatal sections and four prefrontal cortical sections were 
analyzed per rat. DAT binding in METH-pretreated rats was converted to percent 
of average levels in saline-pretreated rats. 
Kinetic analysis. Evoked DA responses are a combination of two 
counteracting mechanisms; release and uptake. These rates were assessed 
using a mathematical model established by Wightman et al. (1988): 
 
    d[DA]/dt = [DA]p*ƒ- k[DA]           (1) 
 
where [DA]p is the concentration of DA release per stimulus pulse, k is the first-
order term for DA uptake rate, and ƒ is the frequency of the electrical stimulation. 
Experimental data were fit to simulated curves to determine k and [DA]p by using 
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a non-linear regression based on a simplex-minimization algorithm (Wu et al., 
2001). 
Principal component regression. In addition to evoked DA concentrations, 
changes in basal DA were assessed using principal component regression 
(Keithley et al., 2009). Here, training sets were collected prior to the beginning of 
experiments, wherein DA was evoked using various electrical stimulation 
parameters (60 Hz, 60 pulses; 60 Hz, 24 pulses; 60 Hz, 12 pulses; 30 Hz, 24 
pulses; 30 Hz, 12 pulses; and 30 Hz, 6 pulses; all at 300 µA; Heien et al., 2005). 
In addition to the DA component, training sets included background drift, which is 
crucial for assessing DA changes (Hermans et al., 2008), and when detectable, 
pH changes. Because electrode background changes were dynamic over time, 
voltammograms for drift just prior to drug administration best predicted changes 
after L-DOPA administration. Therefore, pH and background components were 
collected from predrug files, and predrug files were thus not analyzed for DA 
changes. 
  Unaccounted variance in experimental data sets that cannot be 
encompassed by the training set (Q) must fall below a calculated threshold (Qα) 
to appropriately predict concentration changes (Keithley and Wightman, 2011). 
To avoid “resetting” Q at the beginning of each five minute bin, which has 
previously been described as inappropriate (Keithley and Wightman, 2011), Q 
was cumulatively assessed across all post-L-DOPA recordings. This conservative 
approach resulted in exaggerated Q values, and changes in DA concentration 
were only included when these Q values fell below Qα. Predicted DA changes 
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with Q values under Qα were averaged by pretreatment and subregion. To obtain 
a measure of basal/tonic DA changes, 20 sequential data points in each PCR 
output were averaged at 2 s, 1202 s, and 2398 s after the beginning of the file 
when L-DOPA was injected. These time points were chosen based on the latest 
time at which Q values crossed Qα (see Results). 
Assessment of predrug responses as “fast” and “slow” release sites. 
Previous work using FSCV has reported two distinct profiles of release sites that 
are differentially regulated by D2 autoinhibition (Moquin and Michael, 2009). 
Termed “fast” and “slow” release sites, these types of DA release have different 
release and uptake dynamics, different response to uptake inhibitors, different 
short-term plasticity to subsequent stimulation, and different responses to D2 
antagonism (Moquin and Michael, 2009; Taylor et al., 2012) Therefore, we 
investigated our predrug responses based on criteria defining these two types of 
release sites (Taylor et al., 2012). Predrug responses were analyzed for (1) 
duration to increase following stimulus onset, (2) short-term facilitation (amplitude 
of signal at 200-400 ms normalized to amplitude at 0-200 ms during stimulation), 
(3) duration of “overshoot” or time following stimulation cessation until signal 
maximum ([DA]max), and (4) rate of uptake as assessed using results of kinetic 
analysis. These characteristics were averaged for each pretreatment, subregion, 
and site type (i.e., our “high” and “low” release sites) group and compared. 
Statistical analysis. Levels of DAT binding between pretreatment groups 
(saline and METH) in each brain region were compared by one-way ANOVA. 
Maximal DA response ([DA]max), DA release rate ([DA]p), and DA uptake rate (k) 
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were compared in each subregion with a three-way repeated measures 
pretreatment (saline or METH) x release site type (“high” or “low”) x time (0, 20, 
or 40 min post-L-DOPA) MANOVA. Once high and low release sites were 
determined to respond differently to L-DOPA, further comparisons were made by 
a two-way ANOVA on pretreatment x time, with post hoc tests run when 
significant effects or interactions were revealed. Changes in basal DA were 
assessed with a two-way repeated measures pretreatment x time MANOVA with 
follow-up post hoc t-tests when significant effects of time or an interaction were 
discovered. Characteristics of “fast” and “slow” release types (Moquin and 
Michael, 2009; Taylor et al., 2012) were compared using three-way ANOVA, with 
pretreatment, subregion, and site-type (i.e., our “high” and “low” release sites) as 
factors. Statistics were performed using JMP (v.9.0) and SAS (v.9.3) software 




DAT autoradiography. Pretreatment with a neurotoxic regimen of METH 
resulted in decreases in striatal DAT binding, as revealed by [125I]RTI-55 
autoradiography (Fig. 5.1). Unpaired t-tests showed that METH-pretreated rats 
had significantly less striatal DAT binding than SAL-pretreated rats in both DMS 
(t=9.17, p=0.0001) and DLS (t=8.45, p=0.0001). 
Effect of L-DOPA on evoked DA amplitude in saline- and METH-pretreated 
rats. An injection of 50 mg/kg L-DOPA resulted in increased DA signals evoked 
by phasic-like stimulation of the medial forebrain bundle in DMS and DLS of both 
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saline- and METH-pretreated rats as measured by fast-scan cyclic voltammetry. 
In Fig. 5.2, typical predrug responses and evoked traces 40 min after L-DOPA 
are shown respectively in left and right panels for DMS and DLS of saline-
pretreated (Fig. 5.2A and 5.2C, respectively) and DMS and DLS of METH-
pretreated (Fig. 5.2B and 5.2D, respectively) rats. 
  However, not all recording sites reacted in the same way to L-DOPA. 
Some sites demonstrated complete lack of response to L-DOPA, even when a 
simultaneous recording within the same rat and same brain region showed 
robust activation. Fig. 5.3 demonstrates traces collected within the same 
subregion (DMS) in a saline- (Fig. 5.3A and 5.3B) and METH-pretreated rat (Fig. 
5.3C and 5.3D) before, 20, and 40 min after L-DOPA injection. As seen in the 
figure, within the same subregion (~0.5 mm apart) of the same animal, DA 
response to L-DOPA was highly variable. More interestingly, recordings with 
larger predrug evoked responses appeared to respond more robustly to L-DOPA. 
Therefore, all data were separated into “high release” and “low release” sites 
based on evoked predrug concentration for subsequent analysis. Inclusion 
criteria for high release sites in saline-pretreated animals was predrug evoked 
responses >0.4 µM. As METH-pretreated groups, on average, had lower predrug 
evoked responses, inclusion criteria for high release sites in METH-pretreated 
animals was >0.3 µM. The release site type criterion for the METH-pretreated 
group was set based on expected differences in evoked response between 
pretreatment groups based on previous work (Howard et al., 2011; Howard et al., 
2013b), and accordingly, the criterion difference between saline- and METH-
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pretreated groups (0.4 vs. 0.3 µM or 25%) was similar to differences in average 
evoked predrug differences between saline- and METH-pretreated animals in the 
current study (29.5% reduction in METH pretreated animals).  
As shown in Fig. 5.4, L-DOPA caused robust and long-lasting increases in 
evoked DA amplitude in high release, but not low release sites in DMS of both 
METH- and saline-pretreated animals (Fig. 5.4A). In DLS of METH- and saline-
pretreated animals, increases were noted in high release sites, but were 
diminished relative to DMS and low release sites showed minimal response to L-
DOPA (Fig. 5.4B). Importantly, in high release sites, METH pretreatment reduced 
evoked responses, and this decrement was temporarily remediated by L-DOPA. 
Three timepoints were selected for subsequent analysis: the stimulation event 
just prior to drug injection (time 0), 20 min, and 40 min following L-DOPA 
administration. A repeated measures MANOVA on evoked DA concentration in 
DMS at 0 (baseline), 20, and 40 min post-L-DOPA revealed a significant effect of 
pretreatment (F(1,14)=17.7, p=0.0009), release site type (F(1,14)=60.1, p=0.0001), 
time (F(2,13)=34.7, p=0.0001), a time x pretreatment interaction (F(2,13)=6.68, 
p=0.0101), time x release site type interaction (F(2,13)=16.2, p=0.0003), and time x 
pretreatment x release site type interaction (F(2,13)=3.86, p=0.048; Fig. 5.4C), 
suggesting that the high and low release sites had significantly different 
responses to L-DOPA. Similarly, in DLS, a repeated measures MANOVA on 
evoked [DA]max revealed a significant effect of pretreatment (F(1,20)=11, 
p=0.0035), release site type (F(1,20)=72.5, p=0.0001), time (F(2,19)=19.8, 
p=0.0001), a time x pretreatment interaction (F(2,19)=29.3, p=0.0001), time x 
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release site type interaction (F(2,19)=12.7, p=0.0003), and time x pretreatment x 
release site type interaction (F(2,19)=14.1, p=0.0002; Fig. 5.4D). Therefore, high 
and low release sites responded differently to L-DOPA in both DMS and DLS, 
which justifies separating high and low release sites for subsequent analysis. 
Effect of L-DOPA on average evoked responses, DA uptake, and DA 
release rates. Fig. 5.5 shows average characteristics of electrically evoked DA 
signals before and following L-DOPA administration, where maximal DA 
responses ([DA]max; top four panels), DA release ([DA]p; middle four panels), and 
DA uptake rate (k; bottom two panels) were averaged by pretreatment groups 
and release site type (high vs. low) and are shown for DMS (left) and DLS (right). 
At high release sites in DMS (Fig. 5.5A), two-way repeated measures MANOVA 
revealed a significant effect of pretreatment (F(1,7)=23, p=0.002), a significant 
effect of time (F(2,6)=34.6, p=0.0005), and a time x pretreatment interaction 
(F(2,6)=7.24, p=0.025). Post hoc t-tests showed that there was a significant effect 
of pretreatment (SAL>METH) at 0 (t=3.6, p=0.0087), 20 (t=4.48, p=0.0029), and 
40 (t=4.76, p=0.0021) min post-L-DOPA. A student’s t-test on evoked DA values 
at high release sites in SAL-pretreated rats at 0, 20, and 40 min post-L-DOPA 
revealed that evoked DA levels at 20 and 40 min were both significantly greater 
than at 0 min (20: t=3.9, p=0.0034; 40: t=9.3, p=0.0001) and 40 min was greater 
than 20 min (t=5.4, p=0.0004). At high release sites in METH-pretreated rats, a 
student’s t-test revealed a strong trend for evoked DA levels at 40 min to be 
greater than at 0 min (t=2.0, p=0.07). At low release sites in DMS (Fig. 5.5C), 
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two-way repeated measures MANOVA revealed that there was no effect of 
pretreatment (p=0.11), time (p=0.11), or time x pretreatment interaction (p=0.67). 
 At high release sites in DLS (Fig. 5.5B), two-way repeated measures 
MANOVA revealed a strong trend towards an effect of pretreatment (F(1,5)=6.21, 
p=0.055), a significant effect of time (F(2,4)=29, p=0.0042), and a time x 
pretreatment interaction (F(2,4)=37.1, p=0.0026). Post hoc t-tests showed that 
there was no effect of pretreatment at baseline (p=0.21), but there was at 20 min 
post-L-DOPA (t=3.13, p=0.026), and there was a trend towards an effect at 40 
min post-L-DOPA (t=2.29, p=0.071). A student’s t-test on evoked DA values at 0, 
20, and 40 min post-L-DOPA showed that there were no significant differences 
between DA levels at the different times at high release sites in either METH- or 
saline-pretreated rats (all p>0.05). At low release sites in DLS (Fig. 5.5D), a two-
way repeated measures MANOVA revealed a significant effect of pretreatment 
(F(1,15)=4.63, p=0.048), no effect of time (p=0.35), and a strong trend towards a 
time x pretreatment interaction (F(2,14)=3.6, p=0.055). 
 Kinetic analysis of evoked DA traces was performed. A three-way 
repeated measures MANOVA (pretreatment x release site type x time) on the 
amount of DA released per pulse ([DA]p) in DMS revealed a significant effect of 
pretreatment (F(1,14)=10.9, p=0.0052), release site type (F(1,14)=30.4, p=0.0001), 
time (F(2,13)=33.5, p=0.0001), time x pretreatment interaction (F(2,13)=8.96, 
p=0.0036), time x release site type interaction (F(2,13)=22.4, p=0.0001), and time x 
pretreatment x release site type interaction (F(2,13)=4.02, p=0.044). Based on 
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these significant interactions, we split the [DA]p from high and low release sites 
for subsequent statistical analysis. 
 At high release sites in DMS (Fig. 5.5E), a two-way repeated measures 
MANOVA revealed a significant effect of pretreatment (F(1,7)=6.61, p=0.037), time 
(F(2,6)=38.3, p=0.0004), and a time x pretreatment interaction (F(2,6)=8.4, 
p=0.018). Post hoc t-tests revealed that SAL>METH at 20 (t=2.69, p=0.031) and 
40 (t=2.97, p=0.021) min post-L-DOPA, but not at baseline (p=0.16). A student’s 
t-test on [DA]p values at high release sites in SAL-pretreated rats at 0, 20, and 40 
min post-L-DOPA revealed that [DA]p at 40 min was significantly greater than at 0 
min (t=4.1, p=0.0026) and 20 min (t=2.4, p=0.043). Student’s t-test revealed no 
significant differences between [DA]p at the three different timepoints at high 
release sites in METH-pretreated rats. At low release sites in DMS (Fig. 5.5G), a 
two-way repeated measures MANOVA revealed a trend towards an effect of 
pretreatment (F(1,7)=4.47, p=0.072), but no effect of time (p=0.33) or time x 
pretreatment interaction (p=0.23). 
 At high release sites in DLS (Fig. 5.5F), a two-way repeated measures 
MANOVA revealed a trend towards an effect of pretreatment (F(1,5)=4.18, 
p=0.096), a significant effect of time (F(2,4)=26.9, p=0.0048), and a time x 
pretreatment interaction (F(2,4)=11.2, p=0.023). Post hoc t-tests showed that there 
was a trending effect for SAL>METH at 20 (t=2.46, p=0.057) and 40 (t=2.01, 
p=0.1) min post-L-DOPA, but no significant effect of pretreatment at baseline 
(p=0.22). A student’s t-test on [DA]p values at high release sites in SAL-
pretreated rats at 0, 20, and 40 min post-L-DOPA revealed that [DA]p at 40 min 
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was significantly greater than at 0 min (t=2.3, p=0.0455). At high release sites in 
METH-pretreated rats, a student’s t-test revealed a trend for [DA]p levels at 40 
min to be greater than at 0 min (t=2.1, p=0.08). At low release sites in DLS (Fig. 
5.5H), a two-way repeated measures MANOVA revealed a significant time x 
pretreatment interaction (F(2,12)=4.26, p=0.04), but no effect of pretreatment 
(p=0.26) or time (p=0.68). Post hoc t-tests revealed no significant effect of 
pretreatment at any time point (all p>0.05). 
 A three-way repeated measures MANOVA (pretreatment x release site 
type x time) was performed on values for k, or DA uptake. In DMS (Fig. 5.5I), 
there was a strong trend for a significant effect of pretreatment (F(1,14)=4.55, 
p=0.051) and time (F(2,13)=14.6, p=0.0005), but no other significant effects or 
interactions (p>0.05). In DLS (Fig. 5.5J), there was only a significant effect of 
time (F(2,17)=6.23, p=0.0093). Because of this, we could not statistically separate 
high and low release sites for analysis of k, suggesting that the high and low 
release sites did not differ in response to L-DOPA because of DA uptake rate. 
Post hoc student’s t-tests revealed that values for k at 0, 20, and 40 min post-L-
DOPA were not significantly different in either DMS or DLS (all p>0.05). 
Analysis of evoked responses based on “fast” and “slow” release site 
characteristics. We analyzed predrug responses to investigate if our “low” and 
“high” release sites corresponded to previously described “fast” and “slow” 
release sites (Taylor et al., 2012; Fig. 5.6). Much to our surprise, we report very 
different evoked responses than those described by Taylor et al. (2012); for 
example, we see no true “fast” release sites, as all evoked responses in the 
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current work had some overshoot following the end of stimulation (Fig. 5.2 and 
5.3). Additionally, release sites in the current work demonstrated at least some 
short-term facilitation as opposed to short-term depression exhibited by “fast” 
release sites (Taylor et al., 2012). Three-way ANOVA revealed that our “high” 
and “low” release sites showed no difference in duration to increase (F(7,33)=2.51, 
p=0.1331), short-term facilitation (F(7,33)=0.00, p=0.9769), duration of overshoot 
(F(7,33)=0.83, p=0.3690), or uptake rate (k; F(7,33)=0.44, p=0.5096). However, 
METH pretreatment did increase duration to increase (F(7,33)=4.51, p=0.0412) 
and duration of overshoot (F(7,33)=6.75, p=0.0139), as well as reduce uptake rate 
(F(7,33)=4.56, p=0.0383). There were no significant interactions for any measure 
(all p values>0.05). Therefore, effects of L-DOPA were not attributable to “fast” or 
“slow” release sites in the current study. 
Effect of L-DOPA on evoked and basal DA concentration in saline- and 
METH-pretreated rats. L-DOPA-induced change in basal DA concentration was 
assessed using principal component regression (PCR; Keithley et al., 2009). As 
shown in Fig. 5.7, increases in basal current recorded following L-DOPA 
administration were not attributable to changes in DA. When PCR was used to 
separate the influences of DA, pH, and electrode drift, increases in current were 
dramatically reduced before (Fig. 5.7A) and after L-DOPA administration (50 min 
postdrug shown in Fig. 5.7B). Importantly, PCR accurately assessed DA changes 
as evoked response current, which are thought to be primarily attributable to DA 
changes (Chergui et al., 1994), shows good agreement with PCR output (Fig. 
5.7, INSET). 
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  Predicted DA changes collected from PCR output were averaged by 
subregion and pretreatment (Fig. 5.8). As stated in Materials and Methods, 
changes in basal DA were only included if Q values remained below Qα. In 
general, all Q values tended to pass Qα ~60 min after L-DOPA administration; 
therefore, later time points were excluded. Additionally, in the DMS of METH-
pretreated animals, Q values crossed threshold in all but two experiments prior to 
60 min postdrug; therefore, data were analyzed through 40 min postdrug. We 
chose three time points to analyze: 2 s after the beginning of the file in which L-
DOPA was administered, at 20 min and 2 s (1202 s), and 2 s before the end of 
40 min (2398 s). Additionally, recordings with Q values that quickly crossed 
threshold were excluded. L-DOPA did marginally affect basal DA across all 
pretreatment groups (trending effect of time, F(2,20)=3.28, p=0.0586) though this 
appeared to be marginally related to pretreatment (trending effect of 
pretreatment, F(1,21)=3.16, p=0.0897). Changes in basal DA were also not 
different between subregions (no significant effect of subregion, F(1,21)=0.02, 
p=0.8854; no significant time x pretreatment interaction, F(2,20)=1.02, p=0.3780; 
no significant time x subregion interaction, F(2,20)=0.44, p=0.6526; no significant 
time x pretreatment x subregion interaction, F(2,20)=0.87, p=0.4359;  two-way 
repeated measures MANOVA; Fig. 5.8). Though trends for increases in basal DA 
were noted, lack of significant increases in basal DA indicates L-DOPA may be 







This study demonstrated the novel finding that L-DOPA remediates 
evoked phasic DA signaling impaired by neurotoxic METH pretreatment. 
Unexpectedly, L-DOPA-induced increase of phasic signaling was not uniform 
throughout the striatum, and augmented phasic DA signaling occurred 
irrespective of overt increases in basal DA tone, indicating a specific 
enhancement of phasic activity in both nonlesioned controls and at the partial 
lesion degree seen following METH neurotoxicity. These data indicate that L-
DOPA may partially restore normal striatal functioning by restoring deficits in 
phasic DA signaling in METH-pretreated animals. 
L-DOPA restores normal electrically-evoked DA signaling despite partial 
DA depletion induced by METH neurotoxicity. In agreement with previous work 
from us and others, pretreatment of rats with a neurotoxic dose of METH impairs 
electrically-evoked phasic DA signals (Howard et al., 2011; Loewinger et al., 
2012; Howard et al., 2013b; Fig. 5.4A-D, Fig. 5.5A-D). These deficits were 
restored to control levels in “high release” sites of METH-pretreated animals in 
the current study, though no obvious changes in “low release” sites were noted in 
either DMS or DLS. Our previous work has indicated that electrically-evoked 
phasic signals are indicative of the status of “spontaneous” DA signals, also 
called DA transients (Howard et al., 2013b). However, direct measures of 
naturally-occurring DA transients following L-DOPA administration are yet to be 
reported. 
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 METH-induced partial DA depletions blunted L-DOPA-induced 
augmentation of DA release in the current study (Fig. 5.4 and 5.5). Following 
severe 6-OHDA-induced DA depletion, peak DA concentration in dialysate fails 
to reach those of intact striata after lower (Gerlach et al., 2004), higher (Keller Jr. 
et al., 1988), and identical L-DOPA doses to those used here (Miller and 
Abercrombie, 1999). This is likely due to fewer terminals packaging and releasing 
newly synthesized DA in the 6-OHDA-treated rat. However, relative to pre-L-
DOPA baseline, increases in DA release in severely lesioned striata are vastly 
larger, which is indicative of compensation in DA neurons following large DA 
tissue loss (Abercrombie et al., 1990). Since METH-pretreated rats have a 
relatively mild lesion (~60%) compared to 6-OHDA-treated rats, the lack of a 
relatively larger increase in DA release in METH vs. saline rats following L-DOPA 
likely indicates lack of active compensation of DA neurons. 
L-DOPA restores DA release rates following METH-induced partial DA 
depletion. Remediation of phasic DA signal amplitude occurred with 
simultaneous increases in exocytotic DA release rate (Fig. 5.5). Previous reports 
have also demonstrated L-DOPA-induced increases in DA release as monitored 
by voltammetry (Stamford et al., 1984; Keller Jr. et al., 1988; Wightman et al., 
1988; May and Wightman, 1989b; Garris et al., 1994b). Additionally, L-DOPA has 
been shown to dramatically (>300%) increase quantal size in midbrain DA 
neurons (Pothos et al., 1996; Pothos et al., 1998b). While the modest (~100-
140%) increases in DA release reported here may be linked to dose differences, 
 167 
a potential role of D2 autoreceptors on quantal size in intact preparation (Pothos 
et al., 1998a) may also lead to these differences. 
  Prior to L-DOPA, DA release rate is diminished by partial DA depletion, 
which is consistent with previous work in METH pretreated rats (Howard et al., 
2011; Howard et al., 2013b) and work in a rat model of Parkinson’s disease 
(Garris et al., 1997; Bezard et al., 2000; Bergstrom and Garris, 2003), but is in 
contrast to studies demonstrating compensation of DA release following DA 
denervation (Stachowiak et al., 1987; Snyder et al., 1990; Zigmond et al., 1990; 
Zoli et al., 1998; McCallum et al., 2006; Perez et al., 2008; Bergstrom et al., 
2011). The reason for these discrepant results is beyond the scope of the current 
work (see Bergstrom et al., 2011). 
“High” and “low” release sites exist side-by-side in striatum. DA release 
within the striatum is known to be heterogeneous, with not all sites responding in 
the same way to stimulation or a cue (May and Wightman, 1989b, a; Garris et al., 
1994a; Brown et al., 2011). Besides regional variation, differences in release 
within a region have also been described (Rodriguez et al., 2006; Moquin and 
Michael, 2009; Wang et al., 2010; Moquin and Michael, 2011; Taylor et al., 
2012). However, to our knowledge, the finding that some release sites showed a 
pronounced amplification in amplitude post-L-DOPA, while some do not, is a 
novel one. These high and low release sites reported herein do not appear to 
follow the guidelines for “fast” and “slow” release sites laid out by Michael and 
colleagues (Moquin and Michael, 2009; Taylor et al., 2012). By positioning two 
CFMs within the same brain region in a rat, we were able to rule out injection site 
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contributing to lack of L-DOPA effect. Further, DLS seemed to possess more low 
release sites than DMS; as differences have been described between the 
function and connectivity of DMS and DLS (e.g., Yin et al., 2004, 2006; 
Humphries and Prescott, 2010), it is not entirely surprising that DMS and DLS 
have different contingents of types of release sites. Further, while saline- and 
METH-pretreated rats seemed to have numerous high release sites in DMS, in 
DLS, high release sites were less frequent, even in saline-pretreated rats 
(experimenter observations). The mechanism for different actions of L-DOPA at 
these different sites is unknown, but may be related to D2 autoreceptor density 
(Moquin and Michael, 2009; Taylor et al., 2012). 
L-DOPA preferentially enhances phasic DA release. The accepted 
mechanism of L-DOPA-mediated increases in striatal DA is that L-DOPA 
enhances both phasic and tonic DA signaling (Breitenstein et al., 2006) and that 
L-DOPA augments basal DA via increased tonic DA release (Simuni and Hurtig, 
2002). Here, results of principal component regression indicate increases in 
evoked DA responses without overt increase in basal DA levels (Fig. 5.8), though 
average (nonsignificant) increases of ~30 nM were noted nearly 40 min after L-
DOPA administration in METH-pretreated animals. Years of microdialysis studies 
have demonstrated increases in basal DA after L-DOPA, typically at higher doses 
than those used here (Koshimura et al., 1992). However, microdialysis studies 
have also demonstrated no change or decreases in basal DA at similar doses 
used in the current study (Abercrombie et al., 1990; Kannari et al., 2000; 
Rodríguez et al., 2007), or at lower doses (Touchet and Bennett Jr, 1989). 
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Importantly, microdialysis lacks temporal resolution to differentiate the respective 
influences of tonic and phasic DA signaling on DA tone.  
 Increases in basal DA seen in previous studies utilizing real-time 
electrochemical approaches have demonstrated increases in currents thought to 
reflect DA or DA metabolites following L-DOPA (Rodríguez et al., 2007). 
However, these studies demonstrated changes in basal DA using amperometry 
and chronoamperometry, which are not selective to DA. In fact, as discussed by 
Rodríguez et al. (2007), nonselective electrochemical approaches may oxidize L-
DOPA, as increases in background current mirror changes in L-DOPA availability 
in the brain and occur irrespective of increased DA as monitored by 
microdialysis. 
To the contrary, other studies have shown that L-DOPA preferentially 
increases DA release to high (≥30 Hz) stimulus frequency (May and Wightman, 
1989b; Oksman et al., 2009), which coincides with physiological firing rates 
during burst firing of DA neurons (Grace and Bunney, 1984; Hyland et al., 2002). 
Furthermore, L-DOPA does not alter [11C]raclopride binding in monkeys (Antonini 
et al., 1994) and humans (Flöel et al., 2008) when at rest (an index of basal DA), 
whereas augmented release was noted during formation of motor memory, which 
is thought to reflect phasic DA activity (Flöel et al., 2008). Furthermore, a recent 
study found that L-DOPA was able to restore the reward prediction error in 
elderly subjects (Chowdhury et al., 2013), which is thought to be mediated by 
phasic DA release (Schultz, 2013; Steinberg et al., 2013). 
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 The lack of increased basal DA observed in this study is puzzling, as 
increasing DA release while lowering DA uptake should result in increased basal 
DA levels. However, feedback loops in striatal circuitry may subserve the lack of 
basal increases. Additionally, “low release” sites monitored in the current study 
may display greater D2 autoreceptor regulation of DA release (Taylor et al., 
2012), which may explain lack of increases in DA release and basal DA levels in 
these sites. The use of anesthesia in this work is also a concern, as DA cell firing 
is blunted under anesthesia (Kelland et al., 1990). Finally, increases in DA tone 
may occur below detection limits of voltammetry, although this is unlikely, as 
“efflux” of DA following amphetamine is clearly detectable in both anesthetized 
(Ramsson et al., 2011a) and freely-behaving rats (Daberkow et al., 2013). 
Implications for L-DOPA as a cognitive enhancer. Phasic DA signaling is 
known to be important in cue-based learning (Zweifel et al., 2009), encoding 
errors in reward prediction (Schultz, 1998, 2007, 2013), and “wanting” of rewards 
(Berridge, 2007). We have previously proposed reduced phasic DA signaling as 
a possible link between METH neurotoxicity and METH-induced cognitive 
impairments (Howard et al., 2011; Howard et al., 2013b). Based on the current 
work, it is possible that L-DOPA may remediate some impaired cognitive 
processes following METH neurotoxicity by normalizing phasic DA signaling. 
Work in both healthy (Knecht et al., 2004; Pessiglione et al., 2006; Chowdhury et 
al., 2013) and parkinsonian (Frank et al., 2004; Graef et al., 2010) patients has 
revealed cognitive-enhancing properties of L-DOPA, though L-DOPA treatment is 
also associated with impaired reversal learning and learning from negative 
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outcomes in Parkinson’s patients (Cools et al., 2001; Cools et al., 2004; Frank et 
al., 2004). This bidirectional effect of L-DOPA on cognitive processes has been 
suggested to be caused by enhanced “Go” or direct pathway activity, which is 
specifically facilitated by phasic DA (Dreyer et al., 2010), and simultaneous 
impairments in “No Go” or indirect pathway activation (Frank et al., 2004; Wiecki 
and Frank, 2010), which is influenced by DA tone (Dreyer et al., 2010). 
Therefore, future work should investigate the effects of L-DOPA on these 
important forms of learning in the setting of METH neurotoxicity. 
Conclusions. The results of this study demonstrate for the first time that L-
DOPA can restore phasic DA signaling known to be deficient in METH-pretreated 
rats (Howard et al., 2011; Howard et al., 2013b) without impacting basal DA tone. 
As human METH abusers are known to have cognitive impairments as a result of 
partial monoamine loss (Dean et al., 2013), restoration of normal dopaminergic 
signaling in the brain could improve cognitive function and allow abstinent METH 
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Figure 5.1. A neurotoxic regimen of METH results in decreases in DAT and 
SERT binding. [125I]RTI-55 autoradiography revealed that METH neurotoxicity 
causes decreases in striatal DAT binding. Values in METH-pretreated rats are 











Figure 5.2. Representative evoked DA traces in response to L-DOPA in 
saline- and METH-pretreated animals. Evoked DA responses are shown from 
baseline (predrug, left, thick black trace) and 40 min (right) after L-DOPA in 
saline- (A and C) and METH- (B and D) pretreated rats in both DMS (A and B) 
and DLS (C and D). Under evoked responses, stimulation duration is shown as a 
straight black line. Cyclic voltammograms indicate the measured analyte is DA 
(INSET). Colorplots (below evoked trace) are shown with time as the abscissa 
and voltage as the ordinate. The z axis (color) represents measured current 
during each voltage scan. DA traces are taken from peak DA oxidation potentials 
(horizontal dotted white lines) and cyclic voltammograms are taken from maximal 













Figure 5.3. L-DOPA preferentially increases evoked responses in sites of 
higher predrug DA release in DMS and DLS of saline- and METH-pretreated 
rats. Traces show amplitude of evoked DA release at baseline and 20 and 40 
min after L-DOPA in both a saline- (A and B) and METH- (C and D) pretreated 
rat. CFMs were positioned within 0.5 mm of each other in the same saline- or 
METH-pretreated rat, demonstrating that high and low release sites can be found 
side-by-side within the same brain region of the same rat. The high release site 
in each rat shows a robust increase in evoked [DA]max after L-DOPA, while the 










Figure 5.4. Timecourse of L-DOPA effects on evoked DA signals amplitude. 
(A) L-DOPA increased evoked responses in high release sites in DMS of saline- 
(black squares) and METH-pretreated animals (black circles), but had no effect 
on low release sites of saline- (gray squares) or METH-pretreated animals (gray 
circles; L-DOPA injected at time 0). (B) L-DOPA increased evoked responses in 
high release sites in DLS of saline- and METH-pretreated animals, but these 
responses were blunted relative to those seen in DMS (A). (C) Average evoked 
response by pretreatment and site type revealed that L-DOPA had differential 
actions on high release sites in DMS (black, saline-pretreated high release sites; 
gray, METH-pretreated high release sites; white, saline-pretreated low release 
sites; patterned, METH-pretreated low release sites). (D) Similar to DMS, L-

















Figure 5.5. L-DOPA increases DA release but has no impact on DA uptake 
rates in the DMS and DLS of saline- and METH-pretreated animals. Evoked 
[DA]max, [DA]p, and k at 0, 20, and 40 min post-L-DOPA in both high and low 
release sites in DMS and DLS. Graphs compare saline- and METH-pretreated 
rats. (A-D) Repeated measures MANOVA revealed a significant effect of time in 
DMS high (p=0.0005) and DLS high (p=0.0042) sites. There was a trending 
effect of time in DMS low sites (p=0.11). **Significant effect of pretreatment, 
p<0.01. *Significant effect of pretreatment, p<0.05. #Trend towards effect of 
pretreatment, p<0.11. (E-H) Repeated measures MANOVA revealed a significant 
effect of time in DMS high (p=0.0004) and DLS high (p=0.0048) sites. *Significant 
effect of pretreatment, p<0.05. #Trend towards effect of pretreatment, p<0.1. (I-J) 
Repeated measures MANOVA revealed a significant effect of time in DMS 
(p=0.0005) and DLS (p=0.0093). k for high and low release sites was not 



























Figure 5.6. Amplitude of evoked phasic-like DA signals and DA release are 
greater in high release sites, but other parameters of evoked responses are 
not different between site types. (A-B) When separated by high and low 
release sites, both maximal concentration of evoked phasic-like DA signals (A: 
[DA]max) and DA release (B: [DA]p) are reduced. *Significantly different from high 
release sites, p<0.05. (C-F) DA uptake (C), duration to increase following 
stimulation (D), duration of overshoot following the end of stimulation (E), and 














Figure 5.7. Principal component regression removes interferents from 
voltammetric recordings. Principal component regression indicated that 
increases in current across the peak oxidation potential for DA (red line, FSCV) 
were not attributed to changes in DA (black line, PCR). After subtracting pH and 
drift, dramatic increases in current were negated. Additionally, principal 
component analysis did not detract current attributable to DA from the DA 
component, as evoked responses show good agreement between raw 
voltammetric recordings and the DA component of principal component 










Figure 5.8. L-DOPA selectively increases phasic DA signaling. Traces show 
average principal component regression output (black line) ± SEM (grey lines). 
Traces show first hour following L-DOPA administration (arrow). METH DMS is 
shown only for the first 40 min (see Results). Current was averaged between 20 
points at 2 sec (predrug), 1202 sec, and 2398 sec and then averaged between 















 This dissertation has presented data for three main conclusions: first, 
methamphetamine (METH)-induced neurotoxicity results in an alteration of 
circuitry underlying response-reversal learning. Second, the effector immediate-
early gene Arc (activity-regulated cytoskeleton-associated gene) is critical for 
consolidation of learning in both dorsomedial (DM) striatum and nucleus 
accumbens (NAc) shell when that brain region is necessary for the learning being 
examined on the behavioral task. Third, if phasic dopamine (DA) 
neurotransmission is restored in METH-pretreated rats, either artificially or 
pharmacologically, rescued METH-induced deficits in striatal gene expression 
and evoked DA release are observed. 
 Rats that are pretreated with a neurotoxic regimen of METH have long-
lasting partial DA loss (Seiden et al., 1976; Morgan and Gibb, 1980; Ricaurte et 
al., 1980; Wagner et al., 1980). This partial DA loss causes deficits on some 
learning and memory tasks, but no noticeable impairment on others. For 
example, METH-pretreated rats perform as well as saline-pretreated rats on a 
response-reversal T-maze task, in that they take the same number of trials to 
reach criterion (Daberkow et al., 2008; Pastuzyn et al., 2012; Chapters 2 and 3). 
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However, METH-pretreated rats have no correlation between Arc mRNA 
expression and performance on reversal learning in DM striatum as saline-
pretreated rats do (Daberkow et al., 2007, 2008; Chapter 3). Thus, knocking 
down Arc expression in DM striatum of saline-pretreated rats using an Arc 
antisense oligonucleotide impairs memory consolidation on the response 
reversal-learning task, but has no effect on memory consolidation in METH-
pretreated rats (Pastuzyn et al., 2012; Chapter 2). Instead, METH-pretreated rats 
have a correlation between Arc and performance in NAc shell, which does not 
exist in saline-pretreated rats (Chapter 3). Correspondingly, when Arc is knocked 
down via the Arc antisense oligonucleotide in NAc shell, it impairs memory 
consolidation in METH-, but not saline-, pretreated rats (Chapter 3). These data 
suggest a number of things. First, METH-pretreated rats no longer rely on DM 
striatum to perform the response reversal-learning task, as evidenced by the lack 
of effect of NMDA receptor blockade or Arc antisense on learning and memory 
consolidation in these rats. Second, METH pretreatment appears to induce a 
change in circuitry underlying response-reversal learning, such that METH-
pretreated rats rely on NAc shell rather than DM striatum to consolidate reversal 
learning memories. Finally, the correlation of Arc expression with a measure of 
learning, rather than simply the induction of Arc, appears to indicate the 
necessity of encoding processes in that brain region for the learning taking place 
on the task, as has been previously suggested (Guzowski et al., 2001). 
 METH-pretreated rats have a deficit in phasic DA neurotransmission, but 
not in tonic DA neurotransmission (Cass and Manning, 1999; Howard et al., 
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2011; Loewinger et al., 2012; Howard et al., 2013a; Chapter 5). We previously 
hypothesized that restoring phasic DA neurotransmission in METH-pretreated 
rats may restore proper functioning to the striatum (Keefe and Horner, 2010; 
Barker-Haliski et al., 2012). We have now shown that stimulating the medial 
forebrain bundle (MFB) in a phasic-like manner can rescue impaired 
preprotachykinin (ppt) expression in striatum of METH-pretreated rats, whereas 
stimulating the MFB in a tonic-like manner has no effect on gene expression 
(Howard et al., 2013b; Chapter 4). Phasic-like stimulation of the MFB also 
induces immediate-early gene expression (Arc and zif268) to the same extent in 
both METH- and saline-pretreated rats despite the partial loss of DA terminals in 
METH-pretreated rats, suggesting that the striatum of METH-pretreated rats has 
the capability for proper gene expression if phasic DA neurotransmission is 
provided. 
 L-3,4-dihydroxyphenylalanine (L-DOPA) is the most common treatment for 
the symptoms of Parkinson’s disease and works by increasing the amount of DA 
in the brain. We hypothesized that L-DOPA could rescue phasic DA 
neurotransmission in METH-pretreated rats simply by providing more DA for 
neurons to release. When L-DOPA was given to anesthetized rats and the MFB 
was stimulated in a phasic-like manner, fast-scan cyclic voltammetry for DA at 
sites in DM and dorsolateral (DL) striatum revealed that L-DOPA increased the 
amplitude of DA release evoked by phasic-like stimulation of the MFB in METH-
pretreated rats back to evoked levels seen in saline-pretreated rats (Chapter 5). 
Interestingly, this did not occur at all recording sites in DM and DL striatum 
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irrespective of pretreatment with METH or saline—some sites responded robustly 
to L-DOPA (“high release sites”), whereas other sites did not increase evoked DA 
release after L-DOPA (“low release sites”). At this time, the basis for the 
differences between these sites in the same brain region of the same animal is 
unknown. Finally, using principal component regression, we were able to 
separate out the tonic/basal component of the DA recording from the phasic 
component. We found that 50 mg/kg L-DOPA specifically increased phasic-like 
DA release in both METH- and saline-pretreated rats without altering basal 
release, suggesting that one dose of L-DOPA can impact just phasic DA 
neurotransmission, the mode of firing impaired in METH-pretreated rats. 
 In conclusion, METH-pretreated rats have altered circuitry underlying 
reversal learning and deficits in striatal gene expression and phasic DA 
neurotransmission. The impairment in gene expression and DA 
neurotransmission can be rescued by restoring phasic-like DA 
neurotransmission, either via artificial electrical stimulation or pharmacologically 
using L-DOPA. These findings suggest that it may be possible to restore function 
to the striatum as a whole in METH-pretreated rats and, consequently, the 
normal circuitry used in behavioral tasks. Restoration of striatal function has 
obvious implications for translational therapeutic use of L-DOPA in recovering 
METH addicts, and could help them function better while they are trying to 
abstain from this highly addictive drug. In the future, it would be interesting to test 
whether L-DOPA could restore striatal function in METH-pretreated rats on the 
response-reversal T-maze task. If L-DOPA restores phasic DA release in DM 
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striatum of METH-pretreated rats back to normal and they could once again use 
DM striatum on the reversal task, then NMDA receptor blockade or Arc antisense 
in DM striatum would be expected to impair reversal learning or retention of 
learning, respectively. These findings would prove that METH-pretreated rats 
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